Personensuche
Personensuche
Es wurde 1 Person gefunden.
Institut für Dermatologie der Medizinischen Fakultät am Universitätsklinikum Essen
Anschrift
Hufelandstraße 55
45122 Essen
45122 Essen
Telefon
Funktionen
-
Direktor/in, Klinik für Dermatologie
Aktuelle Veranstaltungen
-
2024 WS
- Pathophysiologie u. Praxis der Wundheilung (WA)
- Dermatologie und Venerologie (3. Sem. zweiter Abschnitt) (WA)
- Integriertes Seminar klinische Untersuchungen (1. Abschnitt der Ärztlichen Ausbildung) (nur Wintersemester) (PV)
- Dermatologische Untersuchungsmethoden (PV) (1. Sem. zweiter Abschnitt)
- Klinischer Untersuchungskurs (1. Semester des zweiten Abschnittes) (PV)
- Berufsdermatologisches Praktikum (WA)
- Aktuelle Forschungsthemen
- Kurs der allgemeinen klinischen Untersuchungen (PV)
Vergangene Veranstaltungen (max. 10)
-
2024 SS
- Berufsdermatologisches Praktikum (WA)
- Pathophysiologie u. Praxis der Wundheilung (WA)
- Dermatologie und Venerologie (3. Sem. zweiter Abschnitt) (WA)
- Dermatologische Untersuchungsmethoden (PV) (1. Sem. zweiter Abschnitt)
- Kurs der allgemeinen klinischen Untersuchungen (PV)
- Aktuelle Forschungsthemen
- Klinischer Untersuchungskurs (1. Semester des zweiten Abschnittes) (PV)
-
2023 WS
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
A Systematic Comparison of Task Adaptation Techniques for Digital HistopathologyIn: Bioengineering Jg. 11 (2024) Nr. 1, 19Online Volltext: dx.doi.org/ (Open Access)
-
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1) : Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6In: Journal of the American Academy of Dermatology: JAAD (2024) in pressOnline Volltext: dx.doi.org/
-
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054) : Long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trialIn: The Lancet Oncology Jg. 25 (2024) Nr. 9, S. 1202 - 1212Online Volltext: dx.doi.org/
-
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanomaIn: European Journal of Cancer (EJC) Jg. 202 (2024) 113976Online Volltext: dx.doi.org/ (Open Access)
-
Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastasesIn: European Journal of Cancer (EJC) Jg. 205 (2024) 114101Online Volltext: dx.doi.org/
-
Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockadeIn: European Journal of Cancer (EJC) Jg. 200 (2024) 113536Online Volltext: dx.doi.org/ (Open Access)
-
BioKGrapher : Initial evaluation of automated knowledge graph construction from biomedical literatureIn: Computational and Structural Biotechnology Journal Jg. 24 (2024) S. 639 - 660Online Volltext: dx.doi.org/ (Open Access)
-
Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumorsIn: Clinical and Translational Science (CTS) Jg. 17 (2024) Nr. 2, e13736Online Volltext: dx.doi.org/ (Open Access)
-
COLUMBUS 7-year update : A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanomaIn: European Journal of Cancer (EJC) Jg. 204 (2024) 114073Online Volltext: dx.doi.org/ (Open Access)
-
Case report: : Durable complete response of a mucosal melanoma of the rectum after neoadjuvant immunotherapy with ipilimumab plus nivolumabIn: Frontiers in Immunology Jg. 15 (2024) 1369190Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Clinical and genetic characteristics of BAP1-mutated non-uveal and uveal melanomaIn: Frontiers in Immunology Jg. 15 (2024) 1383125Online Volltext: dx.doi.org/ (Open Access)
-
Comparison of visual diagnostic accuracy of dermatologists practicing in Germany in patients with light skin and skin of colorIn: Scientific Reports Jg. 14 (2024) Nr. 1, 8740Online Volltext: dx.doi.org/ (Open Access)
-
Deep learning based histological classification of adnex tumorsIn: European Journal of Cancer (EJC) Jg. 196 (2024) 113431Online Volltext: dx.doi.org/
-
Determining the cut-off value for the Minimal Documentation System (MIDOS2) screening tool to initiate specialized palliative care based on patient’s subjective need for palliative support and symptom burden in inpatients with advanced cancerIn: Journal of Cancer Research and Clinical Oncology Jg. 150 (2024) Nr. 7, 360Online Volltext: dx.doi.org/ (Open Access)
-
Die interdisziplinäre Behandlung von HautkrebsIn: Laryngo-Rhino-Otologie Jg. 103 (2024) Nr. S 01, S. S100 - S124Online Volltext: dx.doi.org/ (Open Access)
-
Drivers and barriers of patients’ acceptance of video consultation in cancer careIn: Digital Health Jg. 10 (2024)Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Early versus late response to PD-1-based immunotherapy in metastatic melanomaIn: European Journal of Cancer (EJC) Jg. 210 (2024) 114295Online Volltext: dx.doi.org/ (Open Access)
-
Federated Learning for Decentralized Artificial Intelligence in Melanoma DiagnosticsIn: JAMA Dermatology Jg. 160 (2024) Nr. 3, S. 303 - 311Online Volltext: dx.doi.org/ (Open Access)
-
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III MelanomaIn: The New England Journal of Medicine (2024) in pressOnline Volltext: dx.doi.org/
-
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumorsIn: Journal for ImmunoTherapy of Cancer Jg. 12 (2024) Nr. 3, e007364Online Volltext: dx.doi.org/ (Open Access)
-
First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma : An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial DataIn: Journal of Clinical Oncology (JCO) Jg. 42 (2024) Nr. 33, S. 3926 - 3934Online Volltext: dx.doi.org/ (Open Access)
-
First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma : Safety lead-in results from the randomized phase III STARBOARD studyIn: European Journal of Cancer (EJC) Jg. 213 (2024) 115070Online Volltext: dx.doi.org/ (Open Access)
-
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinomaIn: Journal for ImmunoTherapy of Cancer Jg. 12 (2024) Nr. 3, e008325Online Volltext: dx.doi.org/ (Open Access)
-
Influence of adjuvant therapies on organ-specific recurrence of cutaneous melanoma : A multicenter study on 1383 patients of the prospective DeCOG registry ADORegIn: International Journal of Cancer Jg. 155 (2024) Nr. 10, S. 1808 - 1823Online Volltext: dx.doi.org/ (Open Access)
-
Loss of Pip4k2c confers liver-metastatic organotropism through insulin-dependent PI3K-AKT pathway activationIn: Nature Cancer Jg. 5 (2024) Nr. 3, S. 433 - 447Online Volltext: dx.doi.org/
-
Loss of p14 diminishes immunogenicity in melanoma via non‐canonical Wnt signaling by reducing the peptide surface densityIn: Molecular Oncology (2024) in pressOnline Volltext: dx.doi.org/ (Open Access)
-
Merkel-cell carcinoma : ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-upIn: ESMO Open Jg. 9 (2024) Nr. 5, 102977Online Volltext: dx.doi.org/ (Open Access)
-
Mitigating cognitive bias with clinical decision support systems : An experimental studyIn: Journal of Decision Systems Jg. 33 (2024) Nr. 3, S. 439 - 458Online Volltext: dx.doi.org/
-
Neurofeedback Reduces P300 Amplitudes to Intensely Emotive Pictures in Depressed Cancer PatientsIn: Clinical EEG and Neuroscience (2024) in pressOnline Volltext: dx.doi.org/ (Open Access)
-
Orthanq: transparent and uncertainty-aware haplotype quantification with application in HLA-typingIn: BMC Bioinformatics Jg. 25 (2024) Nr. 1, 240Online Volltext: dx.doi.org/ (Open Access)
-
Pathogenic mitochondrial DNA mutations inhibit melanoma metastasisIn: Science Advances Jg. 10 (2024) Nr. 44, eadk8801Online Volltext: dx.doi.org/ (Open Access)
-
Patients’ and dermatologists’ preferences in artificial intelligence–driven skin cancer diagnostics : A prospective multicentric survey studyIn: Journal of the American Academy of Dermatology: JAAD Jg. 91 (2024) Nr. 2, S. 366 - 370Online Volltext: dx.doi.org/ (Open Access)
-
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma : Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 StudyIn: Journal of Clinical Oncology (JCO) Jg. 42 (2024) Nr. 14, S. 1619 - 1624Online Volltext: dx.doi.org/ (Open Access)
-
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma : Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trialIn: Journal for ImmunoTherapy of Cancer Jg. 12 (2024) Nr. 3, e007501Online Volltext: dx.doi.org/ (Open Access)
-
Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanomaIn: European Journal of Cancer (EJC) Jg. 201 (2024) 113585Online Volltext: dx.doi.org/
-
Prognostic value of patient-reported outcomes in advanced or metastatic melanoma patients treated with immunotherapy : Findings from the CheckMate-067 studyIn: European Journal of Cancer (EJC) Jg. 213 (2024) 115099Online Volltext: dx.doi.org/ (Open Access)
-
Prospective multicenter study using artificial intelligence to improve dermoscopic melanoma diagnosis in patient careIn: Communications Medicine Jg. 4 (2024) Nr. 1, 177Online Volltext: dx.doi.org/ (Open Access)
-
Psychosocial distress and psychosocial resources in couples facing non-melanoma skin cancers and malignant melanomaIn: Journal of Psychosocial Oncology (2024) in pressOnline Volltext: dx.doi.org/
-
Requirements for a dashboard optimized for melanoma patient care through user-centered context explorationIn: Scientific Reports Jg. 14 (2024) Nr. 1, 17471Online Volltext: dx.doi.org/ (Open Access)
-
Retrotransposons are co-opted to activate hematopoietic stem cells and erythropoiesisIn: Science Jg. 386 (2024) Nr. 6722, S. eado6836Online Volltext: dx.doi.org/
-
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors : Findings from a phase 1/1b studyIn: Clinical and Translational Science (CTS) Jg. 17 (2024) Nr. 6, e13854Online Volltext: dx.doi.org/ (Open Access)
-
Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsyIn: European Journal of Cancer (EJC) Jg. 202 (2024) 113989Online Volltext: dx.doi.org/ (Open Access)
-
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trialIn: European Journal of Cancer (EJC) Jg. 211 (2024) 114327Online Volltext: dx.doi.org/
-
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomasIn: European Journal of Cancer (EJC) Jg. 208 (2024) 114208Online Volltext: dx.doi.org/ (Open Access)
-
Skin cancers are the most frequent cancers in fair-skinned populations, but we can prevent themIn: European Journal of Cancer (EJC) Jg. 204 (2024) 114074Online Volltext: dx.doi.org/ (Open Access)
-
T lymphocyte recruitment to melanoma brain tumors depends on distinct venous vesselsIn: Immunity (2024) in pressOnline Volltext: dx.doi.org/ (Open Access)
-
The Association of HIV-Specific Risk Factors with Cardiovascular Events in Addition to Traditional Risk Factors in People Living with HIVIn: AIDS Research and Human Retroviruses Jg. 40 (2024) Nr. 4, S. 235 - 245Online Volltext: dx.doi.org/
-
The Mappability of Clinical Real-World Data of Patients with Melanoma to Oncological Fast Healthcare Interoperability Resources (FHIR) Profiles : A Single-Center Interoperability StudyIn: Informatics Jg. 11 (2024) Nr. 3, 42Online Volltext: dx.doi.org/ (Open Access)
-
The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrationsIn: European Journal of Cancer (EJC) Jg. 202 (2024) 113984Online Volltext: dx.doi.org/ (Open Access)
-
The side effect registry immuno-oncology (SERIO) : A tool for systematic analysis of immunotherapy-induced side effectsIn: European Journal of Cancer (EJC) Jg. 199 (2024) 113505Online Volltext: dx.doi.org/
-
Tinea capitis due to Trichophyton soudanense and Microsporum audouinii : A surprising findingIn: JEADV Clinical Practice Jg. 3 (2024) Nr. 3, Skin Diversity, S. 887 - 890Online Volltext: dx.doi.org/ (Open Access)
-
Using multiple real-world dermoscopic photographs of one lesion improves melanoma classification via deep learningIn: Journal of the American Academy of Dermatology: JAAD Jg. 90 (2024) Nr. 5, S. 1028 - 1031Online Volltext: dx.doi.org/ (Open Access)
-
Active Remodeling of Capillary Endothelium via Cancer Cell-Derived MMP9 Promotes Metastatic Brain ColonizationIn: Cancer Research Jg. 83 (2023) Nr. 8, S. 1299 - 1314Online Volltext: dx.doi.org/ (Open Access)
-
Adjuvant Therapy of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Patients with Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)In: Journal of Clinical Oncology (JCO) Jg. 41 (2023) Nr. 3, S. 517 - 527Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O) : disease-free survival results from a randomised, open-label, phase 2 trialIn: Lancet Jg. 402 (2023) Nr. 10404, S. 798 - 808Online Volltext: dx.doi.org/
-
Adjuvant treatment and outcome of stage III melanoma patients : Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) studyIn: European Journal of Cancer (EJC) Jg. 191 (2023) 112957Online Volltext: dx.doi.org/
-
Advancements in melanoma cancer metastasis modelsIn: Pigment Cell and Melanoma Research Jg. 36 (2023) Nr. 2, S. 206 - 223Online Volltext: dx.doi.org/ (Open Access)
-
Alternatives and reduced need for sentinel lymph node biopsy (SLNB) staging for melanomaIn: European Journal of Cancer (EJC) Jg. 182 (2023) S. 163 - 169Online Volltext: dx.doi.org/
-
Analyses of non-coding somatic drivers in 2,658 cancer whole genomesIn: Nature Jg. 578 (2023) Nr. 7793, S. 102 - 111Online Volltext: dx.doi.org/
-
Author Correction : Genomic basis for RNA alterations in cancerIn: Nature Jg. 614 (2023) Nr. 7948, S. E37Online Volltext: dx.doi.org/
-
Author Correction : The evolutionary history of 2,658 cancersIn: Nature Jg. 614 (2023) S. E42Online Volltext: dx.doi.org/
-
Author Correction : Patterns of somatic structural variation in human cancer genomesIn: Nature Jg. 614 (2023) Nr. 7948, S. E38Online Volltext: dx.doi.org/ (Open Access)
-
Author Correction : Butler enables rapid cloud-based analysis of thousands of human genomesIn: Nature Biotechnology Jg. 41 (2023) Nr. 4, S. 577Online Volltext: dx.doi.org/
-
Author Correction: : The repertoire of mutational signatures in human cancerIn: Nature Jg. 614 (2023) S. E41Online Volltext: dx.doi.org/ (Open Access)
-
Author Correction: Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencingIn: Nature Genetics Jg. 55 (2023) Nr. 6, 1076Online Volltext: dx.doi.org/ (Open Access)
-
Author Correction: Comprehensive molecular characterization of mitochondrial genomes in human cancersIn: Nature Genetics Jg. 55 (2023) Nr. 6, S. 1078Online Volltext: dx.doi.org/ (Open Access)
-
Author Correction: Disruption of chromatin folding domains by somatic genomic rearrangements in human cancerIn: Nature Genetics Jg. 55 (2023) Nr. 6, S. 1079Online Volltext: dx.doi.org/ (Open Access)
-
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanomaIn: Nature Cancer Jg. 4 (2023) Nr. 9, S. 1395Online Volltext: dx.doi.org/ (Open Access)
-
Author Correction: Pan-cancer analysis of whole genomesIn: Nature Jg. 614 (2023) Nr. 7948, S. E39Online Volltext: dx.doi.org/ (Open Access)
-
Author Correction: Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotranspositionIn: Nature Genetics Jg. 55 (2023) Nr. 6, 1080Online Volltext: dx.doi.org/ (Open Access)
-
Author Correction: The landscape of viral associations in human cancersIn: Nature Genetics Jg. 55 (2023) Nr. 6, S. 1077Online Volltext: dx.doi.org/ (Open Access)
-
B-cell lymphoma extra-large (Bcl-xL) is a promising drug target in Merkel cell carcinomaIn: British Journal of Dermatology: BJD (2023)Online Volltext: dx.doi.org/
-
BRAF inhibitor cessation prior to disease progression in metastatic melanoma : Long-term outcomesIn: European Journal of Cancer (EJC) Jg. 179 (2023) S. 87 - 97Online Volltext: dx.doi.org/
-
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREGIn: Journal for ImmunoTherapy of Cancer Jg. 11 (2023) Nr. 4,Online Volltext: dx.doi.org/ (Open Access)
-
COLUMBUS 5-year update : a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAFIn: Future Oncology Jg. 19 (2023) Nr. 16, S. 1091 - 1098Online Volltext: dx.doi.org/ (Open Access)
-
COMBI-r : A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant MelanomaIn: Cancers Jg. 15 (2023) Nr. 18, 4436Online Volltext: dx.doi.org/ (Open Access)
-
COVID-19 vaccination in psoriasis patients receiving systemic treatment : A prospective single-center studyIn: Frontiers in Immunology Jg. 14 (2023) S. 1107438Online Volltext: dx.doi.org/ (Open Access)
-
Cancer Patients’ Age-Related Benefits from Mobile Neurofeedback-Therapy in Quality of Life and Self-efficacy : A Clinical Waitlist Control StudyIn: Applied Psychophysiology Biofeedback Jg. 48 (2023) Nr. 2, S. 217 - 227Online Volltext: dx.doi.org/ (Open Access)
-
Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemicIn: Journal of Cancer Research and Clinical Oncology Jg. 149 (2023) Nr. 2, S. 913 - 919Online Volltext: dx.doi.org/ (Open Access)
-
Changes in body mass index, weight, and waist-to-hip ratio over five years in HIV-positive individuals in the HIV Heart Aging Study compared to the general populationIn: Infection - A Journal of Infectious Disease Jg. 51 (2023) Nr. 4, S. 1081 - 1091Online Volltext: dx.doi.org/ (Open Access)
-
Characterisation and outcome of RAC1 mutated melanomaIn: European Journal of Cancer (EJC) Jg. 183 (2023) S. 1 - 10Online Volltext: dx.doi.org/
-
Clinical, histopathological and molecular features of dedifferentiated melanomas : An EORTC Melanoma Group Retrospective AnalysisIn: European Journal of Cancer (EJC) Jg. 187 (2023) S. 7 - 14Online Volltext: dx.doi.org/
-
Combined immunotherapy with ipilimumab plus nivolumab in metastatic PD-1/PD-L1-refractory Merkel cell carcinoma : a case reportIn: International Journal of Dermatology Jg. 63 (2023) Nr. 2, S. e69 - e71Online Volltext: dx.doi.org/
-
Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencingIn: Nature Genetics Jg. 52 (2023) S. 331 - 341Online Volltext: dx.doi.org/ (Open Access)
-
Comprehensive molecular characterization of mitochondrial genomes in human cancersIn: Nature Genetics Jg. 52 (2023) S. 342 - 352Online Volltext: dx.doi.org/ (Open Access)
-
Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma : Part 2 of the Randomized, Open-Label, Phase III COLUMBUS TrialIn: Journal of Clinical Oncology (JCO) Jg. 41 (2023) Nr. 29, S. 4621 - 4631Online Volltext: dx.doi.org/ (Open Access)
-
Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma ADOREG/TRIM : Analysis of the DeCOG prospective multicenter cohort studyIn: EBioMedicine Jg. 96 (2023) 104774Online Volltext: dx.doi.org/ (Open Access)
-
Database for queries of melanoma cohorts with molecular and clinical dataIn: Pigment Cell and Melanoma Research Jg. 36 (2023) Nr. 2, S. 252 - 258Online Volltext: dx.doi.org/ (Open Access)
-
Deep learning detection of melanoma metastases in lymph nodesIn: European Journal of Cancer (EJC) Jg. 188 (2023) S. 161 - 170Online Volltext: dx.doi.org/
-
Deep learning in computational dermatopathology of melanoma : A technical systematic literature reviewIn: Computers in Biology and Medicine Jg. 163 (2023) 107083Online Volltext: dx.doi.org/ (Open Access)
-
Disruption of chromatin folding domains by somatic genomic rearrangements in human cancerIn: Nature Genetics Jg. 52 (2023) Nr. 3, S. 294 - 305Online Volltext: dx.doi.org/ (Open Access)
-
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma : The ImmunoCobiVem phase 2 randomised trialIn: European Journal of Cancer (EJC) Jg. 190 (2023) 112941Online Volltext: dx.doi.org/
-
Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanomaIn: European Journal of Cancer (EJC) Jg. 181 (2023) S. 188 - 197Online Volltext: dx.doi.org/
-
Falling off the screening grid : Predictors for postponed utilization of psycho-oncological support in cancer patients and its implications for distress assessment and managementIn: Psycho-Oncology Jg. 32 (2023) Nr. 11, S. 1727 - 1735Online Volltext: dx.doi.org/ (Open Access)
-
Genomic basis for RNA alterations in cancerIn: Nature Jg. 578 (2023) Nr. 7793, S. 129 - 136Online Volltext: dx.doi.org/
-
Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanomaIn: Journal for ImmunoTherapy of Cancer Jg. 11 (2023) Nr. 4, e004150Online Volltext: dx.doi.org/ (Open Access)
-
HLA class II loss and JAK1/2 deficiency coevolve in melanoma leading to CD4 T cell and IFNγ cross-resistanceIn: Clinical Cancer Research Jg. 29 (2023) Nr. 15, S. 2894 - 2907Online Volltext: dx.doi.org/
-
Health literacy and information needs among German skin cancer patients in comparison to people without skin cancer : A surveyIn: JEADV Clinical Practice Jg. 2 (2023) Nr. 4, S. 830 - 838Online Volltext: dx.doi.org/ (Open Access)
-
Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma : RELATIVITY-047 trialIn: European Journal of Cancer (EJC) Jg. 187 (2023) S. 164 - 173Online Volltext: dx.doi.org/ (Open Access)
-
Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma : a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREGIn: European Journal of Cancer (EJC) Jg. 188 (2023) S. 140 - 151Online Volltext: dx.doi.org/
-
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitorsIn: Med Jg. 4 (2023) Nr. 2, S. 113 - 129.e7Online Volltext: dx.doi.org/ (Open Access)
-
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma : Results From the Expansion Arm of a Phase Ib, Open-Label StudyIn: Journal of Clinical Oncology (JCO) Jg. 41 (2023) Nr. 14, S. 2651 - 2660Online Volltext: dx.doi.org/
-
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanomaIn: Nature Cancer Jg. 4 (2023) Nr. 9, S. 1292 - 1308Online Volltext: dx.doi.org/ (Open Access)
-
Leptomeningeal metastasis from solid tumours : EANO–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upIn: ESMO Open Jg. 8 (2023) Nr. 5, 101624Online Volltext: dx.doi.org/ (Open Access)
-
Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoms : results from a retrospective multicenter trialIn: Frontiers of Medicine Jg. 17 (2023) Nr. 5, S. 878 - 888Online Volltext: dx.doi.org/ (Open Access)
-
Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanomaIn: European Journal of Cancer (EJC) Jg. 194 (2023) 113354Online Volltext: dx.doi.org/
-
Medikamentöse Therapie des inoperablen MelanomsIn: Die Onkologie Jg. 29 (2023) Nr. 8, S. 680 - 686Online Volltext: dx.doi.org/
-
Multimodal integration of image, epigenetic and clinical data to predict BRAF mutation status in melanomaIn: European Journal of Cancer (EJC) Jg. 183 (2023) S. 131 - 138Online Volltext: dx.doi.org/ (Open Access)
-
Multispectral optoacoustic tomography to differentiate between lymph node metastases and coronavirus-19 vaccine-associated lymphadenopathyIn: Journal of the European Academy of Dermatology and Venereology Jg. 37 (2023) Nr. 5: Special issue on melanoma: Immune check point and BRAF‐MEK inhibitors in melanoma, S. 907 - 913Online Volltext: dx.doi.org/ (Open Access)
-
Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous squamous-cell carcinoma : follow-up and survival outcomes of a single-arm, multicentre, phase 2 studyIn: The Lancet Oncology Jg. 24 (2023) Nr. 11, S. 1196 - 1205Online Volltext: dx.doi.org/
-
Neoadjuvant immunotherapy for melanoma is now ready for clinical practiceIn: Nature Medicine Jg. 29 (2023) Nr. 6, S. 1310 - 1312Online Volltext: dx.doi.org/
-
Neurofeedback Treatment Affects Affective Symptoms, But Not Perceived Cognitive Impairment in Cancer Patients : Results of an Explorative Randomized Controlled TrialIn: Integrative Cancer Therapies Jg. 22 (2023)Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy : Results From the Phase I/IIa RELATIVITY-020 TrialIn: Journal of Clinical Oncology (JCO) Jg. 41 (2023) Nr. 15, S. 2724 - 2735Online Volltext: dx.doi.org/ (Open Access)
-
One Website to Gather them All : Usability Testing of the New German SKin Cancer INFOrmation (SKINFO) Website - A Mixed-methods ApproachIn: Journal of Cancer Education Jg. 38 (2023) Nr. 4, S. 1264 - 1270Online Volltext: dx.doi.org/ (Open Access)
-
Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotranspositionIn: Nature Genetics Jg. 52 (2023) Nr. 3, S. 306 - 319Online Volltext: dx.doi.org/ (Open Access)
-
Patterns of somatic structural variation in human cancer genomesIn: Nature Jg. 578 (2023) Nr. 7793, S. 112 - 121Online Volltext: dx.doi.org/
-
Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafuspIn: European Journal of Cancer (EJC) Jg. 191 (2023) 112986Online Volltext: dx.doi.org/ (Open Access)
-
Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanomaIn: European Journal of Cancer (EJC) Jg. 189 (2023) 112900Online Volltext: dx.doi.org/ (Open Access)
-
Prognostic factors in the primary care of patients with Merkel cell carcinoma : A monocentric cohort study of 108 patients from a tertiary referral centreIn: JEADV Clinical Practice Jg. 2 (2023) Nr. 4, S. 810 - 818Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Proteasome inhibition potentiates Kv1.3 potassium channel expression as therapeutic target in drug-sensitive and -resistant human melanoma cellsIn: Biomedicine & Pharmacotherapy Jg. 168 (2023) 115635Online Volltext: dx.doi.org/ (Open Access)
-
Reduced Staphylococcus Abundance Characterizes the Lesional Microbiome of Actinic Keratosis Patients after Field-Directed TherapiesIn: Microbiology Spectrum Jg. 11 (2023) Nr. 3, e04401-22Online Volltext: dx.doi.org/ (Open Access)
-
Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and RecurrenceIn: Cancer Research Communications Jg. 3 (2023) Nr. 4, S. 672 - 683Online Volltext: dx.doi.org/ (Open Access)
-
TERT expression is associated with metastasis from thin primaries, exhausted CD4+ T cells in melanoma and with DNA repair across cancer entitiesIn: PLoS ONE Jg. 18 (2023) Nr. 7, e0281487Online Volltext: dx.doi.org/ (Open Access)
-
The "Intimarzt" (intimate doctor) Model Project : Anonymous Remote Diagnosis of Sexually Transmitted DiseasesIn: Deutsches Ärzteblatt international Jg. 120 (2023) Nr. 6, S. 94 - 95Online Volltext: dx.doi.org/ (Open Access)
-
The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunityIn: Cancer Cell Jg. 41 (2023) Nr. 7, S. 1207 - 1221.e12Online Volltext: dx.doi.org/ (Open Access)
-
The German Network for Personalized Medicine to enhance patient care and translational researchIn: Nature Medicine Jg. 29 (2023) Nr. 6, S. 1298 - 1301Online Volltext: dx.doi.org/
-
The Latest Option: Nivolumab and Relatlimab in Advanced MelanomaIn: Current Oncology Reports Jg. 25 (2023) Nr. 6, :647-657Online Volltext: dx.doi.org/ (Open Access)
-
The landscape of viral associations in human cancersIn: Nature Genetics (2023) Nr. 52, S. 320 - 330Online Volltext: dx.doi.org/ (Open Access)
-
The repertoire of mutational signatures in human cancerIn: Nature Jg. 578 (2023) Nr. 7793, S. 94 - 101Online Volltext: dx.doi.org/ (Open Access)
-
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimabIn: Journal of Translational Medicine Jg. 21 (2023) Nr. 1, 753Online Volltext: dx.doi.org/ (Open Access)
-
Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy : A multicenter study from the prospective skin cancer registry ADOREGIn: Journal for ImmunoTherapy of Cancer Jg. 11 (2023) Nr. 9, e007630Online Volltext: dx.doi.org/ (Open Access)
-
Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responsesIn: Immunity Jg. 56 (2023) Nr. 6, S. 1341 - 1358.e11Online Volltext: dx.doi.org/ (Open Access)
-
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED) : Final results of a randomised, double-blind, phase 2 trialIn: Lancet Jg. 400 (2022) Nr. 10358, S. 1117 - 1129Online Volltext: dx.doi.org/
-
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma : Health-related quality of life from the randomized phase 3 KEYNOTE-716 studyIn: European Journal of Cancer (EJC) (2022) in pressOnline Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Author Correction : Inferring structural variant cancer cell fractionIn: Nature Communications Jg. 13 (2022) 7568Online Volltext: dx.doi.org/ (Open Access)
-
Author Correction : Divergent mutational processes distinguish hypoxic and normoxic tumoursIn: Nature Communications Jg. 13 (2022) 7569Online Volltext: dx.doi.org/ (Open Access)
-
Author Correction : Combined burden and functional impact tests for cancer driver discovery using DriverPowerIn: Nature Communications Jg. 13 (2022) 7571Online Volltext: dx.doi.org/ (Open Access)
-
Author Correction : A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patternsIn: Nature Communications Jg. 13 (2022) 7573Online Volltext: dx.doi.org/ (Open Access)
-
Author Correction : Genomic footprints of activated telomere maintenance mechanisms in cancerIn: Nature Communications Jg. 13 (2022) 7574Online Volltext: dx.doi.org/ (Open Access)
-
Author Correction : High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterationsIn: Nature Communications Jg. 13 (2022) 7572Online Volltext: dx.doi.org/ (Open Access)
-
Author Correction : Integrative pathway enrichment analysis of multivariate omics dataIn: Nature Communications Jg. 13 (2022) 7570Online Volltext: dx.doi.org/ (Open Access)
-
Author Correction : Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSigIn: Nature Communications Jg. 13 (2022) 7567Online Volltext: dx.doi.org/ (Open Access)
-
Author Correction : Pathway and network analysis of more than 2500 whole cancer genomesIn: Nature Communications Jg. 13 (2022) 7566Online Volltext: dx.doi.org/ (Open Access)
-
Blood Eosinophils Are Associated with Efficacy of Targeted Therapy in Patients with Advanced MelanomaIn: Cancers Jg. 14 (2022) Nr. 9, 2294Online Volltext: dx.doi.org/ (Open Access)
-
COLUMBUS 5-Year Update : A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant MelanomaIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 36, S. 4178 - 4188Online Volltext: dx.doi.org/ (Open Access)
-
COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment : A prospective singlecenter study investigating seroconversion ratesIn: Frontiers in Oncology Jg. 12 (2022) 879876Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
CTLA-4 Blockade Resistance after Relatlimab and NivolumabIn: The New England Journal of Medicine Jg. 386 (2022) Nr. 17, S. 1668 - 1669Online Volltext: dx.doi.org/ (Open Access)
-
Checkpoint immunotherapy of cutaneous squamous cell carcinoma in patients suffering from chronic lymphocytic leukaemia : divergent outcomes in two men treated with PD-1 inhibitorsIn: Journal of the European Academy of Dermatology and Venereology Jg. 36 (2022) Nr. S1: Anti PD-1 Therapy of Advanced Cutaneous Squamous Cell Carcinoma, S. 41 - 44Online Volltext: dx.doi.org/ (Open Access)
-
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma : a retrospective multicentre analysisIn: European Journal of Cancer (EJC) Jg. 162 (2022) S. 22 - 33Online Volltext: dx.doi.org/
-
Circulating cell‐free messenger RNA enables non‐invasive pan‐tumour monitoring of melanoma therapy independent of the mutational genotypeIn: Clinical and Translational Medicine Jg. 12 (2022) Nr. 11, e1090Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic MelanomaIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 10, S. 1068 - 1080Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinomaIn: Journal for ImmunoTherapy of Cancer Jg. 10 (2022) Nr. 1, e003198Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Clinical and pathological characteristics of familial melanoma with germline TERT promoter variantsIn: Pigment Cell and Melanoma Research Jg. 35 (2022) Nr. 6, S. 573 - 586Online Volltext: dx.doi.org/ (Open Access)
-
Comparison of mutation profiles in primary melanomas and corresponding nodal naevi using next-generation sequencingIn: Clinical and Experimental Dermatology (CED) Jg. 47 (2022) Nr. 2, S. 373 - 380Online Volltext: dx.doi.org/ (Open Access)
-
Corrigendum to ‘Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)’In: European Journal of Cancer (EJC) Jg. 160 (2022) S. 287 - 288Online Volltext: dx.doi.org/ (Open Access)
-
Corrigendum to “Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group Molecular Diagnostics and Therapy”In: European Journal of Cancer (EJC) Jg. 162 (2022) S. 245 - 246Online Volltext: dx.doi.org/
-
Deep Learning Assisted Diagnosis of Onychomycosis on Whole-Slide ImagesIn: Journal of Fungi Jg. 8 (2022) Nr. 9, 912Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions : Non-interventional Cohort Study JONASIn: Acta Dermato-Venereologica Jg. 102 (2022) adv00695Online Volltext: dx.doi.org/ (Open Access)
-
Evaluation of a Deep Learning Approach to Differentiate Bowen’s Disease and Seborrheic KeratosisIn: Cancers Jg. 14 (2022) Nr. 14, 3518Online Volltext: dx.doi.org/ (Open Access)
-
Explainable artificial intelligence in skin cancer recognition : A systematic reviewIn: European Journal of Cancer (EJC) Jg. 167 (2022) S. 54 - 69Online Volltext: dx.doi.org/ (Open Access)
-
Genetic and Clinical Characteristics of ARID1A Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient SurvivalIn: Cancers Jg. 14 (2022) Nr. 9, 2090Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Genetic and Methylation Analysis of CTNNB1 in Benign and Malignant Melanocytic LesionsIn: Cancers Jg. 14 (2022) Nr. 17, 4066Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumorsIn: International Journal of Cancer Jg. 151 (2022) Nr. 9, S. 1542 - 1554Online Volltext: dx.doi.org/ (Open Access)
-
Genetic characterization of advanced conjunctival melanoma and response to systemic treatmentIn: European Journal of Cancer (EJC) Jg. 166 (2022) S. 60 - 72Online Volltext: dx.doi.org/
-
Immune Checkpoint Blockade for Metastatic Uveal Melanoma : Re-Induction following Resistance or ToxicityIn: Cancers Jg. 14 (2022) Nr. 3, 518Online Volltext: dx.doi.org/ (Open Access)
-
Immune checkpoint blockade for organ-transplant recipients with cancer : A reviewIn: European Journal of Cancer (EJC) Jg. 175 (2022) S. 326 - 335Online Volltext: dx.doi.org/ (Open Access)
-
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis : a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREGIn: Journal for ImmunoTherapy of Cancer Jg. 10 (2022) Nr. 6, e004509Online Volltext: dx.doi.org/ (Open Access)
-
Innate immune receptor signaling induces transient melanoma dedifferentiation while preserving immunogenicityIn: Journal for ImmunoTherapy of Cancer Jg. 10 (2022) Nr. 6, e003863Online Volltext: dx.doi.org/ (Open Access)
-
Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma : A multicenter study of the prospective skin cancer registry ADOREGIn: Journal for ImmunoTherapy of Cancer Jg. 10 (2022) Nr. 11, e005930Online Volltext: dx.doi.org/ (Open Access)
-
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced MelanomaIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 2, S. 127 - 137Online Volltext: dx.doi.org/ (Open Access)
-
MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma : An evaluation of the multicenter prospective skin cancer registry ADOREGIn: European Journal of Cancer (EJC) Jg. 167 (2022) S. 32 - 41Online Volltext: dx.doi.org/ (Open Access)
-
MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma : A multi-centre, retrospective studyIn: European Journal of Cancer (EJC) Jg. 166 (2022) S. 24 - 32Online Volltext: dx.doi.org/
-
Management of partial and non-responding cutaneous squamous cell carcinomaIn: Journal of the European Academy of Dermatology and Venereology Jg. 36 (2022) Nr. S1, S. 29 - 34Online Volltext: dx.doi.org/ (Open Access)
-
Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanomaIn: Cancer Imaging Jg. 22 (2022) Nr. 1,Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Model soups improve performance of dermoscopic skin cancer classifiersIn: European Journal of Cancer (EJC) Jg. 173 (2022) S. 307 - 316Online Volltext: dx.doi.org/ (Open Access)
-
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell CarcinomaIn: The New England Journal of Medicine Jg. 387 (2022) Nr. 17, S. 1557 - 1568Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
PIVOT-12 : A Phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrenceIn: Future Oncology Jg. 18 (2022) Nr. 8, S. 903 - 913Online Volltext: dx.doi.org/ (Open Access)
-
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716) : a randomised, double-blind, phase 3 trialIn: Lancet Jg. 399 (2022) Nr. 10336, S. 1718 - 1729Online Volltext: dx.doi.org/
-
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716) : distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trialIn: The Lancet Oncology Jg. 23 (2022) Nr. 11, S. 1378 - 1388Online Volltext: dx.doi.org/
-
Persister state-directed transitioning and vulnerability in melanoma
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Nature Communications Jg. 13 (2022) Nr. 1, S. 35 - 36 -
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts : Implications for Adjuvant TreatmentIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 32, S. 3741 - 3749Online Volltext: dx.doi.org/ (Open Access)
-
Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanomaIn: European Journal of Cancer (EJC) Jg. 165 (2022) S. 97 - 112Online Volltext: dx.doi.org/ (Open Access)
-
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic MelanomaIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 13, S. 1428 - 1438Online Volltext: dx.doi.org/ (Open Access)
-
Real-World Therapy with Pembrolizumab : Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in GermanyIn: Cancers Jg. 14 (2022) Nr. 7, 1804Online Volltext: dx.doi.org/ (Open Access)
-
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced MelanomaIn: The New England Journal of Medicine Jg. 386 (2022) Nr. 1, S. 24 - 34Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Reply to: Letter comments on: Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancersIn: European Journal of Cancer (EJC) Jg. 162 (2022) S. 243 - 244Online Volltext: dx.doi.org/
-
Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell CarcinomaIn: Journal of Nuclear Medicine (JNM) Jg. 63 (2022) Nr. 3, S. 396 - 398Online Volltext: dx.doi.org/ (Open Access)
-
Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma : A Multicenter, Retrospective Analysis from the German ADOReg RegistryIn: Cancers Jg. 14 (2022) Nr. 22, 5543Online Volltext: dx.doi.org/ (Open Access)
-
SIRT1‐mediated deacetylation of FOXO3a transcription factor supports pro‐angiogenic activity of interferon‐deficient tumor‐associated neutrophilsIn: International Journal of Cancer Jg. 150 (2022) Nr. 7, S. 1198 - 1211Online Volltext: dx.doi.org/ (Open Access)
-
STARBOARD : encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanomaIn: Future Oncology Jg. 18 (2022) Nr. 17, S. 2041 - 2051Online Volltext: dx.doi.org/ (Open Access)
-
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma : exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)In: Journal for ImmunoTherapy of Cancer Jg. 10 (2022) Nr. 6, e004226Online Volltext: dx.doi.org/ (Open Access)
-
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapyIn: European Journal of Cancer (EJC) Jg. 161 (2022) S. 99 - 107Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapyIn: European Heart Journal Jg. 43 (2022) Nr. 4, S. 316 - 329Online Volltext: dx.doi.org/
-
The Prognostic Relevance of PMCA4 Expression in Melanoma : Gender Specificity and Implications for Immune Checkpoint InhibitionIn: International Journal of Molecular Sciences (IJMS) Jg. 23 (2022) Nr. 6, 3324Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Update in the treatment of non-melanoma skin cancers : the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinomaIn: Journal for ImmunoTherapy of Cancer Jg. 10 (2022) Nr. 12, e005082Online Volltext: dx.doi.org/ (Open Access)
-
Validating Automatic Concept-Based Explanations for AI-Based Digital HistopathologyIn: Sensors Jg. 22 (2022) Nr. 14, 5346Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Web-based mindfulness and skills-based distress reduction for patients with cancer : study protocol of the multicentre, randomised, controlled confirmatory intervention trial ReductIn: BMJ Open Jg. 12 (2022) Nr. 6, e056973Online Volltext: dx.doi.org/ (Open Access)
-
A benchmark for neural network robustness in skin cancer classificationIn: European Journal of Cancer (EJC) Jg. 155 (2021) S. 191 - 199Online Volltext: dx.doi.org/ (Open Access)
-
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054) : health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trialIn: The Lancet Oncology Jg. 22 (2021) Nr. 5, S. 655 - 664Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054) : distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trialIn: The Lancet Oncology Jg. 22 (2021) Nr. 5, S. 643 - 654Online Volltext: dx.doi.org/
-
Allosteric and ATP-competitive MEK-inhibition in a novel spitzoid melanoma model with a raf-and phosphorylation-independent mutationIn: Cancers Jg. 13 (2021) Nr. 4, S. 829Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Anticancer innovative therapy congress : Highlights from the 10th anniversary editionIn: Cytokine & Growth Factor Reviews Jg. 59 (2021) S. 1 - 8Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition : Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 ImmunohistochemistryIn: Frontiers in Oncology Jg. 11 (2021) 725549Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib : results from a preplanned sensitivity analysisIn: BMC Cancer Jg. 21 (2021) Nr. 1, 1244Online Volltext: dx.doi.org/ (Open Access)
-
BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytesIn: Cancer Immunology, Immunotherapy Jg. 70 (2021) Nr. 6, S. 1635 - 1647Online Volltext: dx.doi.org/ (Open Access)
-
Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib : A clinical validation studyIn: The Lancet Oncology Jg. 22 (2021) Nr. 3, S. 370 - 380Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Classical and Variant Merkel Cell Carcinoma Cell Lines Display Different Degrees of Neuroendocrine Differentiation and Epithelial-Mesenchymal TransitionIn: Journal of Investigative Dermatology Jg. 141 (2021) Nr. 7, S. 1675 - 1686.e4Online Volltext: dx.doi.org/ (Open Access)
-
Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastasesIn: European Journal of Cancer (EJC) Jg. 152 (2021) S. 139 - 154Online Volltext: dx.doi.org/
-
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibitionIn: Journal for ImmunoTherapy of Cancer Jg. 9 (2021) Nr. 1, S. e001931Online Volltext: dx.doi.org/ (Open Access)
-
Combining CNN-based histologic whole slide image analysis and patient data to improve skin cancer classificationIn: European Journal of Cancer (EJC) Jg. 149 (2021) S. 94 - 101Online Volltext: dx.doi.org/ (Open Access)
-
Computed tomography-guided biopsy of radiologically unclear lesions in advanced skin cancer : A retrospective analysis of 47 casesIn: European Journal of Cancer (EJC) Jg. 150 (2021) S. 119 - 129Online Volltext: dx.doi.org/
-
Coronavirus disease 2019 vaccine mimics lymph node metastases in patients undergoing skin cancer follow-up : A monocentre studyIn: European Journal of Cancer (EJC) Jg. 154 (2021) S. 167 - 174Online Volltext: dx.doi.org/ (Open Access)
-
Deep learning approach to predict sentinel lymph node status directly from routine histology of primary melanoma tumoursIn: European Journal of Cancer (EJC) Jg. 154 (2021) S. 227 - 234Online Volltext: dx.doi.org/ (Open Access)
-
Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell responseIn: Proceedings of the National Academy of Sciences of the United States of America (PNAS) Jg. 118 (2021) Nr. 43, e2102849118Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic MelanomaIn: Frontiers in Oncology Jg. 11 (2021) 741993Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Discontinuation of braf/mek-directed targeted therapy after complete remission of metastatic melanoma : a retrospective multicenter adoreg studyIn: Cancers Jg. 13 (2021) Nr. 10, S. 2312Online Volltext: dx.doi.org/ (Open Access)
-
EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumoursIn: Annals of Oncology Jg. 32 (2021) Nr. 11, S. 1332 - 1347Online Volltext: dx.doi.org/ (Open Access)
-
Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma : A Retrospective Multicenter DeCOG StudyIn: Frontiers in Oncology Jg. 11 (2021) 672172Online Volltext: dx.doi.org/ (Open Access)
-
Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real-world conditions in Germany : The non-interventional study NIELSIn: Journal of the European Academy of Dermatology and Venereology Jg. 35 (2021) Nr. 8, S. 1678 - 1685Online Volltext: dx.doi.org/ (Open Access)
-
Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV⁶⁰⁰ mutant melanoma : safety and tolerability results from the phase I IMMU-TARGET trialIn: European Journal of Cancer (EJC) Jg. 158 (2021) S. 72 - 84Online Volltext: dx.doi.org/
-
Evaluation of the reporting quality of clinical practice guidelines on melanoma using the RIGHT checklistIn: Annals of Translational Medicine Jg. 9 (2021) Nr. 14, 1172Online Volltext: dx.doi.org/ (Open Access)
-
Factors influencing the adjuvant therapy decision : Results of a real-world multicenter data analysis of 904 melanoma patientsIn: Cancers Jg. 13 (2021) Nr. 10, S. 2319Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
GNA14, GNA11, and GNAQ Mutations Are Frequent in Benign but Not Malignant Cutaneous Vascular TumorsIn: Frontiers in Genetics Jg. 12 (2021) 663272Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition : A Descriptive Observational Retrospective Multicenter AnalysisIn: Frontiers in Oncology Jg. 11 (2021) 765608Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
High-resolution three-dimensional imaging for precise staging in melanomaIn: European Journal of Cancer (EJC) Jg. 159 (2021) S. 182 - 193Online Volltext: dx.doi.org/ (Open Access)
-
Immune checkpoint blockade for metastatic uveal melanoma : Patterns of response and survival according to the presence of hepatic and extrahepatic metastasisIn: Cancers Jg. 13 (2021) Nr. 13, 3359Online Volltext: dx.doi.org/ (Open Access)
-
Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanomaIn: European Journal of Cancer (EJC) Jg. 158 (2021) S. 225 - 233Online Volltext: dx.doi.org/ (Open Access)
-
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma : Extended follow-up of outcomes and quality of life analysisIn: Journal for ImmunoTherapy of Cancer Jg. 9 (2021) Nr. 8, e002757Online Volltext: dx.doi.org/ (Open Access)
-
Integrating patient data into skin cancer classification using convolutional neural networks : Systematic reviewIn: Journal of Medical Internet Research (JMIR) Jg. 23 (2021) Nr. 7, e20708Online Volltext: dx.doi.org/ (Open Access)
-
Integrative genomic analyses of patient-matched intracranial and extracranial metastases reveal a novel brain-specific landscape of genetic variants in driver genes of malignant melanomaIn: Cancers Jg. 13 (2021) Nr. 4, S. 731Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Kutanes Angiosarkom mit klinischem Bild eines Quincke-ÖdemsIn: Der Hautarzt Jg. 72 (2021) Nr. 9, S. 801 - 804Online Volltext: dx.doi.org/ (Open Access)
-
Leptomeningeal disease from melanoma : Poor prognosis despite new therapeutic modalitiesIn: European Journal of Cancer (EJC) Jg. 148 (2021) S. 395 - 404Online Volltext: dx.doi.org/
-
Male fertility during and after immune checkpoint inhibitor therapy : A cross-sectional pilot studyIn: European Journal of Cancer (EJC) Jg. 152 (2021) S. 41 - 48Online Volltext: dx.doi.org/
-
Melanoma Differentiation Trajectories Determine Sensitivity Toward Pre-Existing CD8⁺ Tumor-Infiltrating LymphocytesIn: Journal of Investigative Dermatology Jg. 141 (2021) Nr. 10, S. 2480 - 2489Online Volltext: dx.doi.org/ (Open Access)
-
Melanoma recurrence patterns and management after adjuvant targeted therapy : A multicentre analysisIn: British Journal of Cancer (BJC) Jg. 124 (2021) Nr. 3, S. 574 - 580Online Volltext: dx.doi.org/ (Open Access)
-
Mental health burden of german cancer patients before and after the outbreak of covid-19 : Predictors of mental health impairmentIn: International Journal of Environmental Research and Public Health = IJERPH Jg. 18 (2021) Nr. 5, 2318Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Merkel cell carcinoma-derived exosome-shuttle miR-375 induces fibroblast polarization by inhibition of RBPJ and p53In: Oncogene Jg. 40 (2021) Nr. 5, S. 980 - 996Online Volltext: dx.doi.org/ (Open Access)
-
Merkel-Zell-KarzinomIn: Der Onkologe Jg. 27 (2021) Nr. 6, S. 569 - 578Online Volltext: dx.doi.org/
-
Metastatic pigmented epithelioid melanocytoma in a 7-year-old femaleIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. 8, S. 1217 - 1219Online Volltext: dx.doi.org/ (Open Access)
-
Molecular pathology as a diagnostic aid in difficult-to-classify melanocytic tumours with spitzoid morphologyIn: European Journal of Cancer (EJC) Jg. 148 (2021) S. 340 - 347Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasionIn: Nature Genetics Jg. 53 (2021) Nr. 3, S. 332 - 341Online Volltext: dx.doi.org/; Online Volltext: dx.doi.org/ (Open Access)
-
Mutations in the IFNγ-JAK-STAT pathway causing resistance to immune checkpoint inhibitors in melanoma increase sensitivity to oncolytic virus treatmentIn: Clinical Cancer Research Jg. 27 (2021) Nr. 12, S. 3432 - 3442Online Volltext: dx.doi.org/ (Open Access)
-
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitorsIn: European Journal of Cancer (EJC) Jg. 159 (2021) S. 113 - 124Online Volltext: dx.doi.org/ (Open Access)
-
Nuclear receptor coactivator NCOA3 regulates UV radiation⇓induced DNA damage and melanoma susceptibilityIn: Cancer Research Jg. 81 (2021) Nr. 11, S. 2956 - 2969Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibitionIn: European Journal of Cancer (EJC) Jg. 148 (2021) S. 61 - 75Online Volltext: dx.doi.org/
-
Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries : A multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG)In: Journal of Cancer Research and Clinical Oncology Jg. 147 (2021) Nr. 6, S. 1763 - 1771Online Volltext: dx.doi.org/ (Open Access)
-
Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancersIn: European Journal of Cancer (EJC) Jg. 153 (2021) S. 234 - 241Online Volltext: dx.doi.org/ (Open Access)
-
Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib : Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)In: European Journal of Cancer (EJC) Jg. 152 (2021) S. 116 - 128Online Volltext: dx.doi.org/
-
Rare TERT Promoter Mutations Present in Benign and Malignant Cutaneous Vascular TumorsIn: Dermato Jg. 1 (2021) Nr. 1, S. 18 - 25Online Volltext: dx.doi.org/ (Open Access)
-
Reply to E. HindiéIn: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 8, S. 944 - 946Online Volltext: dx.doi.org/ (Open Access)
-
Response to comment : Molecular pathology as a diagnostic aid in difficult to classify melanocytic tumours with spitzoid morphologyIn: European Journal of Cancer (EJC) Jg. 157 (2021) S. 514 - 515Online Volltext: dx.doi.org/
-
Robustness of convolutional neural networks in recognition of pigmented skin lesionsIn: European Journal of Cancer (EJC) Jg. 145 (2021) S. 81 - 91Online Volltext: dx.doi.org/ (Open Access)
-
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus TrametinibIn: Clinical Cancer Research Jg. 27 (2021) Nr. 16, S. 4500 - 4510Online Volltext: dx.doi.org/ (Open Access)
-
Skin cancer classification via convolutional neural networks : Systematic review of studies involving human expertsIn: European Journal of Cancer (EJC) Jg. 156 (2021) S. 202 - 216Online Volltext: dx.doi.org/ (Open Access)
-
Surveillance of patients with conjunctival melanoma in German-speaking countries : A multinational survey of the German dermatologic cooperative oncology groupIn: European Journal of Cancer (EJC) Jg. 143 (2021) S. 43 - 45Online Volltext: dx.doi.org/
-
TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced MelanomaIn: Cancer Immunology Research Jg. 9 (2021) Nr. 10, S. 1202 - 1213Online Volltext: dx.doi.org/ (Open Access)
-
Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions : Findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanomaIn: Journal for ImmunoTherapy of Cancer Jg. 9 (2021) Nr. 3, S. e001621Online Volltext: dx.doi.org/ (Open Access)
-
Targeting the Atf7ip–Setdb1 complex augments antitumor immunity by boosting tumor immunogenicityIn: Cancer Immunology Research Jg. 9 (2021) Nr. 11, S. 1298 - 1315Online Volltext: dx.doi.org/ (Open Access)
-
The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patientsIn: European Journal of Cancer (EJC) Jg. 155 (2021) S. 268 - 280Online Volltext: dx.doi.org/
-
The predictive and prognostic significance of cell-free DNA concentration in melanomaIn: Journal of the European Academy of Dermatology and Venereology Jg. 35 (2021) Nr. 2, S. 387 - 395Online Volltext: dx.doi.org/ (Open Access)
-
A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patternsIn: Nature Communications Jg. 11 (2020) 728Online Volltext: dx.doi.org/ (Open Access)
-
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV⁶⁰⁰-mutant, stage III melanoma (COMBI-AD) : Exploratory biomarker analyses from a randomised, phase 3 trialIn: The Lancet Oncology Jg. 21 (2020) Nr. 3, S. 358 - 372Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED) : A randomised, double-blind, placebo-controlled, phase 2 trialIn: Lancet Jg. 395 (2020) Nr. 10236, S. 1558 - 1568Online Volltext: dx.doi.org/
-
Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary : Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trialIn: European Journal of Cancer (EJC) Jg. 133 (2020) S. 94 - 103Online Volltext: dx.doi.org/
-
Arenavirus Induced CCL5 Expression Causes NK Cell-Mediated Melanoma RegressionIn: Frontiers in Immunology Jg. 11 (2020) S. 1849Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Artificial Intelligence in Skin Cancer Diagnostics : The Patients' PerspectiveIn: Frontiers in Medicine Jg. 7 (2020) S. 233Online Volltext: dx.doi.org/ (Open Access)
-
Association between Immune-Related Adverse Events and Recurrence-Free Survival among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo : A Secondary Analysis of a Randomized Clinical TrialIn: JAMA Oncology Jg. 6 (2020) Nr. 4, S. 519 - 527Online Volltext: dx.doi.org/ (Open Access)
-
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced Melanoma : Pooled Analysis of 3 Clinical TrialsIn: JAMA Oncology Jg. 6 (2020) Nr. 8, S. 1256 - 1264Online Volltext: dx.doi.org/ (Open Access)
-
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaIn: Nature Medicine Jg. 26 (2020) Nr. 7, S. 1147Online Volltext: dx.doi.org/ (Open Access)
-
Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samplesIn: Nature Communications Jg. 11 (2020) Nr. 1, S. 6232Online Volltext: dx.doi.org/ (Open Access)
-
Author Correction: Tertiary lymphoid structures improve immunotherapy and survival in melanomaIn: Nature Jg. 580 (2020) Nr. 7801, S. E1Online Volltext: dx.doi.org/ (Open Access)
-
COVID-19-Related Fear and Health-Related Safety Behavior in Oncological PatientsIn: Frontiers in Psychology Jg. 11 (2020) S. 1984Online Volltext: dx.doi.org/ (Open Access)
-
Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumoursIn: Nature Communications Jg. 11 (2020) Nr. 1, S. 1335Online Volltext: dx.doi.org/ (Open Access)
-
Cemiplimab in locally advanced cutaneous squamous cell carcinoma : results from an open-label, phase 2, single-arm trialIn: The Lancet Oncology Jg. 21 (2020) Nr. 2, S. 294 - 305Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Chondroitin polymerizing factor (CHPF) promotes development of malignant melanoma through regulation of CDK1In: Cell Death and Disease Jg. 11 (2020) Nr. 7, 496Online Volltext: dx.doi.org/ (Open Access)
-
Combination immunotherapy with anti-PD-L1 antibody and depletion of regulatory T cells during acute viral infections results in improved virus control but lethal immunopathologyIn: PLoS Pathogens Jg. 16 (2020) Nr. 3, e1008340Online Volltext: dx.doi.org/ (Open Access)
-
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma : safety run-in and biomarker cohorts of COMBI-iIn: Nature Medicine Jg. 26 (2020) Nr. 10, S. 1557 - 1563Online Volltext: dx.doi.org/
-
Combined burden and functional impact tests for cancer driver discovery using DriverPowerIn: Nature Communications Jg. 11 (2020) 734Online Volltext: dx.doi.org/ (Open Access)
-
Dedifferentiated melanomas : Morpho-phenotypic profile, genetic reprogramming and clinical implicationsIn: Cancer Treatment Reviews Jg. 88 (2020) S. 102060Online Volltext: dx.doi.org/
-
Divergent mutational processes distinguish hypoxic and normoxic tumoursIn: Nature Communications Jg. 11 (2020) 737Online Volltext: dx.doi.org/ (Open Access)
-
Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy : Increased rate and mimicker of metastasisIn: European Journal of Cancer (EJC) Jg. 131 (2020) S. 18 - 26Online Volltext: dx.doi.org/
-
Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade : A Case ReportIn: Frontiers in Oncology Jg. 10 (2020) S. 592609Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
ECG Changes in Melanoma Patients Undergoing Cancer Therapy : Data from the ECoR RegistryIn: Journal of Clinical Medicine (JCM) Jg. 9 (2020) Nr. 7, 2060Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
ER-aminopeptidase 1 determines the processing and presentation of an immunotherapy-relevant melanoma epitopeIn: European Journal of Immunology Jg. 50 (2020) Nr. 2, S. 270 - 283Online Volltext: dx.doi.org/ (Open Access)
-
Effect of a Face-Aging Mobile App-Based Intervention on Skin Cancer Protection Behavior in Secondary Schools in Brazil : A Cluster-Randomized Clinical TrialIn: JAMA Dermatology Jg. 156 (2020) Nr. 7, S. 737 - 745Online Volltext: dx.doi.org/ (Open Access)
-
Effects of Label Noise on Deep Learning-Based Skin Cancer ClassificationIn: Frontiers in Medicine Jg. 7 (2020) S. 177Online Volltext: dx.doi.org/ (Open Access)
-
Efficacy of cold atmospheric plasma vs. diclofenac 3% gel in patients with actinic keratoses : A prospective, randomized and rater-blinded study (ACTICAP)In: Journal of the European Academy of Dermatology and Venereology Jg. 34 (2020) Nr. 12, S. E844 - E846Online Volltext: dx.doi.org/
-
Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanomaIn: Annals of Oncology Jg. 31 (2020) Nr. 1, S. 144 - 152Online Volltext: dx.doi.org/ (Open Access)
-
Externe wissenschaftliche Evaluation der ersten Teledermatologie-App ohne direkten Patientenkontakt in Deutschland („Online Hautarzt – AppDoc“)In: Der Hautarzt Jg. 71 (2020) Nr. 11, S. 887 - 897Online Volltext: dx.doi.org/ (Open Access)
-
Fatal swelling of the groin – Clear cell sarcoma : A rare but important differential diagnosis to malignant melanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. 10, S. 1165 - 1168Online Volltext: dx.doi.org/ (Open Access)
-
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III MelanomaIn: The New England Journal of Medicine Jg. 383 (2020) Nr. 12, S. 1139 - 1148Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced MelanomaIn: Journal of Clinical Oncology (JCO) Jg. 38 (2020) Nr. 33, S. 3937 - 3946Online Volltext: dx.doi.org/ (Open Access)
-
GNAQ and GNA11 mutant nonuveal melanoma : A subtype distinct from both cutaneous and uveal melanomaIn: British Journal of Dermatology: BJD Jg. 183 (2020) Nr. 5, S. 928 - 939Online Volltext: dx.doi.org/ (Open Access)
-
Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibilityIn: Nature Genetics Jg. 52 (2020) Nr. 5, S. 494 - 504Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Genomic footprints of activated telomere maintenance mechanisms in cancerIn: Nature Communications Jg. 11 (2020) 733Online Volltext: dx.doi.org/ (Open Access)
-
Healthcare Resource Utilization in Patients Treated with Encorafenib PLUS Binimetinib for BRAF-Mutant Metastatic Melanoma : DATA from Columbus, a Phase 3 Trial in BRAF-Mutant MelanomaIn: Value in Health Jg. 23 (2020) Nr. Suppl. 2, S. 428Online Volltext: dx.doi.org/ (Open Access)
-
High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterationsIn: Nature Communications Jg. 11 (2020) 736Online Volltext: dx.doi.org/ (Open Access)
-
Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy : A retrospective multicenter DeCOG study of 84 patientsIn: Journal for ImmunoTherapy of Cancer Jg. 8 (2020) Nr. 2, S. e000897Online Volltext: dx.doi.org/ (Open Access)
-
Immuntherapie beim malignen MelanomIn: Der Internist Jg. 61 (2020) Nr. 7, S. 669 - 675Online Volltext: dx.doi.org/ (Open Access)
-
Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma : A multicenter retrospective cohort study of the DeCOGIn: Journal for ImmunoTherapy of Cancer Jg. 8 (2020) Nr. 1, S. e000395Online Volltext: dx.doi.org/ (Open Access)
-
Indirect treatment comparison of nivolumab versus placebo for the adjuvant treatment of melanomaIn: European Journal of Cancer (EJC) Jg. 132 (2020) S. 176 - 186Online Volltext: dx.doi.org/ (Open Access)
-
Inferring structural variant cancer cell fractionIn: Nature Communications Jg. 11 (2020) 730Online Volltext: dx.doi.org/ (Open Access)
-
Inhibition of haspin kinase promotes cell-intrinsic and extrinsic antitumor activityIn: Cancer Research Jg. 80 (2020) Nr. 4, S. 798 - 810Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Integrated molecular drivers coordinate biological and clinical states in melanomaIn: Nature Genetics Jg. 52 (2020) Nr. 12, S. 1373 - 1383Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Integrative pathway enrichment analysis of multivariate omics dataIn: Nature Communications Jg. 11 (2020) 735Online Volltext: dx.doi.org/ (Open Access)
-
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy : Analysis from phase 2 and 3 clinical trialsIn: European Journal of Cancer (EJC) Jg. 125 (2020) S. 114 - 120Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma : Updated results from the EORTC 1325-MG/KEYNOTE-054 trialIn: Journal of Clinical Oncology (JCO) Jg. 38 (2020) Nr. 33, S. 3925 - 3936Online Volltext: dx.doi.org/ (Open Access)
-
Macrophages/microglia represent the major source of indolamine 2,3-dioxygenase expression in melanoma metastases of the brainIn: Frontiers in Immunology Jg. 11 (2020) Article-No: 120Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Malignes Melanom : Stellenwert der BRAF-Inhibition beim malignen MelanomIn: Der Onkologe Jg. 26 (2020) Nr. 8, S. 713 - 720Online Volltext: dx.doi.org/
-
Melanoma brain metastases – Interdisciplinary management recommendations 2020In: Cancer Treatment Reviews Jg. 89 (2020) S. 102083Online Volltext: dx.doi.org/
-
Metabolic heterogeneity confers differences in melanoma metastatic potentialIn: Nature Jg. 577 (2020) Nr. 7788, S. 115 - 120Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Onkokardiologie : Neue Herausforderungen, neue MöglichkeitenIn: Herz: Cardiovascular Diseases Jg. 45 (2020) S. 619 - 625Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanomaIn: Journal for ImmunoTherapy of Cancer Jg. 8 (2020) Nr. 1,Online Volltext: dx.doi.org/ (Open Access)
-
Pan-cancer analysis of whole genomesIn: Nature Jg. 578 (2020) Nr. 7793, S. 82 - 93Online Volltext: dx.doi.org/ (Open Access)
-
Pathway and network analysis of more than 2500 whole cancer genomesIn: Nature Communications Jg. 11 (2020) 729Online Volltext: dx.doi.org/ (Open Access)
-
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma : Primary analysis of fixed-dosing, long-term outcome of weight-based dosingIn: Journal for ImmunoTherapy of Cancer Jg. 8 (2020) Nr. 1, S. e000775Online Volltext: dx.doi.org/ (Open Access)
-
Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell CarcinomaIn: Clinical Cancer Research Jg. 26 (2020) Nr. 9, S. 2257 - 2267Online Volltext: dx.doi.org/ (Open Access)
-
Prognosis of patients with stage III melanoma according to American joint committee on cancer version 8 : A reassessment on the basis of 3 independent stage III melanoma cohortsIn: Journal of Clinical Oncology (JCO) Jg. 38 (2020) Nr. 22, S. 2543 - 2551Online Volltext: dx.doi.org/ (Open Access)
-
Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv⁶⁰⁰ mutation–positive melanoma receiving adjuvant vemurafenibIn: Annals of Oncology Jg. 31 (2020) Nr. 1, S. 153 - 159Online Volltext: dx.doi.org/ (Open Access)
-
Quality‐of‐life analysis with intermittent vismodegib regimens in patients with multiple basal cell carcinomas : Patient‐reported outcomes from the MIKIE studyIn: Journal of the European Academy of Dermatology and Venereology Jg. 34 (2020) Nr. 9, S. e526 - e529Online Volltext: dx.doi.org/
-
Rationale for Immune Checkpoint Inhibitors plus Targeted Therapy in Metastatic Melanoma : A ReviewIn: JAMA Oncology Jg. 6 (2020) Nr. 12, S. 1957 - 1966Online Volltext: dx.doi.org/
-
Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSigIn: Nature Communications Jg. 11 (2020) 731Online Volltext: dx.doi.org/ (Open Access)
-
Reply to the letter to the editor: ‘Deep learning outperformed 11 pathologists in the classification of histopathological melanoma images’In: European Journal of Cancer (EJC) Jg. 130 (2020) S. 262 - 264Online Volltext: dx.doi.org/ (Open Access)
-
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samplesIn: Nature Communications Jg. 11 (2020) Nr. 1, S. 4748Online Volltext: dx.doi.org/ (Open Access)
-
Salivary cortisol levels and anxiety in melanoma patients undergoing sentinel lymph node excision under local anesthesia versus general anesthesia : A prospective studyIn: World Journal of Surgical Oncology Jg. 18 (2020) Nr. 1, S. 53Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapyIn: Journal for ImmunoTherapy of Cancer Jg. 8 (2020) Nr. 2, S. e001689Online Volltext: dx.doi.org/ (Open Access)
-
Sex differences in oncogenic mutational processesIn: Nature Communications Jg. 11 (2020) Nr. 1, S. 4330Online Volltext: dx.doi.org/ (Open Access)
-
Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma : A joint expert opinionIn: Journal of the European Academy of Dermatology and Venereology Jg. 34 (2020) Nr. 9, S. 1944 - 1956Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Survival of patients with advanced metastatic melanoma : The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019In: European Journal of Cancer (EJC) Jg. 130 (2020) S. 126 - 138Online Volltext: dx.doi.org/
-
T-Cell Repertoire in Combination with T-Cell Density Predicts Clinical Outcomes in Patients with Merkel Cell CarcinomaIn: Journal of Investigative Dermatology Jg. 140 (2020) Nr. 11, S. 2146 - 2156.e4Online Volltext: dx.doi.org/ (Open Access)
-
Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapyIn: The Journal of Clinical Investigation (JCI) Jg. 130 (2020) Nr. 8, S. 4266 - 4281Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Tertiary lymphoid structures improve immunotherapy and survival in melanomaIn: Nature Jg. 577 (2020) Nr. 7791, S. 561 - 565Online Volltext: dx.doi.org/
-
The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitionsIn: European Journal of Cancer (EJC) Jg. 138 (2020) S. 68 - 76Online Volltext: dx.doi.org/
-
Update on tolerability and overall survival in COLUMBUS : landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanomaIn: European Journal of Cancer (EJC) Jg. 126 (2020) S. 33 - 44Online Volltext: dx.doi.org/ (Open Access)
-
Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma : A multi-institutional retrospective studyIn: The Journal of Dermatology Jg. 47 (2020) Nr. 6, S. 629 - 635Online Volltext: dx.doi.org/
-
A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification taskIn: European Journal of Cancer (EJC) Jg. 111 (2019) S. 148 - 154Online Volltext: dx.doi.org/ (Open Access)
-
Adverse events 2.0—Let us get SERIOs : New reporting for adverse event outcomes needed in the era of immunooncologyIn: European Journal of Cancer (EJC) Jg. 112 (2019) S. 29 - 31Online Volltext: dx.doi.org/
-
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study : incidence, course and managementIn: European Journal of Cancer (EJC) Jg. 119 (2019) S. 97 - 106Online Volltext: dx.doi.org/ (Open Access)
-
An Animal Model of Cutaneous Cyst Development Enables the Identification of Three Quantitative Trait Loci, Including the Homologue of a Human Locus (TRICY1)In: Journal of Investigative Dermatology Jg. 139 (2019) Nr. 10, S. 2235 - 2238.e5Online Volltext: dx.doi.org/ (Open Access)
-
Antiretroviral therapy suppresses rectal HIV-RNA shedding despite inflammation in MSM with rectal C. trachomatis and N. gonorrhoeae infections - A cross-sectional, single-center studyIn: Sexually Transmitted Infections Jg. 95 (2019) Nr. 2, S. 95 - 98Online Volltext: dx.doi.org/ (Open Access)
-
Application of circulating cell-free tumor DNA profiles for therapeutic monitoring and outcome prediction in genetically heterogeneous metastatic melanomaIn: JCO Precision Oncology Jg. 3 (2019)Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Assessment of Nonradioactive Multispectral Optoacoustic Tomographic Imaging With Conventional Lymphoscintigraphic Imaging for Sentinel Lymph Node Biopsy in MelanomaIn: JAMA Network Open Jg. 2 (2019) Nr. 8, S. e199020Online Volltext: dx.doi.org/ (Open Access)
-
B-type natriuretic peptides for the prediction of cardiovascular events and mortality in patients living with HIV : Results from the HIV-HEART studyIn: International Journal of Cardiology Jg. 281 (2019) S. 127 - 132Online Volltext: dx.doi.org/
-
Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanomaIn: OncoTarget Jg. 10 (2019) Nr. 19, S. 1850 - 1859Online Volltext: dx.doi.org/ (Open Access)
-
Cardiovascular Adverse Events Associated with BRAF and MEK Inhibitors : A Systematic Review and Meta-analysisIn: JAMA Network Open Jg. 2 (2019) Nr. 8, S. e198890Online Volltext: dx.doi.org/ (Open Access)
-
Circulating tumor DNA (ctDNA) kinetics to predict survival in patients (pts) with unresectable or metastatic melanoma treated with dabrafenib (D) or D + trametinib (T)In: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 15_suppl, S. 9510Online Volltext: dx.doi.org/
-
Clinical and genetic analysis of melanomas arising in acral sitesIn: European Journal of Cancer (EJC) Jg. 119 (2019) S. 66 - 76Online Volltext: dx.doi.org/ (Open Access)
-
Comparing artificial intelligence algorithms to 157 German dermatologists : the melanoma classification benchmarkIn: European Journal of Cancer (EJC) Jg. 111 (2019) S. 30 - 37Online Volltext: dx.doi.org/ (Open Access)
-
Complex formation with monomeric α-tubulin and importin 13 fosters c-jun protein stability and is required for c-jun’s nuclear translocation and activityIn: Cancers Jg. 11 (2019) Nr. 11, S. 1806Online Volltext: dx.doi.org/ (Open Access)
-
Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma : final update of the pivotal ERIVANCE BCC studyIn: BMC Cancer Jg. 19 (2019) S. 366Online Volltext: dx.doi.org/ (Open Access)
-
Deep learning outperformed 11 pathologists in the classification of histopathological melanoma imagesIn: European Journal of Cancer (EJC) Jg. 118 (2019) S. 91 - 96Online Volltext: dx.doi.org/ (Open Access)
-
Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification taskIn: European Journal of Cancer (EJC) Jg. 113 (2019) S. 47 - 54Online Volltext: dx.doi.org/ (Open Access)
-
Deep neural networks are superior to dermatologists in melanoma image classificationIn: European Journal of Cancer (EJC) Jg. 119 (2019) S. 11 - 17Online Volltext: dx.doi.org/ (Open Access)
-
Distinct immunogenomic properties of melanomas with stable disease as best response to immune checkpoint blockade (ICB)In: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 15_Suppl, S. 2515 - 2515Online Volltext: dx.doi.org/
-
Efficacy of PD-1–based immunotherapy after radiologic progression on targeted therapy in stage IV melanomaIn: European Journal of Cancer (EJC) Jg. 116 (2019) S. 207 - 215Online Volltext: dx.doi.org/
-
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma : Results From the Phase IIIb/IV CheckMate 511 TrialIn: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 11, S. 867 - 875Online Volltext: dx.doi.org/ (Open Access)
-
First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysisIn: Cancer Immunology, Immunotherapy Jg. 68 (2019) Nr. 5, S. 765 - 772Online Volltext: dx.doi.org/
-
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaIn: The New England Journal of Medicine Jg. 381 (2019) Nr. 16, S. 1535 - 1546Online Volltext: dx.doi.org/ (Open Access)
-
Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K–mutant advanced or metastatic melanomaIn: European Journal of Cancer (EJC) Jg. 109 (2019) S. 61 - 69Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Five-year outcomes with dabrafenib plus trametinib in metastatic melanomaIn: The New England Journal of Medicine Jg. 381 (2019) Nr. 7, S. 626 - 636Online Volltext: dx.doi.org/ (Open Access)
-
Frequent Occurrence of NRAS and BRAF Mutations in Human Acral NaeviIn: Cancers Jg. 11 (2019) Nr. 4, S. 546Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapyIn: Cancer Research Jg. 79 (2019) Nr. 11, S. 2947 - 2961Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Health-related quality of life in patients with fully resected BRAFV⁶⁰⁰ mutation–positive melanoma receiving adjuvant vemurafenibIn: European Journal of Cancer (EJC) Jg. 123 (2019) S. 155 - 161Online Volltext: dx.doi.org/ (Open Access)
-
High PD-1 or PD-L1 Concentrations in the Serum of Melanoma Patients are predictive for reduced Therapeutic Success of PD-1 InhibitionIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 17 (2019) Nr. Suppl. 5, S. 7 - 7
-
Immunotherapy in non-melanoma skin cancer : Updates and new perspectivesIn: Drugs in Context Jg. 8 (2019) S. 212583Online Volltext: dx.doi.org/ (Open Access)
-
Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanomaIn: European Journal of Cancer (EJC) Jg. 119 (2019) S. 18 - 29Online Volltext: dx.doi.org/
-
Informations- und Hilfsangebote für Melanompatienten : Präferenzielle Unterschiede zwischen Patienten und ÄrztenIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 17 (2019) Nr. 6, S. 652 - 654Online Volltext: dx.doi.org/
-
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaIn: Nature Medicine Jg. 25 (2019) Nr. 12, S. 1916 - 1927Online Volltext: dx.doi.org/ (Open Access)
-
MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition : a case seriesIn: Cancer Immunology, Immunotherapy Jg. 68 (2019) Nr. 6, S. 983 - 990Online Volltext: dx.doi.org/
-
MerkelzellkarzinomIn: Best Practice Onkologie Jg. 14 (2019) Nr. 7/8, S. 312 - 323Online Volltext: dx.doi.org/
-
Metastatic Merkel cell carcinoma and myasthenia gravis : contraindication for therapy with immune checkpoint inhibitors?In: Journal for ImmunoTherapy of Cancer Jg. 7 (2019) Nr. 1, S. 141Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
NAMPT signaling is critical for the proangiogenic activity of tumor-associated neutrophilsIn: International Journal of Cancer Jg. 144 (2019) Nr. 1, S. 136 - 149Online Volltext: dx.doi.org/ (Open Access)
-
Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL) : a multicentre, open-label, randomised, controlled phase II trialIn: Annals of Oncology Jg. 30 (2019) Nr. 2, S. 317 - 324Online Volltext: dx.doi.org/ (Open Access)
-
Pathologist-level classification of histopathological melanoma images with deep neural networksIn: European Journal of Cancer (EJC) Jg. 115 (2019) S. 79 - 83Online Volltext: dx.doi.org/ (Open Access)
-
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD) : a randomised, placebo-controlled, phase 3 trialIn: The Lancet Oncology Jg. 20 (2019) Nr. 5, S. 701 - 710Online Volltext: dx.doi.org/
-
Prediction of melanoma evolution in melanocytic nevi via artificial intelligence : A call for prospective dataIn: European Journal of Cancer (EJC) Jg. 119 (2019) S. 30 - 34Online Volltext: dx.doi.org/ (Open Access)
-
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanomaIn: European Journal of Cancer (EJC) Jg. 116 (2019) S. 148 - 157Online Volltext: dx.doi.org/
-
Prognostic factors for pulmonary metastasectomy in malignant melanoma : Size mattersIn: European Journal of Cardio-Thoracic Surgery Jg. 56 (2019) Nr. 6, S. 1104 - 1109Online Volltext: dx.doi.org/ (Open Access)
-
Publisher Correction : Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathwaysIn: Nature Communications Jg. 10 (2019) Nr. 1, S. 299Online Volltext: dx.doi.org/ (Open Access)
-
Publisher Correction: Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathwaysIn: Nature Communications Jg. 10 (2019) Nr. 1, S. 299Online Volltext: dx.doi.org/ (Open Access)
-
Quality of life (QoL) and symptom burden in patients (pts) with advanced melanoma during the treatment-free interval (TFI) after discontinuation of nivolumab (NIVO) or NIVO plus ipilimumab (IPI)In: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 15_Suppl, S. 9568Online Volltext: dx.doi.org/
-
Quality, Readability, and Understandability of German Booklets Addressing Melanoma PatientsIn: Journal of Cancer Education Jg. 34 (2019) Nr. 4, S. 760 - 767Online Volltext: dx.doi.org/
-
Reply to E. Hindié and K.R. HessIn: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 15, S. 1356 - 1358Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment : A single-arm, open-label, phase II study (CheckMate 172)In: European Journal of Cancer (EJC) Jg. 121 (2019) S. 144 - 153Online Volltext: dx.doi.org/
-
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment : a single-arm, open-label, phase II study (CheckMate 172)In: European Journal of Cancer (EJC) Jg. 119 (2019) S. 168 - 178Online Volltext: dx.doi.org/ (Open Access)
-
Salvage therapy after failure from anti-PD-1 single agent treatment : A Study by the German ADOReg melanoma registryIn: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 15_Suppl, S. 9505Online Volltext: dx.doi.org/
-
Sentinel lymph node excision with or without preoperative hybrid single-photon emission computed tomography/computed tomography (SPECT/CT) in melanoma : Study protocol for a multicentric randomized controlled trialIn: Trials Jg. 20 (2019) Nr. 1, S. 99Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV⁶⁰⁰E inhibition in melanomaIn: European Journal of Cancer (EJC) Jg. 109 (2019) S. 137 - 153Online Volltext: dx.doi.org/
-
Sources of information and support for melanoma patients : differences between patients' and clinicians' preferences, Clinical letterIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 17 (2019) Nr. 6, S. 652 - 654Online Volltext: dx.doi.org/
-
Superior skin cancer classification by the combination of human and artificial intelligenceIn: European Journal of Cancer (EJC) Jg. 120 (2019) S. 114 - 121Online Volltext: dx.doi.org/ (Open Access)
-
Survival Outcomes in Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma Treated with Nivolumab Therapy : Three-Year Follow-up of a Randomized Phase 3 TrialIn: JAMA Oncology Jg. 5 (2019) Nr. 2, S. 187 - 194Online Volltext: dx.doi.org/ (Open Access)
-
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockadeIn: Cell Research Jg. 29 (2019) Nr. 10, S. 846 - 861Online Volltext: dx.doi.org/ (Open Access)
-
Systematic outperformance of 112 dermatologists in multiclass skin cancer image classification by convolutional neural networksIn: European Journal of Cancer (EJC) Jg. 119 (2019) S. 57 - 65Online Volltext: dx.doi.org/ (Open Access)
-
Targeting the H3K4 Demethylase KDM5B Reprograms the Metabolome and Phenotype of Melanoma CellsIn: Journal of Investigative Dermatology Jg. 139 (2019) Nr. 12, S. 2506 - 2516.e10Online Volltext: dx.doi.org/ (Open Access)
-
The X-Linked DDX3X RNA Helicase Dictates Translation Reprogramming and Metastasis in MelanomaIn: Cell Reports Jg. 27 (2019) Nr. 12, S. 3573 - 3586.e7Online Volltext: dx.doi.org/ (Open Access)
-
The prognostic value of sentinel lymph nodes on distant metastasis–free survival in patients with high-risk squamous cell carcinomaIn: European Journal of Cancer (EJC) Jg. 111 (2019) S. 107 - 115Online Volltext: dx.doi.org/
-
Treatment in metastatic melanoma : Time to re-thinkIn: Annals of Oncology Jg. 30 (2019) Nr. 4, S. 501 - 503Online Volltext: dx.doi.org/ (Open Access)
-
Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodiesIn: Journal for ImmunoTherapy of Cancer Jg. 7 (2019) Nr. 1, S. 343Online Volltext: dx.doi.org/ (Open Access)
-
Unmet information needs of patients with melanoma in GermanyIn: Melanoma Research Jg. 29 (2019) Nr. 2, S. 196 - 204Online Volltext: dx.doi.org/
-
ctDNA as a noninvasive monitoring tool in metastatic melanomaIn: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. Suppl. 15, S. 9548Online Volltext: dx.doi.org/
-
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint BlockadeIn: Cell Jg. 175 (2018) Nr. 4, S. 984 - 997.e24Online Volltext: dx.doi.org/ (Open Access)
-
A Face-Aging App for Smoking Cessation in a Waiting Room Setting : Pilot Study in an HIV Outpatient ClinicIn: Journal of Medical Internet Research (JMIR) Jg. 20 (2018) Nr. 8, S. e10976Online Volltext: dx.doi.org/ (Open Access)
-
A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanomaIn: Investigational New Drugs: The Journal of New Anticancer Agents Jg. 36 (2018) Nr. 1, S. 103 - 113Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
A skin cancer prevention facial-aging mobile app for secondary schools in Brazil : Appearance-focused interventional studyIn: JMIR mhealth and uhealth Jg. 6 (2018) Nr. 3, e60Online Volltext: dx.doi.org/ (Open Access)
-
A skin cancer prevention photoageing intervention for secondary schools in Brazil delivered by medical students : protocol for a randomised controlled trialIn: BMJ Open Jg. 8 (2018) Nr. 3, S. e018299Online Volltext: dx.doi.org/ (Open Access)
-
Actinic keratoses treated with cold atmospheric plasmaIn: Journal of the European Academy of Dermatology and Venereology Jg. 32 (2018) Nr. 1, S. e37 - e39Online Volltext: dx.doi.org/
-
Adjuvant melanoma therapy with new drugs : Should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?In: The Lancet Oncology Jg. 19 (2018) Nr. 12, S. e720 - e725Online Volltext: dx.doi.org/
-
Adjuvant pembrolizumab versus placebo in resected stage III melanomaIn: The New England Journal of Medicine Jg. 378 (2018) Nr. 19, S. 1789 - 1801Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Adjuvant vemurafenib in resected, BRAF mutation-positive melanoma (BRIM8) : a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialIn: The Lancet Oncology Jg. 19 (2018) Nr. 4, S. 510 - 520Online Volltext: dx.doi.org/
-
Advanced cutaneous squamous cell carcinoma : A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOGIn: European Journal of Cancer (EJC) Jg. 96 (2018) S. 34 - 43Online Volltext: dx.doi.org/
-
Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trialIn: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 8, S. viii446Online Volltext: dx.doi.org/ (Open Access)
-
Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-Cell populationsIn: Clinical Cancer Research Jg. 24 (2018) Nr. 21, S. 5347 - 5356Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy : a retrospective, multicohort analysisIn: The Lancet Oncology Jg. 19 (2018) Nr. 3, S. 310 - 322Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Atypical fibroxanthoma and pleomorphic dermal sarcoma harbor frequent NOTCH1/2 and FAT1 mutations and similar DNA copy number alteration profilesIn: Modern Pathology Jg. 31 (2018) Nr. 3, S. 418 - 428Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Can integrated 18F-FDG PET/MR replace sentinel lymph node resection in malignant melanoma?In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 45 (2018) Nr. 12, S. 2093 - 2102Online Volltext: dx.doi.org/
-
Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 BlockadeIn: Cell Jg. 173 (2018) Nr. 3, S. 624 - 633.e8Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity : A meta-analysis of approximately 29,000 cancer patientsIn: European Journal of Preventive Cardiology Jg. 25 (2018) Nr. 5, S. 482 - 494Online Volltext: dx.doi.org/
-
Circulating cell-free miR-375 as surrogate marker of tumor burden in Merkel cell carcinomaIn: Clinical Cancer Research Jg. 24 (2018) Nr. 23, S. 5873 - 5882Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patientsIn: British Journal of Cancer (BJC) Jg. 118 (2018) Nr. 6, S. 785 - 792Online Volltext: dx.doi.org/ (Open Access)
-
Corrigendum to “Rechallenge with BRAF-directed treatment in metastatic melanoma : A multi-institutional retrospective study*” [Eur J Cancer 91 (2018) 116–124]In: European Journal of Cancer (EJC) Jg. 93 (2018) S. 158Online Volltext: dx.doi.org/ (Open Access)
-
Dose-dependent toxicity of ipilimumab in metastatic melanomaIn: European Journal of Cancer (EJC) Jg. 95 (2018) S. 104 - 108Online Volltext: dx.doi.org/
-
Eighth American Joint Committee on Cancer (AJCC) melanoma classification : Let us reconsider stage IIIIn: European Journal of Cancer (EJC) Jg. 91 (2018) S. 168 - 170Online Volltext: dx.doi.org/
-
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS) : a multicentre, open-label, randomised phase 3 trialIn: The Lancet Oncology Jg. 19 (2018) Nr. 5, S. 603 - 615Online Volltext: dx.doi.org/; Online Volltext: dx.doi.org/ (Open Access)
-
Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trialIn: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 8, S. viii445Online Volltext: dx.doi.org/ (Open Access)
-
Evolution of melanoma cross-resistance to CD8⁺ T cells and MAPK inhibition in the course of BRAFi treatmentIn: OncoImmunology Jg. 7 (2018) Nr. 8, e1450127Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
F-18-FDG PET/MR including DWI in initial N-Staging in patients with malignant melanoma : Is it a possible replacement for sentinel lymph node biopsy?In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 45 (2018) Nr. Suppl. 1, S. 38
-
Facial-aging app availability in waiting rooms as a potential opportunity for skin cancer preventionIn: JAMA Dermatology Jg. 154 (2018) Nr. 9, S. 1085 - 1086Online Volltext: dx.doi.org/ (Open Access)
-
Fear of cancer progression in patients with stage IA malignant melanomaIn: European Journal of Cancer Care Jg. 27 (2018) Nr. 5, e12901Online Volltext: dx.doi.org/
-
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumorsIn: Nature Genetics Jg. 50 (2018) Nr. 9, S. 1271 - 1281Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Information-seeking and use of information resources among melanoma patients of German skin cancer centersIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. 9, S. 1093 - 1101Online Volltext: dx.doi.org/
-
Informationsangebote für Melanompatienten und ihre Bekanntheit unter BetroffenenIn: Der Hautarzt Jg. 69 (2018) Nr. 4, S. 335 - 339Online Volltext: dx.doi.org/
-
Integrated genomic classification of melanocytic tumors of the central nervous system using mutation analysis, copy number alterations, and DNA methylation profilingIn: Clinical Cancer Research Jg. 24 (2018) Nr. 18, S. 4494 - 4504Online Volltext: dx.doi.org/ (Open Access)
-
Intraoperative use of LIGHTVISION : a novel fluorescence navigation system using indocyanine green for sentinel lymph node biopsy in skin cancer patientsIn: European Journal of Dermatology (EJD) Jg. 28 (2018) Nr. 4, S. 532 - 534Online Volltext: dx.doi.org/
-
Intraventricular melanocytoma diagnosis confirmed by gene mutation profileIn: Neuropathology Jg. 38 (2018) Nr. 3, S. 288 - 292Online Volltext: dx.doi.org/
-
Liquid profiling of circulating tumor DNA in plasma of melanoma patients for companion diagnostics and monitoring of BRAF inhibitor therapyIn: Clinical Chemistry Jg. 64 (2018) Nr. 5, S. 830 - 842Online Volltext: dx.doi.org/ (Open Access)
-
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III MelanomaIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. 35, S. 3441 - 3449Online Volltext: dx.doi.org/ (Open Access)
-
MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade : Results of a retrospective multicentre analysis of 364 patientsIn: European Journal of Cancer (EJC) Jg. 98 (2018) S. 10 - 16Online Volltext: dx.doi.org/
-
MerkelzellkarzinomIn: Der Onkologe Jg. 24 (2018) Nr. 12, S. 1037 - 1049Online Volltext: dx.doi.org/
-
Mit Nivolumab und Pembrolizumab gegen das Melanom : Wirkprinzip und Umgang mit immunvermittelten Nebenwirkungen der Anti-PD1-TherapieIn: Deutsche Apotheker Zeitung Jg. 158 (2018) Nr. 30,
-
NF1 mutations in conjunctival melanomaIn: British Journal of Cancer (BJC) Jg. 118 (2018) Nr. 9, S. 1243 - 1247Online Volltext: dx.doi.org/ (Open Access)
-
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067) : 4-year outcomes of a multicentre, randomised, phase 3 trialIn: The Lancet Oncology Jg. 19 (2018) Nr. 11, S. 1480 - 1492Online Volltext: dx.doi.org/
-
Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathwaysIn: Nature Communications Jg. 9 (2018) Nr. 1, S. 4774Online Volltext: dx.doi.org/ (Open Access)
-
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006 : A randomised clinical trialIn: European Journal of Cancer (EJC) Jg. 101 (2018) S. 236 - 243Online Volltext: dx.doi.org/ (Open Access)
-
Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)In: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 8, S. viii735Online Volltext: dx.doi.org/ (Open Access)
-
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS) : A multicentre, open-label, randomised, phase 3 trialIn: The Lancet Oncology Jg. 19 (2018) Nr. 10, S. 1315 - 1327Online Volltext: dx.doi.org/
-
Overall survival in patients with advanced melanoma who received nivolumab versus investigator's choice chemotherapy in CheckMate 037 : A Randomized, Controlled, Open-Label Phase III TrialIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. 4, S. 383 - 390Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Oxygenation Status in Chronic Leg Ulcer After Topical Hemoglobin Application May Act as a Surrogate Marker to Find the Best Treatment Strategy and to Avoid Ineffective Conservative Long-term TherapyIn: Molecular Imaging and Biology Jg. 20 (2018) Nr. 1, S. 124 - 130Online Volltext: dx.doi.org/
-
PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinomaIn: The New England Journal of Medicine Jg. 379 (2018) Nr. 4, S. 341 - 351Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanomaIn: European Journal of Cancer (EJC) Jg. 88 (2018) S. 67 - 76Online Volltext: dx.doi.org/
-
PHIP as a therapeutic target for driver-negative subtypes of melanoma, breast, and lung cancerIn: Proceedings of the National Academy of Sciences of the United States of America (PNAS) Jg. 115 (2018) Nr. 25, S. E5766 - E5775Online Volltext: dx.doi.org/ (Open Access)
-
Patient-reported outcomes with nivolumab in advanced solid cancersIn: Cancer Treatment Reviews Jg. 70 (2018) S. 75 - 87Online Volltext: dx.doi.org/ (Open Access)
-
Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockadeIn: European Journal of Cancer (EJC) Jg. 99 (2018) S. 58 - 65Online Volltext: dx.doi.org/
-
Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanomaIn: ESMO Open Jg. 3 (2018) Nr. 5, S. e000388Online Volltext: dx.doi.org/ (Open Access)
-
Postsurgical treatment of split skin graft donor sites in dermatological departmentsIn: The International Journal of Lower Extremity Wounds Jg. 17 (2018) Nr. 1, S. 22 - 29Online Volltext: dx.doi.org/
-
Predictors of quality of life in melanoma patients 4 years after diagnosis : Results of a nationwide cohort study in GermanyIn: Journal of Psychosocial Oncology Jg. 36 (2018) Nr. 6, S. 734 - 753Online Volltext: dx.doi.org/
-
Re: van Poppelen et al.: Genetic background of iris melanomas and iris melanocytic tumors of uncertain malignant potential (Ophthalmology. 2018;125:904-912)In: Ophthalmology Jg. 125 (2018) Nr. 11, S. e78 - e79Online Volltext: dx.doi.org/ (Open Access)
-
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective studyIn: European Journal of Cancer (EJC) Jg. 91 (2018) S. 116 - 124Online Volltext: dx.doi.org/ (Open Access)
-
Reply to M. Horiguchi et al [Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab as a Result of Adverse Events Lived Significantly Longer Than Patients Who Continued Treatment]In: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. 7, S. 721Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Role of elevated PHIP copy number as a prognostic and progression marker for cutaneous melanomaIn: Clinical Cancer Research Jg. 24 (2018) Nr. 17, S. 4119 - 4125Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon-αIn: Melanoma Research Jg. 28 (2018) Nr. 3, S. 204 - 210Online Volltext: dx.doi.org/
-
Sebaceous tumours: more than skin deepIn: Gut Jg. 67 (2018) Nr. 11, S. 2045 - 2053Online Volltext: dx.doi.org/
-
Skin Cancer Classification using Convolutional Neural Networks : Systematic ReviewIn: Journal of Medical Internet Research (JMIR) Jg. 20 (2018) Nr. 10, S. e11936Online Volltext: dx.doi.org/ (Open Access)
-
Teledermatology : Comparison of Store-and-Forward Versus Live Interactive Video ConferencingIn: Journal of Medical Internet Research (JMIR) Jg. 20 (2018) Nr. 10, e11871Online Volltext: dx.doi.org/ (Open Access)
-
Telomere length, telomerase reverse transcriptase promoter mutations, and melanoma riskIn: Genes, Chromosomes and Cancer Jg. 57 (2018) Nr. 11, S. 564 - 572Online Volltext: dx.doi.org/
-
The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy : A survey in German melanoma patients and their treating physiciansIn: OncoTarget Jg. 9 (2018) Nr. 40, S. 26217 - 26225Online Volltext: dx.doi.org/ (Open Access)
-
The safety and efficacy of dabrafenib and trametinib for the treatment of melanomaIn: Expert Opinion on Drug Safety Jg. 17 (2018) Nr. 1, S. 73 - 87Online Volltext: dx.doi.org/
-
Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy ResistanceIn: Journal of the National Cancer Institute (JNCI) Jg. 110 (2018) Nr. 6, S. 677 - 681Online Volltext: dx.doi.org/ (Open Access)
-
Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanomaIn: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 8, S. viii734 - viii735Online Volltext: dx.doi.org/ (Open Access)
-
Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib plus trametinib (D plus T) in patients (pts) with resected BRAF V600-mutant stage III melanomaIn: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 8,
-
Willingness to pay for a cure of low-risk melanoma patients in GermanyIn: PLoS ONE Jg. 13 (2018) Nr. 5, S. e0197780Online Volltext: dx.doi.org/ (Open Access)
-
A Dermatologist's ammunition in the war against smoking : a photoaging appIn: Journal of Medical Internet Research (JMIR) Jg. 19 (2017) Nr. 9, S. e326Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
A medical student-delivered smoking prevention program, education against tobacco, for secondary schools in Germany : Randomized controlled trialIn: Journal of Medical Internet Research (JMIR) Jg. 19 (2017) Nr. 6, S. e199Online Volltext: dx.doi.org/ (Open Access)
-
A smoking prevention photoageing intervention for secondary schools in Brazil delivered by medical students: protocol for a randomised trial.In: BMJ Open Jg. 7 (2017) S. e018589Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Acquired IFNγ 3 resistance impairs anti-Tumor immunity and gives rise to T-cell-resistant melanoma lesionsIn: Nature Communications Jg. 8 (2017) 15440Online Volltext: dx.doi.org/ (Open Access)
-
Activating CYSLTR2 and PLCB4 Mutations in Primary Leptomeningeal Melanocytic TumorsIn: Journal of Investigative Dermatology Jg. 137 (2017) Nr. 9, S. 2033 - 2035Online Volltext: dx.doi.org/
-
Activating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue neviIn: Modern Pathology Jg. 30 (2017) Nr. 3, S. 350 - 356Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanomaIn: The New England Journal of Medicine Jg. 377 (2017) Nr. 19, S. 1813 - 1823Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO) : a multicentre, open-label, randomised, phase 3 trialIn: The Lancet Oncology Jg. 18 (2017) Nr. 4, S. 435 - 445Online Volltext: dx.doi.org/
-
CheckpointinhibitorenIn: Der Onkologe Jg. 23 (2017) Nr. 8, S. 619 - 625Online Volltext: dx.doi.org/
-
Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma : a multicenter randomized phase-3 DeCOG trialIn: OncoTarget Jg. 8 (2017) Nr. 44, S. 76029 - 76043Online Volltext: dx.doi.org/ (Open Access)
-
Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitisIn: European Journal of Cancer (EJC) Jg. 86 (2017) S. 248 - 256Online Volltext: dx.doi.org/
-
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma : long-term survival and safety analysis of a phase 3 studyIn: Annals of Oncology Jg. 28 (2017) Nr. 7, S. 1631 - 1639Online Volltext: dx.doi.org/ (Open Access)
-
Efficacy and safety of nilotinib in patients with kit-mutated metastatic or inoperable melanoma : Final results from the global, single-arm, phase ii team trialIn: Annals of Oncology Jg. 28 (2017) Nr. 6, S. 1380 - 1387Online Volltext: dx.doi.org/ (Open Access)
-
Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events : a pooled analysis of randomized phase II and III trialsIn: Journal of Clinical Oncology (JCO) Jg. 35 (2017) Nr. 34, S. 3807 - 3814Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in EuropeIn: OncoTarget Jg. 8 (2017) Nr. 45, S. 79731 - 79741Online Volltext: dx.doi.org/ (Open Access)
-
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanomaIn: European Journal of Cancer (EJC) Jg. 86 (2017) S. 37 - 45Online Volltext: dx.doi.org/
-
Frequent GNAQ, GNA11, and EIF1AX Mutations in Iris MelanomaIn: Investigative Ophthalmology & Visual Science, IOVS Jg. 58 (2017) Nr. 9, S. 3464 - 3470Online Volltext: dx.doi.org/ (Open Access)
-
Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanomaIn: European Journal of Cancer (EJC) Jg. 83 (2017) S. 142 - 145Online Volltext: dx.doi.org/
-
HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma modelIn: OncoTarget Jg. 8 (2017) Nr. 17, S. 28312 - 28327Online Volltext: dx.doi.org/ (Open Access)
-
Health-related quality of life results from the phase III CheckMate 067 studyIn: European Journal of Cancer (EJC) Jg. 82 (2017) S. 80 - 91Online Volltext: dx.doi.org/ (Open Access)
-
IRF4 rs12203592 functional variant and melanoma survivalIn: International Journal of Cancer Jg. 140 (2017) Nr. 8, S. 1845 - 1849Online Volltext: dx.doi.org/
-
Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinomaIn: OncoImmunology Jg. 6 (2017) Nr. 10, e1338237Online Volltext: dx.doi.org/ (Open Access)
-
Immunotherapy in melanoma : Recent advances and future directionsIn: European Journal of Surgical Oncology Jg. 43 (2017) Nr. 3, S. 604 - 611Online Volltext: dx.doi.org/
-
Integrative analysis identifies four molecular and clinical subsets in uveal melanomaIn: Cancer Cell Jg. 32 (2017) Nr. 2, S. 204 - 220.e15Online Volltext: dx.doi.org/ (Open Access)
-
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma : a randomised, double-blind, multicentre, phase 3 trialIn: The Lancet Oncology Jg. 18 (2017) Nr. 5, S. 611 - 622Online Volltext: dx.doi.org/
-
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanomaIn: European Journal of Cancer (EJC) Jg. 75 (2017) S. 47 - 55Online Volltext: dx.doi.org/
-
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma : final update of the pivotal ERIVANCE BCC studyIn: BMC Cancer Jg. 17 (2017) S. 332Online Volltext: dx.doi.org/ (Open Access)
-
MAPK signaling and inflammation link melanoma phenotype switching to induction of CD73 during immunotherapyIn: Cancer Research Jg. 77 (2017) Nr. 17, S. 4697 - 4709Online Volltext: dx.doi.org/
-
Mapping heterogeneity in patient-derived melanoma cultures by single-cell RNA-seqIn: OncoTarget Jg. 8 (2017) Nr. 1, S. 846 - 862Online Volltext: dx.doi.org/ (Open Access)
-
Melanoma diagnosed in lesions previously treated by laser therapyIn: The Journal of Dermatology Jg. 44 (2017) Nr. 1, S. 23 - 28Online Volltext: dx.doi.org/
-
Merkel cell carcinoma : Epidemiology, prognosis, therapy and unmet medical needsIn: European Journal of Cancer (EJC) Jg. 71 (2017) S. 53 - 69Online Volltext: dx.doi.org/ (Open Access)
-
Metastatic recurrence of 17-year relapse-free melanoma during anti-TNFa therapyIn: Journal of the European Academy of Dermatology and Venereology Jg. 31 (2017) Nr. 8, S. e368 - e369Online Volltext: dx.doi.org/
-
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression : Analysis of 2 Phase 3 Clinical TrialsIn: JAMA Oncology Jg. 3 (2017) Nr. 11, S. 1511 - 1519Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Overall survival with combined nivolumab and ipilimumab in advanced melanomaIn: The New England Journal of Medicine Jg. 377 (2017) Nr. 14, S. 1345 - 1356Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patientsIn: European Journal of Cancer (EJC) Jg. 73 (2017) S. 61 - 70Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Photoaging Mobile Apps as a Novel Opportunity for Melanoma Prevention: Pilot Study.In: JMIR mhealth and uhealth Jg. 5 (2017) Nr. 7, e101
-
Photoaging mobile apps in school-based melanoma prevention: pilot studyIn: Journal of Medical Internet Research (JMIR) Jg. 19 (2017) Nr. 9, S. e319Online Volltext: dx.doi.org/ (Open Access)
-
Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumabIn: Journal of Cancer Research and Clinical Oncology Jg. 143 (2017) Nr. 10, S. 1977 - 1984Online Volltext: dx.doi.org/
-
Predictors of responses to immune checkpoint blockade in advanced melanomaIn: Nature Communications Jg. 8 (2017) S. 592Online Volltext: dx.doi.org/ (Open Access)
-
Prolongation of the QTc interval in HIV-infected individuals compared to the general populationIn: Infection - A Journal of Infectious Disease Jg. 45 (2017) Nr. 5, S. 659 - 667Online Volltext: dx.doi.org/
-
S3-Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms – Update 2015/2016, Kurzversion 2.0In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 15 (2017) Nr. 6, S. e1 - e41Online Volltext: dx.doi.org/
-
SF3B1 and BAP1 mutations in blue nevus-like melanomaIn: Modern Pathology Jg. 30 (2017) Nr. 7, S. 928 - 939Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Safety profile of nivolumab monotherapy : a pooled analysis of patients with advanced melanomaIn: Journal of Clinical Oncology (JCO) Jg. 35 (2017) Nr. 7, S. 785 - 792Online Volltext: dx.doi.org/
-
Sexual risk behavior, sexually transmitted infections, and HIV transmission risks in HIV-positive men who have sex with men (MSM) – approaches for medical preventionIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 15 (2017) Nr. 4, S. 421 - 428Online Volltext: dx.doi.org/
-
Spatiotemporally restricted arenavirus replication induces immune surveillance and type i interferon-dependent tumour regressionIn: Nature Communications Jg. 8 (2017) S. 14447Online Volltext: dx.doi.org/ (Open Access)
-
Survival of patients with advanced metastatic melanoma : the impact of novel therapies–update 2017In: European Journal of Cancer (EJC) Jg. 83 (2017) S. 247 - 257Online Volltext: dx.doi.org/
-
Systematic screening of isogenic cancer cells identifies DUSP6 as context-specific synthetic lethal target in melanomaIn: OncoTarget Jg. 8 (2017) Nr. 14, S. 23760 - 23774Online Volltext: dx.doi.org/ (Open Access)
-
Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutationsIn: OncoTarget Jg. 8 (2017) Nr. 25, S. 40683 - 40692Online Volltext: dx.doi.org/ (Open Access)
-
Targeting adenosine in BRAF-mutant melanoma reduces tumor growth and metastasisIn: Cancer Research Jg. 77 (2017) Nr. 17, S. 4684 - 4696Online Volltext: dx.doi.org/
-
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trialsIn: European Journal of Cancer (EJC) Jg. 82 (2017) S. 45 - 55Online Volltext: dx.doi.org/
-
Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE) : a randomised, regimen-controlled, double-blind, phase 2 trialIn: The Lancet Oncology Jg. 18 (2017) Nr. 3, S. 404 - 412Online Volltext: dx.doi.org/
-
Update der S3-Leitlinie zum malignen Melanom : aktuelle Empfehlungen für das fortgeschrittene MelanomIn: Best Practice Onkologie Jg. 12 (2017) Nr. 2, S. 110 - 118Online Volltext: dx.doi.org/
-
Update on the clinical use of kinase inhibitors in melanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 15 (2017) Nr. 9, S. 887 - 893Online Volltext: dx.doi.org/
-
Vemurafenib in metastatic melanoma patients with brain metastases : An open-label, single-arm, phase 2, multicentre studyIn: Annals of Oncology Jg. 28 (2017) Nr. 3, S. 634 - 641Online Volltext: dx.doi.org/
-
A phase I, open-label study of pasireotide in patients with BRAF- and NRAS-wild type, unresectable and or metastatic melanomaIn: Annals of Oncology Jg. 27 (2016) Nr. Suppl. 6,Online Volltext: dx.doi.org/
-
Adjuvant treatment with pegylated interferon ?-2a versus low-dose interferon ?-2a in patients with high-risk melanoma : a randomized phase III DeCOG trialIn: Annals of Oncology Jg. 27 (2016) Nr. 8, S. 1625 - 1632Online Volltext: dx.doi.org/ (Open Access)
-
Analysis of BRAF V600E mutation status – concordance of results from circulating tumor DNA and tissue-based testing and impact on prediction of the clinical course in patients undergoing BRAFi therapyIn: Annals of Oncology Jg. 27 (2016) Nr. Suppl. 6, S. 1145POnline Volltext: dx.doi.org/
-
Analysis of patient-reported outcomes by disease progression status in patients (pts) with BRAF V600–mutant metastatic melanoma in the COMBI-d and COMBI-v trialsIn: Annals of Oncology Jg. 27 (2016) Nr. Suppl. 6, S. 1140POnline Volltext: dx.doi.org/
-
Baseline Biomarkers for Outcome of Melanoma Patients Treated with PembrolizumabIn: Clinical Cancer Research Jg. 22 (2016) Nr. 22, S. 5487 - 5496Online Volltext: dx.doi.org/ (Open Access)
-
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with IpilimumabIn: Clinical Cancer Research Jg. 22 (2016) Nr. 12, S. 2908 - 2918Online Volltext: dx.doi.org/ (Open Access)
-
Checkpoint inhibitors : a new standard of care for advanced Merkel cell carcinoma?In: The Lancet Oncology Jg. 17 (2016) Nr. 10, S. 1337 - 1339Online Volltext: dx.doi.org/
-
Checkpoint inhibitors in chronic kidney failure and an organ transplant recipientIn: European Journal of Cancer (EJC) Jg. 67 (2016) S. 66 - 72Online Volltext: dx.doi.org/
-
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockadeIn: Science Jg. 351 (2016) Nr. 6280, S. 1463 - 1469Online Volltext: dx.doi.org/
-
Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical TrialsIn: Clinical Cancer Research Jg. 22 (2016) Nr. 3, S. 567 - 574Online Volltext: dx.doi.org/ (Open Access)
-
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapyIn: European Journal of Cancer (EJC) Jg. 60 (2016) S. 190 - 209Online Volltext: dx.doi.org/
-
Diagnosing a Primary Leptomeningeal Melanoma by Gene Mutation SignatureIn: Journal of Investigative Dermatology Jg. 136 (2016) Nr. 7, S. 1526 - 1528Online Volltext: dx.doi.org/
-
Eine Übersicht über Therapiefortschritte in den letzten 50 Jahren beim Metastasierten MelanomIn: Drug Research Jg. 66 (2016) Nr. S 01, S. 31 - S34Online Volltext: dx.doi.org/
-
Entscheidungsfindung für die klinische Praxis : Aktuelle Konzepte und Behandlungsalgorithmen mit Immun-Checkpoint-Inhibitoren beim MelanomIn: Oncology Research and Treatment Jg. 39 (2016) Nr. Suppl. 4, S. 8 - 12Online Volltext: dx.doi.org/
-
Evaluation of the pharmacokinetic (PK) profile of vismodegib (VISMO) in patients (pts) with multiple basal cell carcinomas (BCCs) across two intermittent treatment regimens in the MIKIE studyIn: Annals of Oncology Jg. 27 (2016) Nr. Suppl. 6, S. 1152POnline Volltext: dx.doi.org/
-
Exposure to Melan-A/MART-126-35 tumor epitope specific CD8(+)T cells reveals immune escape by affecting the ubiquitin-proteasome system (UPS)In: Scientific Reports Jg. 6 (2016) S. 25208Online Volltext: dx.doi.org/ (Open Access)
-
Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment : a pooled analysis of individual patient data from randomised trialsIn: The Lancet Oncology Jg. 17 (2016) Nr. 12, S. 1743 - 1754Online Volltext: dx.doi.org/
-
Final overall survival for KEYNOTE-002 : pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanomaIn: Annals of Oncology Jg. 27 (2016) Nr. Suppl. 6, S. 1107OOnline Volltext: dx.doi.org/
-
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanomaIn: European Journal of Cancer (EJC) Jg. 67 (2016) S. 46 - 54Online Volltext: dx.doi.org/ (Open Access)
-
Health-related quality-of-life (HRQOL) impact of dabrafenib (D) and trametinib (T) vs BRAF inhibitor (BRAFi) monotherapy by lactate dehydrogenase (LDH) in patients (pts) with BRAF V600–mutant melanomaIn: Annals of Oncology Jg. 27 (2016) Nr. Suppl. 6, S. 1137POnline Volltext: dx.doi.org/
-
High TERT promoter mutation frequency in non-acral cutaneous metastatic melanomaIn: Pigment Cell and Melanoma Research Jg. 29 (2016) Nr. 5, S. 598 - 600Online Volltext: dx.doi.org/
-
Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with IpilimumabIn: Clinical Cancer Research Jg. 22 (2016) Nr. 19, S. 4848 - 4858Online Volltext: dx.doi.org/
-
Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survivalIn: International Journal of Cancer Jg. 139 (2016) Nr. 6, S. 1297 - 1302Online Volltext: dx.doi.org/ (Open Access)
-
Initial misdiagnosis of melanoma located on the foot is associated with poorer prognosisIn: Medicine Jg. 95 (2016) Nr. 29, S. e4332Online Volltext: dx.doi.org/ (Open Access)
-
Management of Adverse Events Following Treatment With Anti-Programmed Death-1 AgentsIn: The Oncologist Jg. 21 (2016) Nr. 10, S. 1230 - 1240Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Mapping of deletion breakpoints at the CDKN2A locus in melanoma : Detection of MTAP-ANRIL fusion transcriptsIn: OncoTarget Jg. 7 (2016) Nr. 13, S. 16490 - 16504Online Volltext: dx.doi.org/
-
Medikamentöse Therapie des metastasierten malignen MelanomsIn: Arzneimitteltherapie (AMT) Jg. 34 (2016) Nr. 1-2, S. 14 - 22
-
Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic LatencyIn: Cancer Research Jg. 76 (2016) Nr. 15, S. 4347 - 4358Online Volltext: dx.doi.org/
-
Molecular features of response to anti-PD-1 therapyIn: Chinese Clinical Oncology Jg. 5 (2016) Nr. 6, S. 74Online Volltext: dx.doi.org/ (Open Access)
-
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapyIn: European Journal of Cancer (EJC) Jg. 60 (2016) S. 210 - 225Online Volltext: dx.doi.org/
-
Oncogene Status of an Interdigitating Dendritic Cell Sarcoma : Recurrent Mutations in NF1, TP53, and ARID2 Shared With MelanomaIn: The American Journal of Surgical Pathology Jg. 40 (2016) Nr. 12, S. 1721 - 1723Online Volltext: dx.doi.org/
-
Oncogene status as a diagnostic tool in ocular and cutaneous melanomaIn: European Journal of Cancer (EJC) Jg. 57 (2016) S. 112 - 117Online Volltext: dx.doi.org/
-
PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL) : A pooled analysisIn: Annals of Oncology Jg. 27 (2016) Nr. Suppl. 6, S. 1112PDOnline Volltext: dx.doi.org/
-
Phenotypic characterization and prognostic impact of circulating γδ and αβ T-cells in metastatic malignant melanomaIn: International Journal of Cancer Jg. 138 (2016) Nr. 3, S. 698 - 704Online Volltext: dx.doi.org/ (Open Access)
-
Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanomaIn: European Journal of Cancer (EJC) Jg. 59 (2016) S. 109 - 112Online Volltext: dx.doi.org/
-
Photoacoustic imaging of real-time oxygen changes in chronic leg ulcers after topical application of a haemoglobin spray : a pilot studyIn: Journal of Wound Care Jg. 25 (2016) Nr. 2, S. 87 - 91Online Volltext: dx.doi.org/
-
Pooled analysis of factors to predict durable clinical outcomes with combination dabrafenib (D) and trametinib (T) across registration trialsIn: Annals of Oncology Jg. 27 (2016) Nr. Suppl. 6, S. 1134POnline Volltext: dx.doi.org/
-
Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapyIn: Medicine Jg. 95 (2016) Nr. 46, S. e5375Online Volltext: dx.doi.org/ (Open Access)
-
Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumabIn: European Journal of Cancer (EJC) Jg. 64 (2016) S. 116 - 126Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Proteasomes generate spliced epitopes by two different mechanisms and as efficiently as non-spliced epitopesIn: Scientific Reports Jg. 6 (2016) S. 24032Online Volltext: dx.doi.org/ (Open Access)
-
SERPINB1 expression is predictive for sensitivity and outcome of cisplatin-based chemotherapy in melanomaIn: OncoTarget Jg. 7 (2016) Nr. 9, S. 10117 - 10132Online Volltext: dx.doi.org/ (Open Access)
-
Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma : results of a phase I dose escalation studyIn: ESMO Open Jg. 1 (2016) Nr. 4, S. e000068Online Volltext: dx.doi.org/ (Open Access)
-
Single-strand DNA library preparation improves sequencing of formalin-fixed and paraffin-embedded (FFPE) cancer DNAIn: OncoTarget Jg. 7 (2016) Nr. 37, S. 59115 - 59128Online Volltext: dx.doi.org/ (Open Access)
-
Survival of patients with advanced metastatic melanoma: The impact of novel therapiesIn: European Journal of Cancer (EJC) Jg. 53 (2016) S. 125 - 134Online Volltext: dx.doi.org/
-
Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous systemIn: Journal of Neuro-Oncology Jg. 127 (2016) Nr. 3, S. 435 - 444Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
The Influence of HLA and KIR Genes on Malignant Melanoma Development and ProgressionIn: Archivum Immunologiae et Therapiae Experimentalis Jg. 64 (2016) Nr. Suppl. 1, S. 73 - 81Online Volltext: dx.doi.org/
-
The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor geneIn: Science Translational Medicine Jg. 8 (2016) Nr. 369, S. 369ra177Online Volltext: dx.doi.org/
-
Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanomaIn: Annals of Oncology Jg. 27 (2016) Nr. Suppl. 6, S. LBA40Online Volltext: dx.doi.org/
-
Treatment patterns of advanced malignant melanoma (stage III–IV) – A review of current standards in EuropeIn: European Journal of Cancer (EJC) Jg. 60 (2016) S. 179 - 189Online Volltext: dx.doi.org/
-
sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistanceIn: Nature Jg. 532 (2016) Nr. 7598, S. 250 - 254Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma : pretreatment impacts survivalIn: Annals of Oncology Jg. 26 (2015) Nr. 3, S. 573 - 582Online Volltext: dx.doi.org/ (Open Access)
-
Acquired BRAF inhibitor resistance : A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanismsIn: European Journal of Cancer (EJC) Jg. 51 (2015) Nr. 18, S. 2792 - 2799Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Actual practice of melanoma follow-up and treatment in Germany : results of a prospective, longitudinal cohort studyIn: British Journal of Dermatology: BJD Jg. 172 (2015) Nr. 6, S. 1646 - 1650Online Volltext: dx.doi.org/
-
Analysis of SDHD promoter mutations in various types of melanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 13 (2015) Nr. Suppl. 2, S. 11Online Volltext: dx.doi.org/
-
Analysis of SDHD promoter mutations in various types of melanomaIn: OncoTarget Jg. 6 (2015) Nr. 28, S. 25868 - 25882Online Volltext: dx.doi.org/ (Open Access)
-
Antitumor activity of miR-1280 in melanoma by regulation of SrcIn: Molecular Therapy Jg. 23 (2015) Nr. 1, S. 71 - 78Online Volltext: dx.doi.org/ (Open Access)
-
Assessing quality and functionality of DNA isolated from FFPE tissues through external quality assessment in tissue banksIn: Clinical Chemistry and Laboratory Medicine Jg. 53 (2015) Nr. 12, S. 1927 - 1934Online Volltext: dx.doi.org/
-
CEACAM1-3S drives melanoma cells into NK cell-mediated cytolysis and enhances patient survivalIn: Cancer Research Jg. 75 (2015) Nr. 9, S. 1897 - 1907Online Volltext: dx.doi.org/ (Open Access)
-
CEACAM1-4L promotes anchorage-independent growth in melanomaIn: Frontiers in Oncology Jg. 5 (2015) 234Online Volltext: dx.doi.org/ (Open Access)
-
Clinical application of noninvasive and nonradioactive determination of microscopic lymph node tumor status by multispectral optoacoustic imagingIn: Journal of Nuclear Medicine (JNM) Jg. 56 (2015) Nr. Suppl. 3, S. 40
-
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaIn: The New England Journal of Medicine Jg. 373 (2015) Nr. 1, S. 23 - 34Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Combining BRAF(V) (600E) inhibition with modulators of the mitochondrial bioenergy metabolism to overcome drug resistance in metastatic melanomaIn: Experimental Dermatology Jg. 24 (2015) Nr. 9, S. 709 - 710Online Volltext: dx.doi.org/
-
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v) : results of a phase 3, open-label, randomised trialIn: The Lancet Oncology Jg. 16 (2015) Nr. 13, S. 1389 - 1398Online Volltext: dx.doi.org/
-
Concordance of BRAF V600E mutation status in metastatic melanoma patients by comparison of results from circulating tumor DNA and tissue-based testingIn: European Journal of Cancer (EJC) Jg. 51 (2015) Nr. Suppl. 3, S. S685Online Volltext: dx.doi.org/
-
Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of InfectionIn: PLoS ONE Jg. 10 (2015) Nr. 4, S. e0124590Online Volltext: dx.doi.org/ (Open Access)
-
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma : a multicentre, double-blind, phase 3 randomised controlled trialIn: Lancet Jg. 386 (2015) Nr. 9992, S. 444 - 451Online Volltext: dx.doi.org/
-
Die multispektraloptoakustische Tomographie (MSOT) zur nichtinvasiven Diagnostik des Schildwächterlymphknotens bei Patienten mit malignem MelanomIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 13 (2015) Nr. 12, S. 1323Online Volltext: dx.doi.org/
-
Disease kinetics for decision-making in advanced melanoma : a call for scenario-driven strategy trialsIn: The Lancet Oncology Jg. 16 (2015) Nr. 13, S. e522 - e526Online Volltext: dx.doi.org/
-
Erratum : Anticancer immunotherapy by CTLA-4 blockade: Obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25In: Cell Research Jg. 25 (2015) Nr. 3, S. 399 - 400Online Volltext: dx.doi.org/
-
Evaluation of a radioactive and fluorescent hybrid tracer for sentinel lymph node biopsy in head and neck malignancies : prospective randomized clinical trial to compare ICG-99mTc-nanocolloid hybrid tracer versus 99mTc-nanocolloidIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 42 (2015) Nr. 11, S. 1631 - 1638Online Volltext: dx.doi.org/
-
Expanded access programmes : patient interests versus clinical trial integrityIn: The Lancet Oncology Jg. 16 (2015) Nr. 1, S. 15 - 17Online Volltext: dx.doi.org/
-
Expectation-induced placebo responses fail to accelerate wound healing in healthy volunteers : results from a prospective controlled experimental trialIn: International Wound Journal (IWJ) Jg. 12 (2015) Nr. 6, S. 664 - 668Online Volltext: dx.doi.org/
-
Frequent TERT Promoter Mutations in Ocular Surface Squamous NeoplasiaIn: Investigative Ophthalmology & Visual Science, IOVS Jg. 56 (2015) Nr. 10, S. 5854 - 5861Online Volltext: dx.doi.org/ (Open Access)
-
Genes involved in the WNT and vesicular trafficking pathways are associated with melanoma predispositionIn: International Journal of Cancer Jg. 136 (2015) Nr. 9, S. 2109 - 2119Online Volltext: dx.doi.org/
-
Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanomaIn: Nature Genetics Jg. 47 (2015) Nr. 9, S. 987 - 995Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Genomic Classification of Cutaneous MelanomaIn: Cell Jg. 161 (2015) Nr. 7, S. 1681 - 1696Online Volltext: dx.doi.org/ (Open Access)
-
Genomic correlates of response to CTLA-4 blockade in metastatic melanomaIn: Science Jg. 350 (2015) Nr. 6257, S. 207 - 211Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanomaIn: European Journal of Cancer (EJC) Jg. 51 (2015) Nr. 7, S. 833 - 840Online Volltext: dx.doi.org/
-
Improved overall survival in melanoma with combined dabrafenib and trametinibIn: The New England Journal of Medicine Jg. 372 (2015) Nr. 1, S. 30 - 39Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Independent replication of a melanoma subtype gene signature and evaluation of its prognostic value and biological correlates in a population cohortIn: OncoTarget Jg. 6 (2015) Nr. 13, S. 11683 - 11693Online Volltext: dx.doi.org/ (Open Access)
-
Integrating first-line treatment options into clinical practice : What's new in advanced melanoma?In: Melanoma Research Jg. 25 (2015) Nr. 6, S. 461 - 469Online Volltext: dx.doi.org/
-
Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma : Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group TrialIn: Journal of Clinical Oncology (JCO) Jg. 33 (2015) Nr. 34, S. 4077 - 4084Online Volltext: dx.doi.org/
-
Intraoperative Fluorescence Imaging for Sentinel Lymph Node Detection : Prospective Clinical Trial to Compare the Usefulness of Indocyanine Green vs Technetium Tc 99m for Identification of Sentinel Lymph NodesIn: JAMA Surgery Jg. 150 (2015) Nr. 7, S. 617 - 623Online Volltext: dx.doi.org/ (Open Access)
-
MITF is a critical regulator of the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in malignant melanomaIn: Pigment Cell and Melanoma Research Jg. 28 (2015) Nr. 6, S. 736 - 740Online Volltext: dx.doi.org/
-
Metastatic status of sentinel lymph nodes in melanoma determined noninvasively with multispectral optoacoustic imagingIn: Immunotherapy Jg. 7 (2015) Nr. 317, S. 317ra199Online Volltext: dx.doi.org/
-
Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulationsIn: Experimental Dermatology Jg. 24 (2015) Nr. 2, S. 155 - 157Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with IpilimumabIn: Clinical Cancer Research Jg. 21 (2015) Nr. 24, S. 5453 - 5459Online Volltext: dx.doi.org/ (Open Access)
-
NEMO : A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with advanced NRAS-mutant melanoma who are untreated or have progressed on or after immunotherapyIn: Cancer Research Jg. 75 (2015) Nr. Suppl. 14, S. B16Online Volltext: dx.doi.org/
-
Nachruf für Prof. Dr. med. Christiane Voit (Berlin)In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 13 (2015) Nr. 8, S. 851 - 852Online Volltext: dx.doi.org/
-
Nivolumab in previously untreated melanoma without BRAF mutationIn: The New England Journal of Medicine Jg. 372 (2015) Nr. 4, S. 311 - 319Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanomaIn: Journal of Translational Medicine Jg. 13 (2015) Nr. 1, S. 351Online Volltext: dx.doi.org/ (Open Access)
-
Panel Sequencing MelanomasIn: Journal of Investigative Dermatology Jg. 135 (2015) Nr. 2, S. 335 - 336Online Volltext: dx.doi.org/ (Open Access)
-
Pembrolizumab versus Ipilimumab in Advanced MelanomaIn: The New England Journal of Medicine Jg. 372 (2015) Nr. 26, S. 2521 - 2532Online Volltext: dx.doi.org/
-
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002) : a randomised, controlled, phase 2 trialIn: The Lancet Oncology Jg. 16 (2015) Nr. 8, S. 908 - 918Online Volltext: dx.doi.org/
-
Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal MelanomaIn: PLoS ONE Jg. 10 (2015) Nr. 3, S. e0118564Online Volltext: dx.doi.org/ (Open Access)
-
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic MelanomaIn: Journal of Clinical Oncology (JCO) Jg. 33 (2015) Nr. 17, S. 1889 - 1894Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Prognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patientsIn: International Journal of Cancer Jg. 136 (2015) Nr. 1, S. 138 - 151Online Volltext: dx.doi.org/
-
Prolongation of QTc interval in HIV-infected individuals compared to the general population is not caused by antiretroviral therapyIn: Journal of the International AIDS Society Jg. 18 (2015) Nr. Suppl. 4, S. 20479Online Volltext: dx.doi.org/ (Open Access)
-
Prospective evaluation of follow-up in melanoma patients in Germany : results of a multicentre and longitudinal studyIn: European Journal of Cancer (EJC) Jg. 51 (2015) Nr. 5, S. 653 - 667Online Volltext: dx.doi.org/
-
Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patientsIn: Annals of Oncology Jg. 26 (2015) Nr. 6, S. 1238 - 1244Online Volltext: dx.doi.org/ (Open Access)
-
Reply to the letters to the editor ‘Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma’ by Diwakar et al.In: Annals of Oncology Jg. 26 (2015) Nr. 1, S. 250 - 251Online Volltext: dx.doi.org/
-
ResponseIn: Journal of the National Cancer Institute (JNCI) Jg. 107 (2015) Nr. 4, S. djv051Online Volltext: dx.doi.org/
-
Segmentally arranged seborrhoeic keratoses with impending atypia and squamous cell carcinoma in an elderly womanIn: British Journal of Dermatology: BJD Jg. 172 (2015) Nr. 6, S. 1642 - 1645Online Volltext: dx.doi.org/
-
Systemic therapies for melanoma brain metastases : which drug for whom and when?In: Chinese Clinical Oncology Jg. 4 (2015) Nr. 2, S. 25 - 29Online Volltext: dx.doi.org/
-
Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathwayIn: OncoTarget Jg. 6 (2015) Nr. 34, S. 36041 - 36052Online Volltext: dx.doi.org/ (Open Access)
-
Targeting mitosis-regulating genes in cisplatin-sensitive and -resistant melanoma cells : a live-cell RNAi screen displays differential nucleus-derived phenotypesIn: Biotechnology Journal Jg. 10 (2015) Nr. 9, S. 1467 - 1477Online Volltext: dx.doi.org/
-
The GERMELATOX DeCOG-trial : The attitude of German melanoma patients towards toxicity during adjuvant interferon treatment - Differences between the patient's and the physician's perspectiveIn: European Journal of Cancer (EJC) Jg. 51 (2015) Nr. Suppl. 3, S. S671 - S672Online Volltext: dx.doi.org/
-
Therapie des malignen MelanomsIn: Der Onkologe Jg. 21 (2015) Nr. 10, S. 965 - 974Online Volltext: dx.doi.org/
-
Treatment algorithms in stage IV melanomaIn: American Journal of Therapeutics Jg. 22 (2015) Nr. 1, S. 61 - 67Online Volltext: dx.doi.org/; Online Volltext: dx.doi.org/ (Open Access)
-
Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanomaIn: European Journal of Cancer (EJC) Jg. 51 (2015) Nr. Suppl. 3, S. S663Online Volltext: dx.doi.org/
-
VorwortIn: Oncology Research and Treatment Jg. 38 (2015) Nr. Suppl. 3, S. 1Online Volltext: dx.doi.org/
-
miR-638 promotes melanoma metastasis and protects melanoma cells from apoptosis and autophagyIn: OncoTarget Jg. 6 (2015) Nr. 5, S. 2966 - 2980Online Volltext: dx.doi.org/ (Open Access)
-
An inherited variant in the gene coding for vitamin D-binding protein and survival from cutaneous melanoma : a BioGenoMEL studyIn: Pigment Cell and Melanoma Research Jg. 27 (2014) Nr. 2, S. 234 - 243Online Volltext: dx.doi.org/ (Open Access)
-
Angioplasmacellular hyperplasia - a new histopathologic clue for anogenital herpes simplex recidivans in immunocompromised patients?In: American Journal of Dermatopathology Jg. 36 (2014) Nr. 10, S. 822 - 826Online Volltext: dx.doi.org/
-
Arbeitsgemeinschaft Dermatologische Onkologie – eine dermatologische ErfolgsgeschichteIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 12 (2014) Nr. Suppl. 4, S. 40 - 41Online Volltext: dx.doi.org/
-
Behandlungsalgorithmus bei Patienten mit malignem MelanomIn: Der Onkologe Jg. 20 (2014) Nr. 6, S. 533 - 534Online Volltext: dx.doi.org/
-
Childhood Psoriasis : An Analysis of German Health Insurance DataIn: Pediatric Dermatology Jg. 31 (2014) Nr. 1, S. 8 - 13Online Volltext: dx.doi.org/
-
Circulating CD4+ T cells that produce IL4 or IL17 when stimulated by Melan-A but not by NY-ESO-1 have negative impacts on survival of patients with stage IV melanomaIn: Clinical Cancer Research Jg. 20 (2014) Nr. 16, S. 4390 - 4399Online Volltext: dx.doi.org/
-
Clinical benefit assessment of vismodegib therapy in patients with advanced basal cell carcinomaIn: The Oncologist Jg. 19 (2014) Nr. 8, S. 790 - 796Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Clinical performance of the Nevisense system in cutaneous melanoma detection : an international, multicentre, prospective and blinded clinical trial on efficacy and safetyIn: British Journal of Dermatology: BJD Jg. 171 (2014) Nr. 5, S. 1099 - 1107Online Volltext: dx.doi.org/ (Open Access)
-
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanomaIn: The New England Journal of Medicine Jg. 371 (2014) Nr. 20, S. 1877 - 1888Online Volltext: dx.doi.org/ (Open Access)
-
Cost-effectiveness of preoperative SPECT/CT combined with lymphoscintigraphy vs. lymphoscintigraphy for sentinel lymph node excision in patients with cutaneous malignant melanomaIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 41 (2014) Nr. 9, S. 1723 - 1731Online Volltext: dx.doi.org/
-
Die Photooptoakustische Tomographie zur nicht invasiven und nicht radioaktiven Bestimmung des Schildw € achterlymphknotenstatus bei MelanompatientenIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 12 (2014) Nr. Suppl. 3, S. 5 - 6Online Volltext: dx.doi.org/
-
Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanomaIn: Annals of Oncology Jg. 25 (2014) Nr. 3, S. 747 - 753Online Volltext: dx.doi.org/
-
Expression of stress ligands of the immunoreceptor NKG2D in melanoma : regulation and clinical significanceIn: European Journal of Cell Biology (EJCB) Jg. 93 (2014) Nr. 1-2, S. 49 - 54Online Volltext: dx.doi.org/
-
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma : Quality-of-life analyses of the METRIC studyIn: Annals of Oncology Jg. 25 (2014) Nr. 3, S. 700 - 706Online Volltext: dx.doi.org/
-
Genetic alterations and personalized medicine in melanoma: Progress and future prospectsIn: Journal of the National Cancer Institute (JNCI) Jg. 106 (2014) Nr. 2, S. djt435Online Volltext: dx.doi.org/
-
Genetic and clinico-pathologic analysis of metastatic uveal melanomaIn: Modern Pathology Jg. 27 (2014) Nr. 2, S. 175 - 183Online Volltext: dx.doi.org/
-
Genetic evolution of T-cell resistance in the course of melanoma progressionIn: Clinical Cancer Research Jg. 20 (2014) Nr. 24, S. 6593 - 6604Online Volltext: dx.doi.org/
-
Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021) : A multicentric randomized trialIn: Annals of Oncology Jg. 25 (2014) Nr. 3, S. 742 - 746Online Volltext: dx.doi.org/
-
Immunonkologie "Coming of Age" : die nächste Generation der Immun-Checkpoint-InhibitorenIn: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 4, S. 6 - 9Online Volltext: dx.doi.org/
-
Immunonkologie «Coming of Age» - die nächste Generation der Immun-Checkpoint-InhibitorenIn: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 4, S. 6 - 9
-
Incidence of new primary melanomas after diagnosis of stage III and IV melanomaIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 8, S. 816 - 823Online Volltext: dx.doi.org/
-
Inherited variation in the PARP1 gene and survival from melanomaIn: International Journal of Cancer Jg. 135 (2014) Nr. 7, S. 1625 - 1633Online Volltext: dx.doi.org/ (Open Access)
-
Isoform-specific function of CEACAM1 during tumorigenesis : CEACAM1-3S, a novel prognostic biomarker in malignant melanomaIn: Experimental Dermatology Jg. 23 (2014) Nr. 3, S. E45Online Volltext: dx.doi.org/
-
MIKIE : A randomized, double-blind, regimen-controlled, phase II, multicenter study to assess the efficacy and safety of two different vismodegib regimens in patients with multiple basal cell carcinomasIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15, suppl., S. TPS9121Online Volltext: dx.doi.org/
-
Medikamentöse Systemtherapie des MelanomsIn: Der Onkologe Jg. 20 (2014) Nr. 6, S. 568 - 576Online Volltext: dx.doi.org/
-
Melanoma in 2013 : Melanoma - The run of success continuesIn: Nature Reviews Clinical Oncology Jg. 11 (2014) Nr. 2, S. 75 - 76Online Volltext: dx.doi.org/
-
Metastatic basal cell carcinoma : prognosis dependent on anatomic site and spread of diseaseIn: European Journal of Cancer (EJC) Jg. 50 (2014) Nr. 4, S. 774 - 783Online Volltext: dx.doi.org/ (Open Access)
-
Myeloid-derived suppressor cells predict survival of patients with advanced melanoma : Comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cellsIn: Clinical Cancer Research Jg. 20 (2014) Nr. 6, S. 1601 - 1609Online Volltext: dx.doi.org/
-
Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans : A multicenter phase II DeCOG Trial with Long-Term Follow-UpIn: Clinical Cancer Research Jg. 20 (2014) Nr. 2, S. 499 - 510Online Volltext: dx.doi.org/
-
Peripheral immune signatures and survival in stage IV melanomaIn: Cancer Research Jg. 74 (2014) Nr. 19 Suppl., S. 2547Online Volltext: dx.doi.org/
-
Primary tumor versus metastasis : new experimental models for studies on cancer cell homing and metastasis in melanomaIn: Pigment Cell and Melanoma Research Jg. 27 (2014) Nr. 2, S. 309 - 316Online Volltext: dx.doi.org/
-
Quality assurance for care of melanoma patients based on guideline-derived quality indicators and certificationIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 12 (2014) Nr. 2, S. 139 - 147Online Volltext: dx.doi.org/
-
Reply to M. Perier-Muzet et al [Safety and Management of New Primary Melanomas During Receipt of BRAF Inhibitors ]In: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 28, S. 3203 - 3204Online Volltext: dx.doi.org/
-
Retarded low-dose doxycycline for EGFR or MEK inhibitor-induced papulopustular rashIn: Journal of the European Academy of Dermatology and Venereology Jg. 28 (2014) Nr. 12, S. 1685 - 1689Online Volltext: dx.doi.org/
-
STAT3 single nucleotide polymorphism rs4796793 SNP does not correlate with response to adjuvant IFNα therapy in stage III melanoma patientsIn: Frontiers in Medicine Jg. 1 (2014) Nr. 47,Online Volltext: dx.doi.org/ (Open Access)
-
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3) : extended follow-up of a phase 3, randomised, open-label studyIn: The Lancet Oncology Jg. 15 (2014) Nr. 3, S. 323 - 332Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutationIn: The New England Journal of Medicine Jg. 371 (2014) Nr. 9, S. 880 - 882Online Volltext: dx.doi.org/
-
Statin use and its effect on all-cause mortality of melanoma patients : a population-based Dutch cohort studyIn: Cancer Medicine Jg. 3 (2014) Nr. 5, S. 1284 - 1293Online Volltext: dx.doi.org/ (Open Access)
-
Surrogate endpoints for overall survival in metastatic melanoma: A meta-analysis of randomised controlled trialsIn: The Lancet Oncology Jg. 15 (2014) Nr. 3, S. 297 - 304Online Volltext: dx.doi.org/
-
TERT promoter mutation status as an independent prognostic factor in cutaneous melanomaIn: Journal of the National Cancer Institute (JNCI) Jg. 106 (2014) Nr. 9,Online Volltext: dx.doi.org/
-
TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomasIn: Modern Pathology Jg. 27 (2014) Nr. 4, S. 502 - 508Online Volltext: dx.doi.org/ (Open Access)
-
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic MelanomaIn: Cancer Discovery Jg. 4 (2014) Nr. 1, S. 94 - 109Online Volltext: dx.doi.org/
-
The impact of the immune system on tumor : angiogenesis and vascular remodelingIn: Frontiers in Oncology Jg. 4 (2014) S. 69Online Volltext: dx.doi.org/ (Open Access)
-
The validity of circulating microRNAs in oncology : Five years of challenges and contradictionsIn: Molecular Oncology Jg. 8 (2014) Nr. 4, S. 819 - 829Online Volltext: dx.doi.org/ (Open Access)
-
Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanomaIn: Nature Jg. 507 (2014) Nr. 7490, S. 109 - 113Online Volltext: dx.doi.org/
-
Upstream mitogen-activated protein kinase (MAPK) pathway inhibition : MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patientsIn: European Journal of Cancer (EJC) Jg. 50 (2014) Nr. 2, S. 406 - 410Online Volltext: dx.doi.org/
-
A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF InhibitionIn: Cancer Discovery Jg. 3 (2013) Nr. 3, S. 351 - 362Online Volltext: dx.doi.org/
-
Analysis of dermatologic events in vemurafenib-treated patients with melanomaIn: The Oncologist Jg. 18 (2013) Nr. 3, S. 314 - 322Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Autoimmuno-hypophysitis, Autoimmuno-colitis and Autoimmuno-hepatitis in a Patient with metastatic Melanoma during Therapy with CTLA-4 Antibody IpilimumabIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 11 (2013) Nr. 9, S. 932
-
B-type natriuretic peptide elevation is more frequent in HIV plus patients compared to the general populationIn: Antiviral Therapy Jg. 18 (2013) Nr. Suppl. 3, S. A41 - A42
-
Cognitive factors mediate placebo responses in patients with house dust mite allergyIn: PLoS ONE Jg. 8 (2013) Nr. 11, S. e79576Online Volltext: dx.doi.org/ (Open Access)
-
Combination of BRAF inhibitors and brain radiotherapy in patients with metastatic melanoma shows minimal acute toxicityIn: Journal of Clinical Oncology (JCO) Jg. 31 (2013) Nr. 30, S. 3844 - 3845Online Volltext: dx.doi.org/
-
Conjunctival Melanomas Harbor BRAF and NRAS Mutations—ResponseIn: Clinical Cancer Research Jg. 19 (2013) Nr. 22, S. 6331 - 6332Online Volltext: dx.doi.org/
-
Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomasIn: Clinical Cancer Research Jg. 19 (2013) Nr. 12, S. 3143 - 3152Online Volltext: dx.doi.org/
-
Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma.In: Journal of Investigative Dermatology Jg. 133 (2013) Nr. 6, S. 1610 - 1619Online Volltext: dx.doi.org/ (Open Access)
-
Dermatologic adverse events associated with afatinib : An oral ErbB family blockerIn: Expert Review of Anticancer Therapy Jg. 13 (2013) Nr. 6, S. 721 - 728Online Volltext: dx.doi.org/
-
Die neue S3-Leitlinie "melanom" : Das Wichtigste für die PraxisIn: Best Practice Onkologie Jg. 8 (2013) Nr. 2, S. 40 - 48Online Volltext: dx.doi.org/
-
Die neue S3-leitlinie "Diagnostik, therapie und nachsorge des malignen melanoms" : Wie soll das staging durchgeführt werden?In: Haut: Dermatologie, Allergologie, Kosmetologie Jg. 24 (2013) Nr. 3, S. 124 - 128
-
Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease controlIn: Clinical Cancer Research Jg. 19 (2013) Nr. 8, S. 2232 - 2239Online Volltext: dx.doi.org/
-
Framingham risk score and cardiovascular risk profiles in HIV+ patients and HIV- controls differ by sexIn: European Heart Journal Jg. 34 (2013) Nr. Suppl. 1, S. P5164Online Volltext: dx.doi.org/
-
Hautkrebsforschung reloaded : Paradigmenwechsel in der DermatoonkologieIn: Unikate: Berichte aus Forschung und Lehre (2013) Nr. 44: Medizin: 50 Jahre Universitätsklinikum Essen, S. 136 - 143Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Intracerebral metastases of malignant melanoma and their recurrences : a clinical analysisIn: Clinical Neurology and Neurosurgery Jg. 115 (2013) Nr. 9, S. 1721 - 1728Online Volltext: dx.doi.org/
-
Isolated cerebral susceptibility artefacts in patients with malignant melanoma : Metastasis or not?In: European Radiology Jg. 23 (2013) Nr. 9, S. 2622 - 2627Online Volltext: dx.doi.org/
-
Kombination von BRAF-Inhibitoren (BRAFi) und zerebraler Bestrahlung bei Patienten mit metastasiertem Melanom : Eine mögliche Behandlungsoption für neu aufgetretene oder pro-grediente Hirnmetastasen unter Therapie mit BRAF-InhibitorenIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 11 (2013) Nr. 9, S. 952 - 952
-
Lack of SF3B1 R625 mutations in cutaneous melanomaIn: Diagnostic Pathology Jg. 8 (2013) S. 87Online Volltext: dx.doi.org/ (Open Access)
-
Lecithin retinol acyltransferase as a potential prognostic marker for malignant melanomaIn: Experimental Dermatology Jg. 22 (2013) Nr. 11, S. 757 - 759Online Volltext: dx.doi.org/
-
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: A non-randomised, open-label phase 2 studyIn: The Lancet Oncology Jg. 14 (2013) Nr. 3, S. 249 - 256Online Volltext: dx.doi.org/
-
Malignes melanom S3-leitlinie "Diagnostik, Therapie und Nachsorge des Melanoms"In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 11 (2013) Nr. Suppl. 6, S. 1 - 116; 1 - 126Online Volltext: dx.doi.org/ (Open Access)
-
MiR-101 inhibits melanoma cell invasion and proliferation by targeting MITF and EZH2In: Cancer Letters Jg. 341 (2013) Nr. 2, S. 240 - 247Online Volltext: dx.doi.org/
-
MiR-137 inhibits the invasion of melanoma cells through downregulation of multiple oncogenic target genesIn: Journal of Investigative Dermatology Jg. 133 (2013) Nr. 3, S. 768 - 775Online Volltext: dx.doi.org/ (Open Access)
-
Neue Entwicklungen in der Behandlung von soliden Tumoren mit zielgerichteten Medikamenten. Lunge, Niere, MelanomIn: Der Onkologe Jg. 19 (2013) Nr. 10, S. 821 - 834Online Volltext: dx.doi.org/
-
Neuropilin-1 Deficiency on CD4+Foxp3+Regulatory T Cells Modulates Tumor Angiogenesis and Impaires Tumor Growth in MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 11 (2013) Nr. Suppl. S7, S. 30Online Volltext: dx.doi.org/
-
Neuropilin-1 is a key mediator of VEGF-dependent Treg migration to tumorsIn: International Journal of Molecular Medicine Jg. 32 (2013) Nr. Suppl. 1, S. S36
-
New developments in biomarkers for melanomaIn: Current Opinion in Oncology Jg. 25 (2013) Nr. 2, S. 145 - 151Online Volltext: dx.doi.org/
-
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanomaIn: Journal of Clinical Oncology (JCO) Jg. 31 (2013) Nr. 26, S. 3205 - 3211Online Volltext: dx.doi.org/
-
Prevalence of cardiovascular diseases in HIV-infected outpatients: Results from a prospective, multicenter cohort studyIn: Clinical Research in Cardiology Jg. 102 (2013) Nr. 3, S. 203 - 213Online Volltext: dx.doi.org/
-
Psychotropic drugs are prescribed more frequently in HIV-positive patients compared to the general population. Data from two German prospective cohorts : Heinz Nixdorf Recall Study and HIV HEART StudyIn: Antiviral Therapy Jg. 18 (2013) Nr. Suppl. 3, S. A77 - A78
-
Rapid progression of a splenic aneurysm due to segmental arterial mediolysis: : a rare cause of acute pancreatitisIn: Pancreatology Jg. 13 (2013) Nr. 5, S. 553 - 556Online Volltext: dx.doi.org/
-
Risk loci for coronary artery calcification replicated at 9p21 and 6q24 in the Heinz Nixdorf Recall StudyIn: BMC Medical Genetics Jg. 14 (2013) Nr. 1, S. 23Online Volltext: dx.doi.org/ (Open Access)
-
S3-Guideline "diagnosis, therapy and follow-up of melanoma" - short versionIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 11 (2013) Nr. 6, S. 593 - 602Online Volltext: dx.doi.org/
-
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma : A phase 2 double-blind randomised studyIn: The Lancet Oncology Jg. 14 (2013) Nr. 8, S. 733 - 740Online Volltext: dx.doi.org/
-
TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinomaIn: PLoS ONE Jg. 8 (2013) Nr. 11, S. e80354Online Volltext: dx.doi.org/ (Open Access)
-
TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphismIn: Proceedings of the National Academy of Sciences of the United States of America (PNAS) Jg. 110 (2013) Nr. 43, S. 17426 - 17431Online Volltext: dx.doi.org/
-
TERT promoter mutations in familial and sporadic melanomaIn: Science Jg. 339 (2013) Nr. 6122, S. 959 - 961Online Volltext: dx.doi.org/
-
TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumoursIn: British Journal of Cancer (BJC) Jg. 109 (2013) Nr. 2, S. 497 - 501Online Volltext: dx.doi.org/ (Open Access)
-
Targeting CD4+ T-helper cells improves the induction of antitumor responses in dendritic cell -based vaccinationIn: Cancer Research Jg. 73 (2013) Nr. 1, S. 19 - 29Online Volltext: dx.doi.org/
-
Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.In: Cancer Medicine Jg. 2 (2013) Nr. 1, S. 76 - 85Online Volltext: dx.doi.org/ (Open Access)
-
The price of tumor control : an analysis of rare side effects of Anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab networkIn: PLoS ONE Jg. 8 (2013) Nr. 1, S. e53745Online Volltext: dx.doi.org/ (Open Access)
-
Tumor regression and sirolimus-based therapy in lung transplantationIn: The Journal of Heart and Lung Transplantation Jg. 32 (2013) Nr. 9, S. 938 - 939Online Volltext: dx.doi.org/
-
Valvular manifestations of human immunodeficiency virus infection - Results from the prospective, multicenter HIV-HEART studyIn: Journal of Cardiovascular Medicine Jg. 14 (2013) Nr. 10, S. 733 - 739Online Volltext: dx.doi.org/
-
Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cellsIn: Science Signaling Jg. 6 (2013) Nr. 260,Online Volltext: dx.doi.org/
-
Vemurafenib reverses immunosuppression by myeloid derived suppressor cellsIn: International Journal of Cancer Jg. 133 (2013) Nr. 7, S. 1653 - 1663Online Volltext: dx.doi.org/
-
Vemurafenib reverses immunosuppression by myeloid derived suppressor cellsIn: Cancer Research Jg. 73 (2013) Nr. 8 Suppl., S. 4714Online Volltext: dx.doi.org/
-
β-Blocker use and all-cause mortality of melanoma patients : results from a population-based Dutch cohort studyIn: European Journal of Cancer (EJC) Jg. 49 (2013) Nr. 18, S. 3863 - 3871Online Volltext: dx.doi.org/
-
A Landscape of Driver Mutations in MelanomaIn: Cell Jg. 150 (2012) Nr. 2, S. 251 - 263Online Volltext: dx.doi.org/
-
Advances and perspectives in immunotherapy of melanomaIn: Annals of Oncology Jg. 23 (2012) Nr. Suppl. 10, S. x104 - x108Online Volltext: dx.doi.org/ Online Volltext
-
Advantages of preoperative ultrasound in conjunction with lymphoscintigraphy in detecting malignant melanoma metastases in sentinel lymph nodes : a retrospective analysis in 221 patients with malignant melanoma AJCC Stages i and IIIn: Journal of the European Academy of Dermatology and Venereology Jg. 26 (2012) Nr. 1, S. 79 - 85Online Volltext: dx.doi.org/
-
Association Between Sentinel Lymph Node Excision With or Without Preoperative SPECT/CT and Metastatic Node Detection and Disease-Free Survival in MelanomaIn: JAMA: Journal of the American Medical Association Jg. 308 (2012) Nr. 10, S. 1007 - 1014Online Volltext: dx.doi.org/
-
Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF InhibitionIn: Journal of Clinical Oncology (JCO) Jg. 30 (2012) Nr. 19, S. 2375 - 2383Online Volltext: dx.doi.org/
-
Brain metastasis : Opportunity for drug development?In: Current Opinion in Neurology Jg. 25 (2012) Nr. 6, S. 786 - 794Online Volltext: dx.doi.org/
-
Brain natriuretic peptide (BNP) : A general mortality predictor in HIV-infected patients? - Results from the 5 year follow-up of the HIV-HEART trialIn: European Heart Journal Jg. 33 (2012) Nr. Suppl. 1, S. 337
-
Current advances and perspectives in the treatment of advanced melanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 10 (2012) Nr. 5, S. 319 - 325Online Volltext: dx.doi.org/
-
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB) : A multicentre, open-label, phase 2 trialIn: The Lancet Oncology Jg. 13 (2012) Nr. 11, S. 1087 - 1095Online Volltext: dx.doi.org/
-
Detection of abacavir hypersensitivity by ELISpot methodIn: Inflammation & Allergy - Drug Targets Jg. 11 (2012) Nr. 3, S. 227 - 234Online Volltext: dx.doi.org/
-
EORTC Melanoma Group achievementsIn: European Journal of Cancer / EJC Supplements Jg. 10 (2012) Nr. 1, S. 112 - 119Online Volltext: dx.doi.org/
-
Fluoreszenz-Markierung mittels Indocyanin-Grün bei der Sentinel-Lymphknoten-Exstirpation in der DermatoonkologieIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 10 (2012) Nr. 1, S. 51 - 58Online Volltext: dx.doi.org/; Online Volltext: dx.doi.org/
-
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasisIn: Journal of Clinical Oncology (JCO) Jg. 30 (2012) Nr. 15, S. 1835 - 1841Online Volltext: dx.doi.org/
-
Gegen den Hautkrebs : Forschung zur Überwindung immuntherapeutischer Hürden beim malignen MelanomIn: Unikate: Berichte aus Forschung und Lehre (2012) Nr. 42: Translationale Krebsforschung: Auf dem Weg zu neuen Therapien, S. 32 - 41Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Good shedder or bad shedder : the influence of skin diseases on forensic DNA analysis from epithelial abrasionsIn: International Journal of Legal Medicine Jg. 126 (2012) Nr. 1, S. 179 - 183Online Volltext: dx.doi.org/
-
Immuntherapie des MelanomsIn: Der Hautarzt Jg. 63 (2012) Nr. 12, S. 952 - 960Online Volltext: dx.doi.org/
-
Immuntherapie des MelanomsIn: Der Onkologe Jg. 18 (2012) Nr. 9, S. 801 - 807Online Volltext: dx.doi.org/
-
Improved survival with MEK inhibition in BRAF-mutated melanomaIn: The New England Journal of Medicine Jg. 367 (2012) Nr. 2, S. 107 - 114Online Volltext: dx.doi.org/
-
Influence of Genetic Variants in Type I Interferon Genes on Melanoma Survival and TherapyIn: PLoS ONE Jg. 7 (2012) Nr. 11, S. 0050692Online Volltext: dx.doi.org/ (Open Access)
-
Inherited variants in the MC1R gene and survival from cutaneous melanoma : A BioGenoMEL studyIn: Pigment Cell and Melanoma Research Jg. 25 (2012) Nr. 3, S. 384 - 394Online Volltext: dx.doi.org/
-
Integrin genes and susceptibility to human melanomaIn: Mutagenesis Jg. 27 (2012) Nr. 3, S. 367 - 373Online Volltext: dx.doi.org/
-
Interleukin 21 augments the hepatitis B virus-specific CD8+ T-cell response in vitro in patients coinfected with HIV-1In: AIDS Jg. 26 (2012) Nr. 17, S. 2145 - 2153Online Volltext: dx.doi.org/
-
Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III MelanomaIn: Journal of Clinical Oncology (JCO) Jg. 30 (2012) Nr. 31, S. 3810 - 3818Online Volltext: dx.doi.org/
-
MEK inhibition in BRAF-mutated melanomaIn: The New England Journal of Medicine Jg. 367 (2012) Nr. 14, S. 1365Online Volltext: dx.doi.org/
-
Melanoma genome sequencing reveals frequent PREX2 mutationsIn: Nature Jg. 485 (2012) Nr. 7399, S. 502 - 506Online Volltext: dx.doi.org/
-
Neuropilin 1 deficiency on CD4⁺Foxp3⁺ regulatory T cells impairs mouse melanoma growthIn: Journal of Experimental Medicine (JEM) Jg. 209 (2012) Nr. 11, S. 2001 - 2016Online Volltext: dx.doi.org/ (Open Access)
-
PHH3 immunostaining improves interobserver agreement of mitotic index in thin melanomasIn: American Journal of Dermatopathology Jg. 34 (2012) Nr. 3, S. 266 - 269Online Volltext: dx.doi.org/
-
Panniculitis With Arthralgia in Patients With Melanoma Treated With Selective BRAF Inhibitors and Its ManagementIn: Archives of Dermatology Jg. 148 (2012) Nr. 3, S. 357 - 361Online Volltext: dx.doi.org/
-
Psoriasis im Kindes- und Jugendalter : Eine bundesweite Ärztebefragung zur Versorgungssituation in DeutschlandIn: Der Hautarzt Jg. 63 (2012) Nr. 10, S. 801 - 807Online Volltext: dx.doi.org/
-
RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF InhibitorsIn: Journal of Clinical Oncology (JCO) Jg. 30 (2012) Nr. 3, S. 316 - 321Online Volltext: dx.doi.org/
-
Radio-guided surgery : Advantages of a new portable γ-camera (Sentinella®) for intraoperative real time imaging and detection of sentinel lymph nodes in cutaneous malignanciesIn: Journal of the European Academy of Dermatology and Venereology Jg. 26 (2012) Nr. 3, S. 308 - 313Online Volltext: dx.doi.org/
-
Randomized phase III trial of intravenous (IV) versus hepatic intra-arterial (HIA) fotemustine in patients with liver metastases from uveal melanoma : Final results of the EORTC 18021 studyIn: Journal of Clinical Oncology (JCO) Jg. 30 (2012) Nr. Suppl. 15, S. 8532
-
Reliability and cost-effectiveness of complete lymph node dissection under tumescent local anaesthesia vs. general anaesthesia : A retrospective analysis in patients with malignant melanoma AJCC stage IIIIn: Journal of the European Academy of Dermatology and Venereology Jg. 26 (2012) Nr. 2, S. 200 - 206Online Volltext: dx.doi.org/
-
Side effects of systemic oncological therapies in dermatologyIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 10 (2012) Nr. 7, S. 475 - 486Online Volltext: dx.doi.org/
-
Skin Examination Behavior : The Role of Melanoma History, Skin Type, Psychosocial Factors, and Region of Residence in Determining Clinical and Self-conducted Skin ExaminationIn: Archives of Dermatology Jg. 148 (2012) Nr. 10, S. 1142 - 1151Online Volltext: dx.doi.org/
-
Substance use and sexual risk behaviour among HIV-positive men who have sex with men in specialized out-patient clinicsIn: HIV Medicine Jg. 13 (2012) Nr. 9, S. 533 - 540Online Volltext: dx.doi.org/
-
T-cell mediated immune responses induced in ret transgenic mouse model of malignant melanomaIn: Cancers Jg. 4 (2012) Nr. 2, S. 490 - 503Online Volltext: dx.doi.org/
-
The efficiency of human cytomegalovirus pp65₄₉₅₋₅₀₃ CD8 ⁺T cell epitope generation is determined by the balanced activities of cytosolic and endoplasmic reticulum-resident peptidasesIn: The Journal of Immunology (JI) Jg. 189 (2012) Nr. 2, S. 529 - 538Online Volltext: dx.doi.org/
-
Treatment of Severe Psoriasis With Etanercept in a Pancreas-Kidney Transplant RecipientIn: Transplantation Proceedings Jg. 44 (2012) Nr. 9, S. 2776 - 2777Online Volltext: dx.doi.org/
-
Trial design on prophylaxis and treatment of brain metastases : Lessons learned from the EORTC Brain Metastases Strategic Meeting 2012In: European Journal of Cancer (EJC) Jg. 48 (2012) Nr. 18, S. 3439 - 3447Online Volltext: dx.doi.org/
-
Tumor Suppressive MicroRNAs miR-34a/c Control Cancer Cell Expression of ULBP2, a Stress-Induced Ligand of the Natural Killer Cell Receptor NKG2DIn: Cancer Research Jg. 72 (2012) Nr. 2, S. 460 - 471Online Volltext: dx.doi.org/
-
Ulceration and stage are predictive of interferon efficacy in melanoma : results of the phase III adjuvant trials EORTC 18952 and EORTC 18991In: European Journal of Cancer (EJC) Jg. 48 (2012) Nr. 2, S. 218 - 225Online Volltext: dx.doi.org/
-
Vitamin A metabolism in benign and malignant melanocytic skin cells : Importance of lecithin/retinol acyltransferase and RPE65In: Journal of Cellular Physiology Jg. 227 (2012) Nr. 2, S. 718 - 728Online Volltext: dx.doi.org/
-
A first prospective population-based analysis investigating the actual practice of melanoma diagnosis, treatment and follow-upIn: European Journal of Cancer (EJC) Jg. 47 (2011) Nr. 13, S. 1977 - 1989Online Volltext: dx.doi.org/
-
A randomised, phase II study of intetumumab, an anti-α v-integrin mAb, alone and with dacarbazine in stage IV melanomaIn: British Journal of Cancer (BJC) Jg. 105 (2011) Nr. 3, S. 346 - 352Online Volltext: dx.doi.org/ (Open Access)
-
Advantages of preoperative hybrid SPECT/CT in detection of sentinel lymph nodes in cutaneous head and neck malignanciesIn: Journal of the European Academy of Dermatology and Venereology Jg. 25 (2011) Nr. 10, S. 1213 - 1221Online Volltext: dx.doi.org/
-
Arbeitsgemeinschaft Dermatologische Onkologie (ADO) : Gezielte Blockade des mutierten BRAF führt zu Überlebensvorteil bei Patienten mit metastasiertem MelanomIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 9 (2011) Nr. 4, S. 340Online Volltext: dx.doi.org/
-
Association of Inherited Variation in Toll-Like Receptor Genes with Malignant Melanoma Susceptibility and SurvivalIn: PLoS ONE Jg. 6 (2011) Nr. 9,Online Volltext: dx.doi.org/ (Open Access)
-
Behavioural conditioning as the mediator of placebo responses in the immune systemIn: Philosophical Transactions of the Royal Society B: Biological Sciences Jg. 366 (2011) Nr. 1572, S. 1799 - 1807Online Volltext: dx.doi.org/
-
Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma : One step forward for overcoming anti-angiogenic drug resistance?In: Molecular Oncology Jg. 5 (2011) Nr. 2, S. 137 - 149Online Volltext: dx.doi.org/
-
Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma modelIn: Proceedings of the National Academy of Sciences of the United States of America (PNAS) Jg. 108 (2011) Nr. 41, S. 17111 - 17116Online Volltext: dx.doi.org/
-
Cutaneous melanoma : A model to study cancer metastasisIn: Journal of Surgical Oncology Jg. 103 (2011) Nr. 6, S. 538 - 549Online Volltext: dx.doi.org/
-
DERMA phase III trial of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in patients with MAGE-A3-positive resected stage III melanomaIn: Journal of Clinical Oncology (JCO) Jg. 29 (2011) Nr. 15_suppl, S. TPS232Online Volltext: dx.doi.org/
-
Die Sklerotherapie mit Polidocanolschaum ist eine neue und effektive Behandlung von postoperativen Lymphozelen und LymphorrhoeIn: Vasomed: Die Fachzeitschrift für Gefäßerkrankungen Jg. 23 (2011) Nr. 5, S. 252
-
EGFR-Inhibitoren und Multityrosinkinaseinhibitoren : Interdisziplinäre Behandlung der kutanen NebenwirkungenIn: Deutsche Medizinische Wochenschrift - DMW Jg. 136 (2011) Nr. 1-2, S. 39 - 44Online Volltext: dx.doi.org/
-
ERCC5 p.Asp1104His and ERCC2 p.Lys751Gln polymorphisms are independent prognostic factors for the clinical course of melanomaIn: Journal of Investigative Dermatology Jg. 131 (2011) Nr. 6, S. 1280 - 1290Online Volltext: dx.doi.org/ (Open Access)
-
Endogenous μ-opioid peptides modulate immune response towards malignant melanomaIn: Experimental Dermatology Jg. 20 (2011) Nr. 1, S. 24 - 28Online Volltext: dx.doi.org/
-
Epigenetic deregulation of TCF21 inhibits metastasis suppressor KISS1 in metastatic melanomaIn: Carcinogenesis Jg. 32 (2011) Nr. 10, S. 1467 - 1473Online Volltext: dx.doi.org/
-
Etiology of chronic leg ulcers in 31,619 patients in Germany analyzed by an expert surveyIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 9 (2011) Nr. 2, S. 116 - 121Online Volltext: dx.doi.org/
-
Expectation-induced Placebo effects in Wound healing processes : First results from a prospective clinical StudyIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 9 (2011) Nr. 11, S. 984 - 984
-
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma : Final results of a randomised phase III study (EORTC 18032)In: European Journal of Cancer (EJC) Jg. 47 (2011) Nr. 10, S. 1476 - 1483Online Volltext: dx.doi.org/
-
Foxp3+ Regulatory T Cells and Natural Killer Cells Distinctly Infiltrate Primary Tumors and Draining Lymph Nodes in Pulmonary AdenocarcinomaIn: Journal of Thoracic Oncology Jg. 6 (2011) Nr. 3, S. 432 - 438Online Volltext: dx.doi.org/ (Open Access)
-
Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationIn: The New England Journal of Medicine Jg. 364 (2011) Nr. 26, S. 2507 - 2516Online Volltext: dx.doi.org/
-
Induction of apoptosis by the BRAFV600E kinase inhibitor PLX4032 in BRAFV600E melanoma cells through regulation of endoplasmic reticulum stress-related genesIn: Journal of Clinical Oncology (JCO) Jg. 29 (2011) Nr. 15_suppl, S. 8518Online Volltext: dx.doi.org/
-
Investigation of adhesion of modern wound dressings : a comparative analysis of 56 different wound dressingsIn: Journal of the European Academy of Dermatology and Venereology Jg. 25 (2011) Nr. 8, S. 933 - 939Online Volltext: dx.doi.org/
-
Moderne Pharmakotherapie des malignen MelanomsIn: Der Internist Jg. 52 (2011) Nr. 6, S. 756 - 764Online Volltext: dx.doi.org/
-
Mucosal melanomas of the head and neck : New aspects of the clinical outcome, molecular pathology, and treatment with c-kit inhibitorsIn: Melanoma Research Jg. 21 (2011) Nr. 6, S. 475 - 482Online Volltext: dx.doi.org/
-
Nodular scabies: Hypersensitivity reaction or infection?In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 9 (2011) Nr. 10, S. 840 - 841Online Volltext: dx.doi.org/
-
Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanomaIn: Cancer Jg. 117 (2011) Nr. 8, S. 1697 - 1703Online Volltext: dx.doi.org/
-
P4 Vorschlag für Posterpreis Medizin : Beeinflussung der Wundheilung durch Placeboeffekte: Erste Resultate einer prospektiven klinischen UntersuchungIn: Zeitschrift für Wundheilung Jg. 16 (2011) Nr. Suppl. B, S. 92
-
Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapyIn: Journal of Clinical Oncology (JCO) Jg. 29 (2011) Nr. 15_suppl, S. 8520Online Volltext: dx.doi.org/
-
Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient's choice : A multicentre Dermatologic Cooperative Oncology Group trialIn: Melanoma Research Jg. 21 (2011) Nr. 6, S. 516 - 523Online Volltext: dx.doi.org/
-
Psoriasis therapy with Rtanercept in a Kidney and Pancreas transplant PatientsIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 9 (2011) Nr. Suppl. 1, S. 213Online Volltext: dx.doi.org/
-
Reliability and cost-effectiveness of sentinel lymph node excision under local anaesthesia versus general anaesthesia for malignant melanoma : A retrospective analysis in 300 patients with malignant melanoma AJCC Stages i and IIIn: Journal of the European Academy of Dermatology and Venereology Jg. 25 (2011) Nr. 3, S. 306 - 310Online Volltext: dx.doi.org/
-
Retinal and retinol are potential regulators of gene expression in the keratinocyte cell line HaCaTIn: Experimental Dermatology Jg. 20 (2011) Nr. 4, S. 373 - 375Online Volltext: dx.doi.org/ (Open Access)
-
Schmerzreduktion bei Patienten mit chronischem Ulcus cruris durch ein neu entwickeltes Morphingel : Erste Resultate einer klinischen UntersuchungIn: Der Hautarzt Jg. 62 (2011) Nr. 4, S. 280 - 286Online Volltext: dx.doi.org/
-
Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma : A multicenter phase II DeCOG trialIn: Annals of Oncology Jg. 22 (2011) Nr. 7, S. 1667 - 1674Online Volltext: dx.doi.org/
-
The Farnesyl Transferase Inhibitor Lonafarnib Inhibits mTOR Signaling and Enforces Sorafenib-Induced Apoptosis in Melanoma CellsIn: Journal of Investigative Dermatology Jg. 131 (2011) Nr. 2, S. 468 - 479Online Volltext: dx.doi.org/ (Open Access)
-
The phosphatidyl inositol 3-kinase pathway is central to the pathogenesis of Kit-activated melanomaIn: Pigment Cell and Melanoma Research Jg. 24 (2011) Nr. 4, S. 714 - 723Online Volltext: dx.doi.org/
-
Adjuvant pegylated interferon α-2b therapy for melanomaIn: Oncology Letters Jg. 1 (2010) Nr. 2, S. 237 - 241Online Volltext: dx.doi.org/
-
Association between the germline MC1R variants and somatic BRAF/NRAS mutations in melanoma tumorsIn: Journal of Investigative Dermatology Jg. 130 (2010) Nr. 12, S. 2844 - 2848Online Volltext: dx.doi.org/
-
Bacterial colonization of chronic leg ulcers : current results compared with data 5 years ago in a specialized dermatology departmentIn: Journal of the European Academy of Dermatology and Venereology Jg. 24 (2010) Nr. 9, S. 1017 - 1025Online Volltext: dx.doi.org/
-
Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccineIn: Cancer Immunology, Immunotherapy Jg. 59 (2010) Nr. 6, S. 863 - 873Online Volltext: dx.doi.org/
-
Diagnostik des malignen MelanomsIn: Der Onkologe Jg. 16 (2010) Nr. 12, S. 1121 - 1130Online Volltext: dx.doi.org/
-
Distinct metabolism of cyclic adenosine monophosphate in regulatory and helper CD4+ T cellsIn: Molecular Immunology Jg. 47 (2010) Nr. 4, S. 678 - 684Online Volltext: dx.doi.org/
-
Effect of mTOR inhibitors on sorafenib-induced endoplasmic reticulum stress and apoptosis in melanoma cellsIn: Journal of Clinical Oncology (JCO) Jg. 28 (2010) Nr. Suppl. 15, S. e19027Online Volltext: dx.doi.org/
-
Efficacy of Low-Dose Interferon α2a 18 Versus 60 Months of Treatment in Patients With Primary Melanoma of ≥ 1.5 mm Tumor Thickness : Results of a Randomized Phase III DeCOG TrialIn: Journal of Clinical Oncology (JCO) Jg. 28 (2010) Nr. 5, S. 841 - 846Online Volltext: dx.doi.org/
-
Endoprotease Profiling with Double-Tagged Peptide Substrates : A New Diagnostic Approach in OncologyIn: Clinical Chemistry Jg. 56 (2010) Nr. 2, S. 272 - 280Online Volltext: dx.doi.org/
-
Facial variant of eruptive vellus hair cysts : A case report and brief review of the literatureIn: Kosmetische Medizin Jg. 31 (2010) Nr. 4, S. 200 - 203
-
Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapyIn: European Journal of Immunology Jg. 40 (2010) Nr. 6, S. 1786 - 1794Online Volltext: dx.doi.org/
-
Genetic and morphologic features for melanoma classificationIn: Pigment Cell and Melanoma Research Jg. 23 (2010) Nr. 6, S. 763 - 770Online Volltext: dx.doi.org/
-
Improved Survival with Ipilimumab in Patients with Metastatic MelanomaIn: The New England Journal of Medicine Jg. 363 (2010) Nr. 8, S. 711 - 723Online Volltext: dx.doi.org/
-
Ipilimumab efficacy and safety in patients with advanced melanoma : a retrospective analysis of HLA subtype from four trialsIn: Cancer Immunology: a Journal of the Academy of Cancer Immunology Jg. 10 (2010) Nr. 1, S. 9(Open Access)
-
Ipilimumab monotherapy in patients with pretreated advanced melanoma : a randomised, double-blind, multicentre, phase 2, dose-ranging studyIn: The Lancet Oncology Jg. 11 (2010) Nr. 2, S. 155 - 164Online Volltext: dx.doi.org/
-
Klippel-Trénaunay-Syndrom : eine seltene Ursache eines chronischen Ulcus crurisIn: Medizinische Klinik Jg. 105 (2010) Nr. 11, S. 841 - 844Online Volltext: dx.doi.org/
-
MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcomeIn: British Journal of Cancer (BJC) Jg. 103 (2010) Nr. 6, S. 820 - 826Online Volltext: dx.doi.org/ (Open Access)
-
Melanoma risk factors, perceived threat and intentional tanning : an international online surveyIn: European Journal of Cancer Prevention Jg. 19 (2010) Nr. 3, S. 216 - 226Online Volltext: dx.doi.org/
-
Mixed effect modelling of proteomic mass spectrometry data by using Gaussian mixturesIn: Journal of the Royal Statistical Society / Series C (Applied Statistics) Jg. 59 (2010) S. 617 - 633Online Volltext: dx.doi.org/
-
Multicentre study on standardisation of melanoma cell culture : An initiative of the German Melanoma Research NetworkIn: Pigment Cell and Melanoma Research Jg. 23 (2010) Nr. 2, S. 296 - 298Online Volltext: dx.doi.org/
-
PGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cellsIn: Blood Jg. 116 (2010) Nr. 9, S. 1454 - 1459Online Volltext: dx.doi.org/
-
PGE2 Transiently Enhances DC Expression of CCR7 but Inhibits the Ability of DCs to Produce CCL19 and Attract Naïve T cellsIn: Clinical Immunology Jg. 135 (2010) S. S100Online Volltext: dx.doi.org/
-
PLX4032 : does it keep its promise for metastatic melanoma treatment?In: Expert Opinion on Investigational Drugs Jg. 19 (2010) Nr. 11, S. 1439 - 1449Online Volltext: dx.doi.org/
-
Pegylated interferons : Prospects for the use in the adjuvant and palliative therapy of metastatic melanomaIn: European Journal of Cancer (EJC) Jg. 46 (2010) Nr. 1, S. 41 - 46Online Volltext: dx.doi.org/
-
Perianale Ulzerationen durch KaliumpermanganatbäderIn: Der Hautarzt Jg. 61 (2010) Nr. 5, S. 435 - 438Online Volltext: dx.doi.org/
-
Photopheresis in pediatric patients with low-body weight using the UVAR XTS systemIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 8 (2010) Nr. 1, S. 32 - 37Online Volltext: dx.doi.org/
-
Polidocanol foam sclerotherapy is a new and effective treatment for post-operative lymphorrhea and lymphoceleIn: Journal of the European Academy of Dermatology and Venereology Jg. 24 (2010) Nr. 8, S. 904 - 909Online Volltext: dx.doi.org/
-
Polymorphisms in the CD28/CTLA4/ICOS genes : role in malignant melanoma susceptibility and prognosis?In: Cancer Immunology, Immunotherapy Jg. 59 (2010) Nr. 2, S. 303Online Volltext: dx.doi.org/
-
Predictors of Sun Protection Behaviors and Severe Sunburn in an International Online StudyIn: Cancer Epidemiology, Biomarkers & Prevention Jg. 19 (2010) Nr. 9, S. 2199 - 2210Online Volltext: dx.doi.org/
-
Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanomaIn: Journal of Experimental Medicine (JEM) Jg. 207 (2010) Nr. 3, S. 491 - 503Online Volltext: dx.doi.org/ (Open Access)
-
Screening of Human Tumor Antigens for CD4+ T Cell Epitopes by Combination of HLA-Transgenic Mice, Recombinant Adenovirus and Antigen Peptide LibrariesIn: PLoS ONE Jg. 5 (2010) Nr. 11, S. e14137Online Volltext: dx.doi.org/ (Open Access)
-
Single-nucleotide polymorphisms in DNA-repair genes and cutaneous melanomaIn: Mutation Research / Genetic Toxicology and Environmental Mutagenesis Jg. 702 (2010) Nr. 1, S. 8 - 16Online Volltext: dx.doi.org/
-
Somatic alterations in the melanoma genome : a high-resolution array-based comparative genomic hybridization studyIn: Genes, Chromosomes and Cancer Jg. 49 (2010) Nr. 8, S. 733 - 745Online Volltext: dx.doi.org/
-
Sorafenib and pegylated interferon-alpha-2b in advanced metastatic melanoma : A multicenter phase II DeCOG trialIn: Journal of Clinical Oncology (JCO) Jg. 28 (2010) Nr. Suppl. 15, S. 8526Online Volltext: dx.doi.org/
-
Steroid-induced Periorificial Dermatitis in Children—Clinical Features and Response to Azelaic AcidIn: Pediatric Dermatology Jg. 27 (2010) Nr. 2, S. 137 - 142Online Volltext: dx.doi.org/
-
Systemic allergic contact dermatitis from intravenous piritramideIn: Allergy Jg. 65 (2010) Nr. 9, S. 1203 - 1204Online Volltext: dx.doi.org/
-
Update on Immunologic Therapy With Anti–CTLA-4 Antibodies in Melanoma : Identification of Clinical and Biological Response Patterns, Immune-Related Adverse Events, and Their ManagementIn: Seminars in Oncology Jg. 37 (2010) Nr. 5, S. 485 - 498Online Volltext: dx.doi.org/
-
cGMP-phosphodiesterase 6, transducin and Wnt5a/Frizzled-2-signaling control cGMP and Ca2+ homeostasis in melanoma cellsIn: Cellular and Molecular Life Sciences - CMLS Jg. 67 (2010) Nr. 5, S. 817 - 828Online Volltext: dx.doi.org/
-
Retraction Note to : cGMP-phosphodiesterase 6, transducin and Wnt5a/Frizzled-2-signaling control cGMP and Ca2+ homeostasis in melanoma cellsIn: Cellular and Molecular Life Sciences - CMLS Jg. 77 (2020) Nr. 5, 963Online Volltext: dx.doi.org/ (Open Access)
-
Corrigendum to ‘Prediction of melanoma evolution in melanocytic nevi via artificial intelligence: A call for prospective data’In: European Journal of Cancer (EJC) Jg. 123 (2019) S. 171Online Volltext: dx.doi.org/ (Open Access)
-
Obesity Is Associated with Altered Tumor Metabolism in Metastatic MelanomaIn: Clinical Cancer Research Jg. 29 (2023) Nr. 1, S. 154 - 164Online Volltext: dx.doi.org/
-
Editorial : Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer ImmunotherapyIn: Frontiers in Immunology Jg. 12 (2021) 789473Online Volltext: dx.doi.org/ (Open Access)
-
EditorialIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 14 (2016) Nr. 1, S. 1 - 2Online Volltext: dx.doi.org/
-
VorwortIn: Oncology Research and Treatment Jg. 39 (2016) Nr. Suppl. 4, S. 1Online Volltext: dx.doi.org/
-
VorwortIn: Oncology Research and Treatment Jg. 37 (2014) S. 1Online Volltext: dx.doi.org/ (Open Access)
-
A Randomized, Double-Blind, Phase 2 Study of Perioperative MK-4280A (Coformulation of Favezelimab and Pembrolizumab) vs Pembrolizumab in Patients with Resectable Cutaneous Squamous Cell Carcinoma (cSCC)In: International Journal of Radiation Oncology, Biology, Physics Jg. 118 (2024) Nr. 5, S. E86
-
A phase 3 trial of IMC-F106C (PRAME x CD3) plus nivolumab versus standard nivolumab regimens in HLA-A*02:01+ patients with previously untreated advanced melanoma (PRISM-MEL-301)In: Journal of Clinical Oncology (JCO) Jg. 42 (2024) Nr. Suppl. 16, TPS9602Online Volltext: dx.doi.org/ (Open Access)
-
A randomized phase 2 trial of the IO102-IO103 (IDO and PD-L1) cancer vaccine plus pembrolizumab as neoadjuvant/adjuvant treatment of patients with solid tumorsIn: Journal of Clinical Oncology (JCO) Jg. 42 (2024) Nr. Suppl. 16, TPS2701Online Volltext: dx.doi.org/ (Open Access)
-
Clinical validation of a prognostic 7-marker IHC assay (7-IHC) in 382 patients (pts) with stage IB/IIA cutaneous melanoma (CM; MELARISK-001)In: Journal of Clinical Oncology (JCO) Jg. 42 (2024) Nr. Suppl. 16, 9572Online Volltext: dx.doi.org/ (Open Access)
-
Efficacy and safety of RP1 combined with nivolumab in patients with anti–PD-1–failed melanoma from the IGNYTE clinical trialIn: Journal of Clinical Oncology (JCO) Jg. 42 (2024) Nr. Suppl. 16, 9517Online Volltext: dx.doi.org/ (Open Access)
-
Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma : An indirect treatment comparison (ITC) using patient-level data (PLD)In: Journal of Clinical Oncology (JCO) Jg. 41 (2024) Nr. Suppl. 16, 9552Online Volltext: dx.doi.org/ (Open Access)
-
Length of treatment after partial or complete remission in immunotherapy for metastatic melanoma : An EUMelaReg real world studyIn: Journal of Clinical Oncology (JCO) Jg. 42 (2024) Nr. Suppl. 16, 9531Online Volltext: dx.doi.org/ (Open Access)
-
Long-term follow up for adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma : Final results of the COMBI-AD studyIn: Journal of Clinical Oncology (JCO) Jg. 42 (2024) Nr. Suppl. 16, 9500Online Volltext: dx.doi.org/ (Open Access)
-
Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma (RELATIVITY-047) : Overall survival (OS) and melanoma-specific survival (MSS) outcomes at 3 yearsIn: Journal of Clinical Oncology (JCO) Jg. 42 (2024) Nr. Suppl. 16, 9524Online Volltext: dx.doi.org/ (Open Access)
-
Phase 3 study (PIVOTAL) of neoadjuvant intralesional daromun vs. immediate surgery in fully resectable melanoma with regional skin and/or nodal metastases
2024 ASCO Annual Meeting, May 31 - June 4, 2024, Chicago, Ill., USA and online,In: Journal of Clinical Oncology (JCO) Jg. 42 (2024) Nr. 17, Supplement, LBA9501Online Volltext: dx.doi.org/ -
A low interventional trial addressing the immunological effects of the RANKL-inhibitor Denosumab in combination with dual checkpoint blockade in melanoma patients with bone involvement reveals upregulation of CXCL-13
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 17Online Volltext: dx.doi.org/ (Open Access) -
Adjuvant Pembrolizumab in Stage II Melanoma : Outcomes by Tumor Location in the Phase 3 KEYNOTE-716 StudyIn: Annals of Surgical Oncology Jg. 30 (2023) Nr. Suppl. 1, S. S34 - S35Online Volltext: dx.doi.org/ (Open Access)
-
Außergewöhnlicher Therapiebenefit von Imatinib bei cKIT-mutiertem Schleimhautmelanom mit nachfolgendem KIT-Mutationsverlust
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 21 - 22Online Volltext: dx.doi.org/ (Open Access) -
Die PD-L1-Expression im Tumor prognostiziert je nach Art des untersuchten Gewebes das Outcome einer Anti-PD-1-basierten Immuntherapie bei metastasiertem Melanom
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 27 - 28Online Volltext: dx.doi.org/ (Open Access) -
Efficacy of current antimicrobial treatment for gonorrhoea: A retrospective data analysis from 2016-2022 in the Ruhr area
DÖAK 2023 / German-Austrian AIDS Conference, Bonn, Germany, 23-25 March 2023,In: HIV Medicine Jg. 24 (2023) Nr. 1, S. 43 - 44 -
Etablierung eines Mustererkennungsalgorithmus zur histologischen Detektion von Melanommetastasen im Schildwächterlymphknoten
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 20 - 21Online Volltext: dx.doi.org/ (Open Access) -
Immune-Checkpoint Blockade for Organ-Transplant Recipients with Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 25Online Volltext: dx.doi.org/ (Open Access) -
Molekulare und klinische Charakterisierung von BRAF/NRAS/NF1-wt Melanomen
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 21Online Volltext: dx.doi.org/ (Open Access) -
Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma : Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 studyIn: Journal of Clinical Oncology (JCO) Jg. 41 (2023) Nr. 17_suppl., LBA9505Online Volltext: dx.doi.org/
-
Predictors of long-term survival of Stage IV melanoma patients: a multicenter DeCOG study on 395 patients from the prospective skin cancer registry ADOREG
52. Tagung der Deutschen Dermatologischen Gesellschaft, Vereinigung Deutschsprachiger Dermatologen e. V., 26.-29.04.2023, Berlin,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S1, Special Issue: Abstractband anlässlich der 52. Tagung der Deutschen Dermatologischen Gesellschaft, Vereinigung Deutschsprachiger Dermatologen e. V. 26. bis 29. April 2023, Berlin, S. 9 - 27Online Volltext: dx.doi.org/ (Open Access) -
RCT to Test the Efficacy of an EEG Neurofeedback Intervention in Cancer Patients and Cancer Survivors
Deutscher Kongress für Psychosomatische Medizin und Psychotherapie, 03.-05.05.2023, Berlin,In: Zeitschrift für Psychosomatische Medizin und Psychotherapie Jg. 69 (2023) Nr. 2, S. 148 - 149Online Volltext: dx.doi.org/ -
Relationship between baseline health-related quality of life (HRQoL) measures and clinical outcomes of nivolumab (NIVO) or nivolumab plus ipilimumab (NIVO+IPI) in patients (pts) with unresectable or metastatic melanoma using real-world data from the non-interventional study (NIS) NICO in Germany
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 6 - 8Online Volltext: dx.doi.org/ (Open Access) -
Therapeutic outcomes of human papilloma virus (HPV)-associated anal lesions in HIV-positive and negative patients
DÖAK 2023 / German-Austrian AIDS Conference, Bonn, Germany, 23-25 March 2023,In: HIV Medicine Jg. 24 (2023) Nr. S1, S. 36 - 37 -
Treatment decision for melanoma patients : Identification of similar patients at point of care
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO-Jahrestagung) 06.–09. September 2023 Hamburg, S. 5 - 6Online Volltext: dx.doi.org/ (Open Access) -
Untersuchung des klinischen Verlaufs von Melanompatienten mit einer Super-Response (CR/PR innerhalb von 3 Monaten) unter PD-1-basierter Immuncheckpoint-Inhibition : eine Subgruppen-Analyse der prospektiven multizentrischen Studie ADOREG
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 8 - 9Online Volltext: dx.doi.org/ (Open Access) -
Adjuvant dabrafenib plus trametinib (D + T) versus placebo in patients with resected stage III BRAFᵛ⁶⁰⁰-mutant melanoma : Updated 5-year distant metastases-free survival (DMFS) analysis of COMBI-AD.In: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. 9563Online Volltext: dx.doi.org/ (Open Access)
-
Adjuvant immunotherapy with nivolumab (NIVO) versus observation in completely resected Merkel cell carcinoma (MCC) : Disease-free survival (DFS) results from ADMEC-O, a randomized, open-label phase II trial
ESMO Congress 2022, 9 - 13 September 2022, Paris, France,In: Annals of Oncology Jg. 33 (2022) Nr. Supplement 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S903Online Volltext: dx.doi.org/ (Open Access) -
Adjuvant nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma with no evidence of disease (NED) : Overall survival (OS) results of IMMUNED, a randomized, double-blind multi-center phase II DeCOG trial
ESMO Congress 2022, 9 - 13 September 2022, Paris, France,In: Annals of Oncology Jg. 33 (2022) Nr. Supplement 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S900Online Volltext: dx.doi.org/ (Open Access) -
Analysis of efficacy outcomes using ERIVANCE-like methodology in patients with locally advanced basal cell carcinoma
Australasian College of Dermatologists 54th Annual Scientific Meeting, Discover Connect Collaborate; 30 April to 3 May 2022; online,In: Australasian Journal of Dermatology Jg. 63 (2022) Nr. 1, SI, S. 112Online Volltext: dx.doi.org/ (Open Access) -
Biomarker analyses of baseline tumor specimens and on-treatment changes in sera samples of patients enrolled in the RELATIVITY-047 trial to characterize LAG-3 biologyIn: Journal for ImmunoTherapy of Cancer Jg. 10 (2022) Nr. Suppl. 2, S. A636 - A637Online Volltext: dx.doi.org/ (Open Access)
-
Cold atmospheric plasma versus diclofenac 3% gel in patients with actinic keratosesIn: Experimental Dermatology Jg. 31 (2022) Nr. 2, S. e24 - e24
-
Compartment-based proteomics of CD8high vs. CD8low melanoma regions reveals differential regulation of TOR signaling
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 12Online Volltext: dx.doi.org/ -
Context Sensitive Links 9 of 29 Circulating tumor derived cell-free RNA (cfRNA) as a potential biomarker in melanomaIn: Experimental Dermatology Jg. 31 (2022) Nr. 2, S. e26 - e27
-
Development of brain metastases and survival outcomes upon first-line systemic therapy in BRAF mutant and BRAF wildtype melanoma patients : a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 13 - 14Online Volltext: dx.doi.org/ -
EMRseq : Registry-based outcome analysis on 1,000 patients with BRAF V600–mutated metastatic melanoma in Europe treated with either immune checkpoint or BRAF-/MEK inhibitionIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. 9540Online Volltext: dx.doi.org/ (Open Access)
-
Early safety signals from nivolumab in the adjuvant treatment of real-world melanoma patients derived from the German prospective non-interventional study NICO
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 18 - 19Online Volltext: dx.doi.org/ -
Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAFV600-positive melanoma : Interim analysis of the ImmunoCobiVem studyIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. 9548Online Volltext: dx.doi.org/
-
Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAFᵛ⁶⁰⁰-mutant melanoma : Updated data from the multicenter, multinational, prospective, non-interventional longitudinal study BERINGᴹᴱᴸᴬᴺᴼᴹᴬIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. 9526Online Volltext: dx.doi.org/ (Open Access)
-
Epigenetisch-metabolische Vulnerabilität von medikamententoleranten Persisterzellen im MelanomIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 24Online Volltext: dx.doi.org/
-
Etablierung eines Deep-Learning-Algorithmus zur Differenzierung von Morbus Bowen und seborrhoischen Keratosen
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 15Online Volltext: dx.doi.org/ -
Im Plasma zirkulierende zellfreie mRNA ermöglicht die minimal-invasive und Genotyp-unabhängige Therapieüberwachung bei Patienten mit Melanom
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 12 - 13Online Volltext: dx.doi.org/ -
Inhibition of the mTOR inhibitory protein sirtuin 1 leads to faster tumor growth under PD1-based immune checkpoint blockadeIn: Experimental Dermatology Jg. 31 (2022) Nr. 2, S. e92
-
KDM5B's role in creating radiation synthetic vulnerabilities and its effects on sequential therapy combinations
48th Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF): Virtual, Innsbruck, 23-26 February 2022,In: Experimental Dermatology Jg. 31 (2022) Nr. 2, S. e9 - e10Online Volltext: dx.doi.org/ -
Klinische und pathologische Merkmale des familiären Melanoms bei Keimbahn-TERT-Promotorvarianten
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 6Online Volltext: dx.doi.org/ -
Multicenter real-world data of adjuvant treatment and disease outcome of patients with melanoma with high-risk of recurrenceIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. 9570Online Volltext: dx.doi.org/ (Open Access)
-
Navtemadlin (KRT-232) activity after failure of anti-PD-1/L1 therapy in patients (pts) with TP53ᵂᵀ Merkel cell carcinoma (MCC)In: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. 9506Online Volltext: dx.doi.org/ (Open Access)
-
Phase II study of multiple LXH254 drug combinations in patients (pts) with unresectable/metastatic, BRAF V600- or NRAS-mutant melanoma
ESMO Congress 2022, 9 - 13 September 2022, Paris, France,In: Annals of Oncology Jg. 33 (2022) Nr. Supplement 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S1407Online Volltext: dx.doi.org/ (Open Access) -
Predicting primary resistance and exploring mechanisms in patients with advanced melanoma treated with immune checkpoint inhibitors (ICIs)
37th Annual Meeting of the Society for Immunotherapy of Cancer, SITC 2022 ; November 8 - 12, 2022, Boston, Mass., USA,In: Journal for ImmunoTherapy of Cancer Jg. 10 (2022) Nr. Supplement 2, S. A639 - A640Online Volltext: dx.doi.org/ (Open Access) -
Predictors of long-term survival of stage IV melanoma patients : a multicenter DeCOG study on 539 patients from the prospective skin cancer registry ADOREG
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 16 - 17Online Volltext: dx.doi.org/ -
REINA - Retrospective Multicenter ADOReg Evaluation of Ipilimumab plus Nivolumab in Avelumab-refractory Merkel cell carcinoma
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 21Online Volltext: dx.doi.org/ -
Real-world clinical outcomes of pembrolizumab for advanced melanoma in the German ADOREG skin cancer registry
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 18Online Volltext: dx.doi.org/ -
Therapiemanagement des ersten Rezidivs nach adjuvanter Therapie im Stadium III : multizentrische real-world Daten
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 3Online Volltext: dx.doi.org/ -
Tumor biomarker analysis from COLUMBUS part 1 : Encorafenib + binimetinib for BRAF V600E/K-mutant advanced or metastatic melanoma
ESMO Congress 2022, 9 - 13 September 2022, Paris, France,In: Annals of Oncology Jg. 33 (2022) Nr. Supplement 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S902Online Volltext: dx.doi.org/ (Open Access) -
5-Year Overall Survival in COLUMBUS : A randomized Phase 3 Study of Encorafenib plus Binimetinib versus Vemurafenib or Encorafenib in Patients with BRAF(V600)-mutated MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 56
-
Additional Benefit of FDG-PET when Discontinuing Immune Checkpoint Inhibitor Therapy in Patients with metastatic MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 75 - 76
-
Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915)In: Cancer Research Jg. 81 (2021) Nr. 13, CT004
-
Age-dependent Efficacy and Safety of Nivolumab (NIVO) as Monotherapy or Combination Therapy with Ipilimumab (NIVO plus IPI) in Patients with advanced Melanoma in the non-interventional Study (NIS) NICOIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 16 - 17
-
CheckMate 067 : 6.5-year outcomes in patients (pts) with advanced melanomaIn: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 15_Suppl, S. 9506 - 9506Online Volltext: dx.doi.org/
-
Comparing 5-year body-mass-index gain of people living with HIV (PLH) with the general populationIn: Infection - A Journal of Infectious Disease Jg. 49 (2021) Nr. Suppl. 1, S. 23Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Comparing 5-year body-mass-index gain of people living with HIV (PLH) with the general populationIn: Infection - A Journal of Infectious Disease Jg. 49 (2021) Nr. Suppl. 1, S. 23Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Comparison of Mutation Profiles in primary Melanomas and nodal Nevi using next Generation SequencingIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 80 - 81
-
Comparison of effectiveness and safety of nivolumab monotherapy or in combination therapy with ipilimumab in therapy-naïve and pretreated patients with advanced melanoma within the German noninterventional study NICOIn: Annals of Oncology Jg. 32 (2021) Nr. Suppl. 5, S. 894 - S895Online Volltext: dx.doi.org/ (Open Access)
-
Efficacy of trichloroacetic acid vs. electrocautery for the treatment of anal intraepithelial neoplasia marker lesions in HIV-positive patientsIn: Infection - A Journal of Infectious Disease Jg. 49 (2021) Nr. Suppl. 1, S. 24 - S25Online Volltext: dx.doi.org/ (Open Access)
-
Efficacy of trichloroacetic acid vs. electrocautery for the treatment of anal intraepithelial neoplasia marker lesions in HIV-positive patientsIn: Infection - A Journal of Infectious Disease Jg. 49 (2021) Nr. Suppl. 1, S. 24 - S25Online Volltext: dx.doi.org/ (Open Access)
-
Encorafenib plus Binimetinib in Patients with locally advanced, non-resectable or metastatic BRAF(V600) mutated Melanoma : First Data from the multicenter, multinational, prospective, non-interventional Longitudinal Study BERING(MELANOMA)In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 53
-
Encorafenib plus Binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutant melanoma : First data of the multicenter, multinational, prospective, non-interventional longitudinal study BERINGMELANOMAIn: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 15_Suppl, S. 9555 - 9555Online Volltext: dx.doi.org/
-
Epigenetic-metabolic Vulnerability of drug-tolerant Persister Cells in MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 36
-
Evaluation der Detektion von analen intraepitheliale Neoplasien (AIN) bei HIV‐positiven Menschen durch zytologische Abstriche und HPV Typisierungen beim Screening auf anale HPV‐assoziierte Läsionen
51. Tagung der Deutschen Dermatologischen Gesellschaft ; 14.‐17. April 2021, Virtuell,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 2, S. 22Online Volltext: dx.doi.org/ (Open Access) -
Extended-dose cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC) : Primary analysis of phase II resultsIn: Annals of Oncology Jg. 32 (2021) Nr. Suppl. 5, S. 886 - S887Online Volltext: dx.doi.org/ (Open Access)
-
Immune checkpoint-Inhibition in Patients with NRAS-mutated Melanoma compared to Patients with NRAS Wild-type Melanoma : Results of a Study on 702 Patients from the prospective, multicenter Registry ADOREGIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 59 - 60
-
Interferon-independent enhancement of melanoma cell immunogenicity by RIG-I activation
47th Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF) Virtual, March 04‐06, 2021,In: Experimental Dermatology Jg. 30 (2021) Nr. 3, S. E78 -
Intratumoral Immunotherapy : RIG-I Agonists induce a dedifferentiated yet T-Cell-sensitive Melanoma Cell PhantotypeIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 34
-
No difference in changes of the body mass index categories over 5 years in people living with HIV and the general population from the German Ruhr-area
18th European AIDS Conference (EACS 2021), Online & London, United Kingdom, October 27-30, 2021,In: HIV Medicine Jg. 22 (2021) Nr. S3, S. 140Online Volltext: dx.doi.org/ -
PD-L1-Expression and Mutation Profile in pre-therapeutic Tumor Tissue as Predictors of the Therapeutic Success of PD-1-based Immune Checkpoint Inhibition Therapy in Patients with metastatic Melanoma : Evaluation of the prospective multicentric ADO-Study TRIMIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 19
-
PLATForM : Descriptive analysis from a randomised, phase II study of novel spartalizumab combinations in previously treated unresectable/metastatic melanomaIn: Annals of Oncology Jg. 32 (2021) Nr. Suppl. 5, S. 898Online Volltext: dx.doi.org/ (Open Access)
-
PTHrP-induced hypercalcemia Psychosyndrome under Immune Checkpoint Blockade in Patients with penile Squamous Cell CarcinomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 23
-
Predictors of Super-response (CR/PR within 3 Months) under PD-1-based Immune Checkpoint Inhibition in metastatic Melanoma : A Subgroup Analysis of the prospective multicenter Study ADOREG TRIMIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 6 - 7
-
Preliminary biomarker and pharmacodynamic (PD) activity of the TGFβ inhibitor SAR439459, alone or in combination with cemiplimab, in a phase 1 clinical study in patients with advanced solid tumors
SITC 36th Anniversary Annual Meeting (SITC 2021), 10-14 November 2021, Washington & virtually,In: Journal for ImmunoTherapy of Cancer Jg. 9 (2021) Nr. Suppl. 2, S. A550 - A550Online Volltext: dx.doi.org/ (Open Access) -
Profiling of tumor-infiltrating T cells for guidance of melanoma salvage therapy in immune-checkpoint-blockade resistant patients
47th Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF) Virtual, March 04‐06, 2021,In: Experimental Dermatology Jg. 30 (2021) Nr. 3, S. E52Online Volltext: dx.doi.org/ -
Pyrexia-related outcomes upon application of an adapted pyrexia management algorithm in patients (pts) with BRAF V600 : Mutant unresectable or metastatic melanoma treated with dabrafenib plus trametinib (DabTram) in the COMBI-i trialIn: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 15_Suppl, S. 9560 - 9560Online Volltext: dx.doi.org/
-
Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma : Primary phase III results from RELATIVITY-047 (CA224-047)In: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 15_Suppl, S. 9503 - 9503Online Volltext: dx.doi.org/
-
Results from the phase Ib of the SENSITIZE trial combining domatinostat with pembrolizumab in advanced melanoma patients refractory to prior checkpoint inhibitor therapyIn: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 15_Suppl, S. 9545 - 9545Online Volltext: dx.doi.org/
-
S7/1 Behandlungsergebnisse der Therapie einer Syphilis-Infektion
65. Deutschen STI-Kongresses – virtuell – vom 5./6. Februar 2021,In: Der Hautarzt Jg. 72 (2021) Nr. Supplement 1, S. S5 - S6Online Volltext: dx.doi.org/ (Open Access) -
TERT Promoter Mutations associated with longer progression-free and Overall Survival under BRAF/MEK TherapyIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 31
-
Termination of targeted Therapy with BRAF-/MEK Inhibitors after an initial complete Response in Patients with metastatic Melanoma and its clinical Implications : A retrospective, multicenter ADOReg StudyIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 15 - 16
-
The Effects of Brain Metastases in Melanoma Patients on anti-PD1 Antibody Therapy with PembrolizumabIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 5 - 6
-
The impact of brain involvement in metastatic melanoma patients treated with pembrolizumab
Immunotherapy Bridge and Melanoma Bridge 2020, 02.-03.12.2020, Virtual Meeting,In: Journal of Translational Medicine Jg. 19 (2021) Nr. Suppl. 1, S. 17Online Volltext: dx.doi.org/ (Open Access) -
Treatment outcomes in patients (pts) with melanoma brain metastases (MBM) treated with systemic therapy : A systematic literature review (SLR) and meta-analysis.In: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 15_Suppl, S. 9561 - 9561Online Volltext: dx.doi.org/
-
Treatment outcomes in patients (pts) with melanoma brain metastases (MBM) undergoing systemic therapy : A systematic literature review (SLR) and meta-analysis (MA) of real-world evidence (RWE)In: Annals of Oncology Jg. 32 (2021) Nr. Suppl. 5, S. 892 - S893Online Volltext: dx.doi.org/ (Open Access)
-
Triplet therapy with pembrolizumab (PEM), encorafenib (ENC) and binimetinib (BIN) in advanced, BRAF V600 mutant melanoma : Final results from the dose-finding phase I part of the IMMU-Target trialIn: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 15_Suppl, S. 9532 - 9532Online Volltext: dx.doi.org/
-
Tumor PD-L1 expression and gene panel mutational profile as outcome predictors of PD-1-based checkpoint inhibition therapy in metastatic melanoma : A prospective multicenter DeCOG studyIn: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 15_Suppl, S. 9568 - 9568Online Volltext: dx.doi.org/
-
Tumor PD-L1-Positivity in medical and digital Quantification predicts a favorable Patient Outcome for a PD-1-based Immune Checkpoint-Blockade in metastatic MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 58 - 59
-
5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO plus IPI) or NIVO aloneIn: Annals of Oncology Jg. 31 (2020) Nr. Suppl. 4, S. S734 - S735Online Volltext: dx.doi.org/ (Open Access)
-
Agranulozytose unter Immuncheckpoint‐Blockade : Eine retrospektive, multizentrische AuswertungIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV28Online Volltext: dx.doi.org/ (Open Access)
-
Correlation of BRAF mutation status in circulating tumour DNA (ctDNA) with tumour biopsy and clinical outcomes in COLUMBUSIn: Annals of Oncology Jg. 31 (2020) Nr. Suppl. 4, S. S757 - S758Online Volltext: dx.doi.org/ (Open Access)
-
Die Extracorporale Photopherese verbessert therapierefraktäre autoimmune Nebenwirkungen nach ImmuncheckpointblockadeIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV06Online Volltext: dx.doi.org/ (Open Access)
-
Die diagnostische Bedeutung der CT-gesteuerten Punktion bei HauttumorpatientenIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV49Online Volltext: dx.doi.org/ (Open Access)
-
Die digitale Analyse der Tumor PD‐L1 Expression ist ein guter Prädiktor des Therapieerfolgs einer anti‐PD1‐basierten Immuntherapie : Eine Subgruppenanalyse der multizentrischen translationalen Studie ADOREG/TRIMIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV36Online Volltext: dx.doi.org/ (Open Access)
-
Distinct melanoma differentiation trajectories driven by MAPKi associate with activation of CD8+tumor-infiltrating lymphocytesIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV17Online Volltext: dx.doi.org/ (Open Access)
-
Effect of first-line spartalizumab + dabrafenib + trametinib on immunosuppressive features detected in peripheral blood and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanomaIn: Journal of Clinical Oncology (JCO) Jg. 38 (2020) Nr. 15_Suppl., S. 10034Online Volltext: dx.doi.org/
-
Effektivität von Dabrafenib plus Trametinib bei der Behandlung von Melanompatienten mit BRAFV600‐mutierten HirnmetastasenIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. P128Online Volltext: dx.doi.org/ (Open Access)
-
Eindrucksvolles und schnelles Therapieansprechen eines metastasierten Adnexkarzinoms unter CemiplimabIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV08Online Volltext: dx.doi.org/ (Open Access)
-
Einfluss des BRAF‐V600 Mutationsstatus auf die Effizienz einer Immun‐Checkpoint‐Blockade : Eine Auswertung des ADOREGIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV33Online Volltext: dx.doi.org/ (Open Access)
-
Encorafenib plus Binimetinib bei Patienten mit lokal fortgeschrittenem, inoperablem oder metastasiertem BRAFV600‐mutierten Melanom : Erste Daten der multizentrischen, multinationalen, prospektiven, nicht‐interventionellen Längsschnittstudie BERINGMELANOMIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. P130Online Volltext: dx.doi.org/ (Open Access)
-
E‐Health trifft auf „Real‐World“ : App‐basierte Unterstützung in der adjuvanten Therapie von Melanompatienten im Stadium III mit Dabrafenib und Trametinib (Combi‐EU)In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV45Online Volltext: dx.doi.org/ (Open Access)
-
Immun‐Checkpoint‐Blockade beim Merkelzellkarzinom : Klinische und molekulare Biomarker‐AnalyseIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV22Online Volltext: dx.doi.org/ (Open Access)
-
Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for melanomaIn: Journal for ImmunoTherapy of Cancer Jg. 8 (2020) Nr. Suppl. 3, S. A308Online Volltext: dx.doi.org/ (Open Access)
-
Long-term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected stage III BRAF V600–mutant melanoma : Five-year analysis of COMBI-ADIn: Journal of Clinical Oncology (JCO) Jg. 38 (2020) Nr. 15_Suppl., S. 10001Online Volltext: dx.doi.org/
-
Neoadjuvante Immun‐ und zielgerichtete Therapie bei Melanompatienten im Stadium III BIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV44Online Volltext: dx.doi.org/ (Open Access)
-
Nivolumab (NIVO) monotherapy or combination therapy with ipilimumab (NIVO+IPI) in advanced melanoma patients with brain metastases : Real-world evidence from the German non-interventional study NICOIn: Annals of Oncology Jg. 31 (2020) Nr. Suppl. 4, S. 746 - S747Online Volltext: dx.doi.org/ (Open Access)
-
Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC) : Longer follow-upIn: Journal of Clinical Oncology (JCO) Jg. 38 (2020) Nr. 15_Suppl.,Online Volltext: dx.doi.org/
-
Preclinical and clinical assessment of immune checkpoint inhibitor-associated left ventricular dysfunction
ESC Congress 2020 – The Digital Experience 29 August – 1 September 2020,In: European Heart Journal Jg. 41 (2020) Nr. Supplement_2, S. 3260Online Volltext: dx.doi.org/ -
RIG-I activation enhances melanoma immunogenicity and improves anti-tumor T cell responses in combination with anti-PD-1 immune checkpoint blocking antibodiesIn: Journal for ImmunoTherapy of Cancer Jg. 8 (2020) Nr. Suppl. 2, S. A3Online Volltext: dx.doi.org/ (Open Access)
-
Real World‐ Daten zur Anwendung von Nivolumab (Nivo) als Monotherapie oder in Kombination mit Ipilimumab (Nivo+Ipi) in der Behandlung des fortgeschrittenen Melanoms : Zwischenergebnisse der nicht‐interventionellen Studie NICOIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. P101Online Volltext: dx.doi.org/ (Open Access)
-
Restricted mean survival time (RMST) and cure-rate modeling in estimating survival benefit with adjuvant dabrafenib (D) plus trametinib (T) treatment in melanomaIn: Annals of Oncology Jg. 31 (2020) Nr. Suppl. 4, S. 743 - S744Online Volltext: dx.doi.org/ (Open Access)
-
Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma : Results from the randomized part 3 of the phase III COMBI-i trialIn: Annals of Oncology Jg. 31 (2020) Nr. Suppl. 4, S. S1172Online Volltext: dx.doi.org/ (Open Access)
-
The anti–PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600–mutant melanoma : Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trialIn: Journal of Clinical Oncology (JCO) Jg. 38 (2020) Nr. 15_Suppl., S. 10028Online Volltext: dx.doi.org/
-
Therapieentscheidung bei Indikation zur adjuvanten Therapie des Melanoms : Multizentrische Real World DataIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV43Online Volltext: dx.doi.org/ (Open Access)
-
Tumor necrosis factor alpha blockade prevents immune checkpoint inhibitor therapy-related cardiotoxicity
ESC Congress 2020 – The Digital Experience 29 August – 1 September 2020,In: European Heart Journal Jg. 41 (2020) Nr. Supplement_2, S. 3250Online Volltext: dx.doi.org/ -
Tumorzell‐intrinsiche Aktivierung des Immunrezeptors RIG‐I in Kombination mit Immun‐Checkpoint‐Blockade verbessert anti‐Tumor T‐ZellantwortenIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV18Online Volltext: dx.doi.org/ (Open Access)
-
Update zum Gesamtüberleben in der COLUMBUS‐Studie : Eine randomisierte Phase 3‐Studie mit Encorafenib (ENCO) plus Binimetinib (BINI) vs Vemurafenib (VEM) oder ENCO bei Patienten mit BRAF V600–mutiertem MelanomIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. P127Online Volltext: dx.doi.org/ (Open Access)
-
A randomized, open-label, open-platform, Phase II study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATforM)In: Cancer Research Jg. 79 (2019) Nr. Suppl. 13,Online Volltext: dx.doi.org/
-
Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO)In: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 15, S. 9582 - 9582Online Volltext: dx.doi.org/
-
Der Stellenwert der Schildwächterlymphknotenentnahme auf das metastasenfreie Überleben von Patienten mit Hochrisiko-Plattenepithelkarzinomen
29. Deutscher Hautkrebskongress (ADO–Jahrestagung) ; 11.–14. September 2019, Ludwigshafen,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 17 (2019) Nr. Supplement 5: Abstractband anlässlich des 29. Deutschen Hautkrebskongresses (ADO–Jahrestagung) 11.–14. September 2019, Ludwigshafen, S. 23 - 23Online Volltext: dx.doi.org/ (Open Access) -
Development of therapeutic strategies by resolving the tumor ecosystemIn: Cancer Research Jg. 79 (2019) Nr. Suppl. 13,Online Volltext: dx.doi.org/
-
Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanomaIn: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 15, S. 9507 - 9507Online Volltext: dx.doi.org/
-
Genomic analyses and immunotherapy in advanced melanomaIn: Cancer Research Jg. 79 (2019) Nr. Suppl. 13,Online Volltext: dx.doi.org/
-
Patient-reported quality of life (QoL) of advanced melanoma patients in a Phase 3 study of nivolumab (NIVO) with or without ipilimumab (IPI) versus IPI : CheckMate 067 4-year dataIn: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 15, S. 9551 - 9551Online Volltext: dx.doi.org/
-
Primary analysis of phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma (laCSCC)In: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 15, S. 6015 - 6015Online Volltext: dx.doi.org/
-
Single-cell RNA-sequencing of metastatic melanoma identifies a cancer cell-intrinsic program associated with immune checkpoint inhibitor resistance
4th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, September 30 - October 3, 2018, New York, NY,In: Cancer Immunology Research Jg. 7 (2019) Nr. 2, Supplement, S. A082Online Volltext: dx.doi.org/ -
The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma : Updated efficacy and safety from parts 1 and 2 of COMBI-iIn: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 15, S. 9531 - 9531Online Volltext: dx.doi.org/
-
Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanoma treated with first-line spartalizumab (S) + dabrafenib (D) + trametinib (T)In: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 15, S. 9515 - 9515Online Volltext: dx.doi.org/
-
Update on overall survival in COLUMBUS : A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600–mutant melanomaIn: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 15, S. 9512 - 9512Online Volltext: dx.doi.org/
-
Variants in CD5 and IRF4 impact into melanoma survivalIn: European Journal of Human Genetics Jg. 26 (2019) Nr. Suppl., S. 688 - 689Online Volltext: dx.doi.org/ (Open Access)
-
1246PD - Talimogene laherparepvec (T-VEC) treatment increases intratumoral effector T-cell and natural killer (NK) cell density in noninjected tumors in patients (pts) with stage IIIB–IVM1c melanoma: : Evidence for systemic effects in a phase II, single-arm studyIn: Annals of Oncology Jg. 29 (2018) Nr. 8, S. viii443Online Volltext: dx.doi.org/ (Open Access)
-
A randomized, double-blind, phase II/III study of relatlimab (anti-LAG-3) in combination with nivolumab (anti-PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanomaIn: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 8, S. viii464 - viii465Online Volltext: dx.doi.org/ (Open Access)
-
A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATForM)In: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 8, S. viii465 - viii466Online Volltext: dx.doi.org/ (Open Access)
-
Adjuvant ipilimumab compared with observation in completely resected Merkel cell carcinoma (ADMEC) : A randomized, multicenter DeCOG/ADO studyIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. 9527Online Volltext: dx.doi.org/ (Open Access)
-
Adjuvante Therapie des Merkelzellkarzinoms mit Ipilimumab im Vergleich zur Beobachtung (ADMEC) : eine randomisierte, multizentrische ADO‐Studie
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 6Online Volltext: dx.doi.org/ (Open Access) -
Adverse events of special interest in the phase 3 COLUMBUS studyIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. 9567 - 9567Online Volltext: dx.doi.org/ (Open Access)
-
Angiosarkom im Bereich des Capillitium mit der Symptomatik eines Quincke‐Ödems
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. Suppl. 6, S. 34Online Volltext: dx.doi.org/ (Open Access) -
Application of circulating cell-free tumor DNA (ctDNA) profiles for monitoring metastatic melanoma progression under therapy
45th Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF) ; March 7‐10, 2018, Zürich,In: Experimental Dermatology Jg. 27 (2018) Nr. 3, S. e22 - e23Online Volltext: dx.doi.org/ (Open Access) -
Auswirkungen der überarbeiteten AJCC‐Klassifikation (8. Edition) auf das Essener Melanomkollektiv
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 61 - 62Online Volltext: dx.doi.org/ (Open Access) -
Autoimmunbedingte Gastritis nach Immuncheckpoint‐Blockade : eine Fallserie
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 26 - 27Online Volltext: dx.doi.org/ (Open Access) -
Biomarkers of response to PD‐1 inhibition in Merkel cell carcinoma
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 5Online Volltext: dx.doi.org/ (Open Access) -
CCR5 Δ32 Polymorphismus als prädiktiver Marker für die Therapie mit Immuncheckpoint‐Inhibitoren beim Melanom
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 49 - 50Online Volltext: dx.doi.org/ (Open Access) -
Catch me if you can! : Novel immune escape mechanisms in melanoma metastases of the brain
45th Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF) ; March 7‐10, 2018, Zürich,In: Experimental Dermatology Jg. 27 (2018) Nr. 3, S. e15Online Volltext: dx.doi.org/ (Open Access) -
Clear Cell Sarcoma - a rare Differential Diagnosis of malignant MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. Suppl. 6, S. 3
-
Die Anzahl mutierter Melanom‐assoziierter Gene und die Expression von PD‐L1 sind unabhängige Prädiktoren der anti‐PD1 Immuntherapie ‐ eine prospektive Registerstudie der ADO (ADOREG/TRIM)In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 7 - 8Online Volltext: dx.doi.org/ (Open Access)
-
EUMelaReg : A European platform for outcome research on real world treatment data of patients with advanced melanomaIn: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 8, S. viii459Online Volltext: dx.doi.org/ (Open Access)
-
Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III BRAF-mutant melanoma.In: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. 9590 - 9590Online Volltext: dx.doi.org/ (Open Access)
-
Einfluss einer vorangegangenen Radiatio auf den Erfolg einer immunonkologischen Therapie beim metastasierten Melanom – eine retrospektive multizentrische Studie der ADO
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 28 - 29Online Volltext: dx.doi.org/ (Open Access) -
Evolution of cross‐resistance to CD8+ T cells in the course of BRAF and MEK inhibitor treatment in BRAFV600E melanoma
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. 6, S. 53Online Volltext: dx.doi.org/ (Open Access) -
F-18-FDG PET/MR including DWI in initial N-Staging in patients with malignant melanoma : Is it a possible replacement for sentinel lymph node biopsy?In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 45 (2018) Nr. Suppl. 1, S. 38Online Volltext: dx.doi.org/ (Open Access)
-
Genomic correlates of response to immune checkpoint blockade in microsatellite stable solid tumorsIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. 3036Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Gesamtüberleben (OS) in COLUMBUS: eine Phase‐III‐Studie mit Encorafenib (ENCO) plus Binimetinib (BINI) vs. Vemurafenib (VEM) oder ENCO beim BRAF‐mutierten Melanom
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 41Online Volltext: dx.doi.org/ (Open Access) -
Gesichtsalterungs‐Apps in Warteräumen : Eine neue Möglichkeit für die Hautkrebsprävention?
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 66 - 67Online Volltext: dx.doi.org/ (Open Access) -
Gesichtsalterungs‐Apps in Warteräumen von HIV‐positiven Patienten zur Tabakentwöhnung : Führt die öffentliche Selfiebearbeitung zum Aufhörversuch? – eine Interventionsstudie
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 65 - 66Online Volltext: dx.doi.org/ (Open Access) -
Gesichtsalterungs‐Apps in der schulischen Melanomprävention: : erste Ergebnisse aus Deutschland und Brasilen – Perspektiven für großflächige Implementation
Konferenz 28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 67Online Volltext: dx.doi.org/ (Open Access) -
Health-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote 054 trial : An international randomized double-blind phase III trialIn: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 8, S. viii456Online Volltext: dx.doi.org/ (Open Access)
-
Impact of skin cancer screening on the incidence of advanced melanoma and melanoma mortality : A pilot project for a case-control study in the setting of the German nationwide skin cancer screening (PiKoM)
33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 1, S. 159Online Volltext: dx.doi.org/ (Open Access) -
Interaction of neutrophils and melanoma in the context of MAP kinase inhibition
45th Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF) ; March 7‐10, 2018, Zürich,In: Experimental Dermatology Jg. 27 (2018) Nr. 3, S. e85 - e86Online Volltext: dx.doi.org/ (Open Access) -
Klarzellsarkom – eine seltene Differentialdiagnose des malignen Melanoms
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 3Online Volltext: dx.doi.org/ (Open Access) -
Künstliche Intelligenz in der dermatologischen Diagnostik : Das Skin‐Classification‐Projekt
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 7Online Volltext: dx.doi.org/ (Open Access) -
MEK‐Inhibitoren könnten das Überleben von NRAS‐mutierten Melanompatienten unter Checkpoint‐Inhibitoren verbessern : Ergebnisse einer retrospektiven, multizentrischen Analyse von 364 Patienten
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 4Online Volltext: dx.doi.org/ (Open Access) -
Meningeosis melanomatosa : Schlechte Prognose trotz neuer Systemtherapeutika
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 11 - 12Online Volltext: dx.doi.org/ (Open Access) -
Mutational and immune gene expression profiling at relapse in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (pbo) in the COMBI-AD trialIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. 9574 - 9574Online Volltext: dx.doi.org/ (Open Access)
-
NICO ‐ eine nationale, prospektive, nicht‐interventionelle Studie (NIS) mit Nivolumab als Monotherapie oder in Kombination mit Ipilimumab bei Patienten mit fortgeschrittenem (inoperablem oder metastasiertem) Melanom zur Erhebung von real‐world data
Konferenz 28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 79Online Volltext: dx.doi.org/ (Open Access) -
Overall survival in COLUMBUS : A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanomaIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. 9504 - 9504Online Volltext: dx.doi.org/ (Open Access)
-
PAKOME‐RCT: Projektskizze für die Evaluation des Einsatzes einer evidenzbasierten Patienteninformation (EBPI) zum Melanom in der Praxis
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 60Online Volltext: dx.doi.org/ (Open Access) -
PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E/K–mutant metastatic melanoma (MM) who received dabrafenib + trametinib (D+T) in the randomized phase 3 COMBI-v study.In: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. 5 Suppl., S. 183Online Volltext: dx.doi.org/ (Open Access)
-
Partielle Remission eines fortgeschrittenen Melanoms durch eine Kombinationstherapie mit Nivolumab und Trametinib nach Therapieversagen unter Ipilimumab + Nivolumab
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 38Online Volltext: dx.doi.org/ (Open Access) -
Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma : Efficacy and safety results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trialIn: Cancer Research Jg. 78 (2018) Nr. Suppl. 13,Online Volltext: dx.doi.org/
-
Phase 3 Randomized Eortc 1325‐Mg/Keynote‐054 Study Results: Pembrolizumab Versus Placebo after Complete Resection in Patients with High‐Risk Stage III Melanoma
Medical Oncology Group of Australia Incorporated Annual Scientific Meeting, New Directions in Personalised Cancer Therapy; 1–3 August 2018; Adelaide, Australia,In: Asia-Pacific Journal of Clinical Oncology Jg. 14 (2018) Nr. Supplement 3, S. 48Online Volltext: dx.doi.org/ -
Potential role of TGF-beta signaling in immune-checkpoint-therapy-induced resistance in malignant melanoma
45th Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF) ; March 7‐10, 2018, Zürich,In: Experimental Dermatology Jg. 27 (2018) Nr. 3, S. e63 - e64Online Volltext: dx.doi.org/ (Open Access) -
Primary analysis of phase 2 results for cemiplimab, a human monoclonal anti-PD-1, in patients with metastatic cutaneous squamous cell carcinoma (mCSCC)In: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. 9519 - 9519Online Volltext: dx.doi.org/ (Open Access)
-
Prognostic impact of baseline tumor immune infiltrate on disease-free survival (DFS) in patients with completely resected, BRAF(V600) mutation-positive (BRAF(V600+)) melanoma receiving adjuvant vemurafenib
Immunotherapy Bridge 2017 and Melanoma Bridge 2017 ; 29 November–2 December 2017. Naples, Italy,In: Journal of Translational Medicine Jg. 16 (2018) Nr. Suppl. 1, S. O20Online Volltext: dx.doi.org/ (Open Access) -
Prospektive Studie zur Evaluation der perioperativen Angst und des Speichelkortisollevels bei Melanompatienten mit Schildwächterlymphknotenexstirpationen in Tumeszenz‐ vs. Vollnarkose
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 62Online Volltext: dx.doi.org/ (Open Access) -
Real-world evidence in melanoma : A national, prospective, non-interventional study (NIS) of nivolumab monotherapy or in combination with ipilimumab in patients with advanced (unresected or metastatic) melanoma (NICO)
33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 1, S. 159Online Volltext: dx.doi.org/ (Open Access) -
Single-cell RNA-sequencing and -imaging of melanoma ecosystems reveals sources of resistance to immune checkpoint blockadeIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. 3074 - 3074Online Volltext: dx.doi.org/ (Open Access)
-
The anti-PD-1 antibody spartalizumab (PDR001) in combination with dabrafenib and trametinib in previously untreated patients with advancedBRAFV600-mutant melanoma : First efficacy, safety, and biomarker findings from the part 2 biomarker cohort of COMBi-iIn: Cancer Research Jg. 78 (2018) Nr. Suppl. 13,Online Volltext: dx.doi.org/
-
Therapieversagen der Immuncheckpoint‐Blockade mit PD1‐Antikörpern bei Patienten mit metastasierten Hauttumorerkrankungen und gleichzeitiger Immunsuppression durch eine Chronisch Lymphatische Leukämie
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 28Online Volltext: dx.doi.org/ (Open Access) -
Unerwünschte Ereignisse von besonderem Interesse in der Phase‐3‐COLUMBUS‐Studie
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 42Online Volltext: dx.doi.org/ (Open Access) -
Diagnostik und Therapie der immunvermittelten Thyreoiditis unter Therapie mit Ipilimumab und NivolumabIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 15 (2017) Nr. Suppl. 3, S. 26 - 27Online Volltext: dx.doi.org/
-
Mechanistic analysis of CD3-driven T cell functions reveals a CD32a polymorphism associated with melanoma emergenceIn: Experimental Dermatology Jg. 24 (2015) Nr. 3, 42nd Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF), March 05-07, 2015, Ulm, Germany, S. E18 - E18Online Volltext: dx.doi.org/
-
Senescence-like responses in irradiated melanoma cellsIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 13 (2015) Nr. Suppl.2, S. 34Online Volltext: dx.doi.org/
-
Adjuvant therapy with pegylated interferon alfa-2a (PEG-IFN) versus low-dose interferon alfa-2a (IFN) in patients with malignant melanoma in stages IIa(T3a): IIIb (AJCC 2002) : Decog-trialIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15, suppl., S. 9071Online Volltext: dx.doi.org/
-
BRIM8 : A phase III, randomized, double-blind, placebo-controlled study of vemurafenib adjuvant therapy in patients with surgically resected, cutaneous BRAF-mutant melanoma at high risk for recurrence (NCT01667419)In: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15, Suppl., S. TPS9118Online Volltext: dx.doi.org/
-
Brain natriuretic peptide (BNP) as a prognostic parameter for cardiovascular events and death in HV-infected patients
ESC Congress 2014, Barcelona, Spain, 30 August – 3 September 2014,In: European Heart Journal Jg. 35 (2014) Nr. Suppl. 1, S. 231Online Volltext: dx.doi.org/ -
Effect of the BRAF inhibitor LGX818 on endoplasmic reticulum stress and sensitivity of NRAS-mutant melanoma cells to the MEK inhibitor binimetinibIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15, Suppl., S. 9062Online Volltext: dx.doi.org/
-
Left ventricular ejection fraction as a prognostic marker for all-cause mortality in HIV-infected patients
ESC Congress 2016, 27 - 31 August, Rome, Italy,In: European Heart Journal Jg. 35 (2014) Nr. Suppl. 1, S. 3Online Volltext: dx.doi.org/ -
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma : Final update (30-month) of the pivotal ERIVANCE BCC studyIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15, Suppl., S. 9013Online Volltext: dx.doi.org/
-
Long-term safety and overall survival update for BREAK-2, a phase 2, single-arm, open-label study of dabrafenib in previously treated metastatic melanoma (NCT01153763)In: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15, suppl., S. 9034Online Volltext: dx.doi.org/
-
NEMO : A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with untreated or progressed after first-line immunotherapy unresectable or metastatic NRAS-mutant cutaneous melanomaIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15, suppl., S. TPS9102 - TPS9102Online Volltext: dx.doi.org/
-
Open-label, multicenter, single-arm phase II study (DeCOG-Trial) to further evaluate the efficacy and safety of ipilimumab in patients with cutaneous melanoma and rare subgroupsIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15, Suppl., S. 9031Online Volltext: dx.doi.org/
-
Proktitiden mit N. gonorrhoeae/C. trachomatis führen zur Rekrutierung von HIV-Zielzellen aber nicht zu einer gesteigerten HIV-Sekretion
Leopoldina-Symposium und STI-Kongress, 18. und 19.–21. Juni 2014, Berlin,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 12 (2014) Nr. 10, S. 952 - 953Online Volltext: dx.doi.org/ -
Shift of HIV-Tropism in a HIV-patient with large cell anaplastic T-cell-lymphoma undergoing allogeneic stem cell transplantation from a donor with homozygosity for the CCR5 delta32 mutation
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 10.-14. Oktober 2014, Hamburg,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 5, S. 38Online Volltext: dx.doi.org/ -
The GERMELATOX DeCOG-trial : German melanoma patients and their attitude toward toxicity during adjuvant interferon treatmentIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15, suppl., S. TPS9113Online Volltext: dx.doi.org/
-
Vemurafenib treatment in patients with BRAF-mutated melanoma failing MEK inhibition with trametinibIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15, suppl., S. 9061Online Volltext: dx.doi.org/
-
Neuropilin-1 mediates infiltration of regulatory T cells into tumors favoring immune escapeIn: European Journal of Immunology Jg. 190 (2013) S. P2063
-
Oncogene and copy number analysis of a larger cohort of conjunctival melanomaIn: Experimental Dermatology Jg. 22 (2013) Nr. 3, S. E43
-
A five-year observance of changes in the cardiovascular risk profile in 505 HIV-positive individualsIn: Journal of the International AIDS Society Jg. 15 (2012) Nr. S4, S. P211Online Volltext: dx.doi.org/ (Open Access)
-
A glimpse into the somatic mutation landscape of melanoma through exome sequencing of 121 tumor-normal pairsIn: Cancer Research Jg. 72 (2012) Nr. 8, Suppl., S. 5056Online Volltext: dx.doi.org/
-
HIV-infection during treatment of a chronic hepatitis B virus infection : implications for PrEP?In: Journal of the International AIDS Society Jg. 15 (2012) Nr. S4, S. P234Online Volltext: dx.doi.org/
-
METRIC phase III study : Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM)In: Journal of Clinical Oncology (JCO) Jg. 30 (2012) Nr. 18, Suppl., S. LBA8509Online Volltext: dx.doi.org/
-
Cardiovascular Risk factors of Psoriasis : Results from the Heinz Nixdorf Recall Study
46. Tagung der Deutschen Dermatologischen Gesellschaft Vereinigung Deutschsprachiger Dermatologen e. V., 30. März bis 2. April 2011, Dresden,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 9 (2011) Nr. S1, Abstraktband anläßlich der 46. Tagung der Deutschen Dermatologischen Gesellschaft Vereinigung Deutschsprachiger Dermatologen e. V. in Dresden vom 30. März bis 2. April 2011, S. 147 - 148Online Volltext: dx.doi.org/ -
Gonosome-linked expression of PPP2R3B in cutaneous melanoma correlates with distant metastasis free survivalIn: Cancer Research Jg. 71 (2011) Nr. 8, Suppl., S. 4835Online Volltext: dx.doi.org/
-
Cutaneous melanomaIn: Cardio-Oncology Practice Manual: A Companion to Braunwald's Heart Disease / Herrmann, Joerg (Hrsg.) 2023, S. 370 - 375Online Volltext: dx.doi.org/
-
Guideline-Based Context-Sensitive Decision Modeling for Melanoma PatientsIn: German Medical Data Sciences 2022 – Future Medicine: More Precise, More Integrative, More Sustainable! / Joint Conference of the 67th Annual Meeting of the German Association of Medical Informatics, Biometry, and Epidemiology e.V. (gmds) and the 14th Annual Meeting of the TMF – Technology, Methods, and Infrastructure for Networked Medical Research e.V.; 21–25 August 2022; Kiel, Germany / Röhrig, Rainer; Grabe, Niels; Hoffmann, Verena S.; Hübner, Ursula; König, Jochem; Sax, Ulrich; Schreiweis, Björn; Sedlmayr, Martin (Hrsg.) 2022, S. 50 - 57Online Volltext: dx.doi.org/ (Open Access)
-
Biomarkers for MelanomaIn: Cutaneous Melanoma / Balch, Charles M.; Atkins, Michael B.; Garbe, Claus; Gershenwald, Jeffrey E.; Halpern, Allan C.; Kirkwood, John M.; McArthur, Grant A.; Thompson, John F.; Sober, Arthur J. (Hrsg.) 2020, S. 73 - 104Online Volltext: dx.doi.org/
-
The era of checkpoint inhibition : Lessons learned from melanomaIn: Current Immunotherapeutic Strategies in Cancer / Theobald, Matthias (Hrsg.) 2020, S. 169 - 187Online Volltext: dx.doi.org/
-
Immune checkpoint inhibitors in melanoma define a new era in immunotherapy aiming for cureIn: Melanoma Development: Molecular Biology, Genetics and Clinical Application / Bosserhoff, Anja K. (Hrsg.) 2017, S. 427 - 436Online Volltext: dx.doi.org/
-
The common and the unusual presentation of skin metastases in cancer patientsIn: Handbook of Skin Care in Cancer Patients / Awada, Ahmad; Vereecken, Pierre (Hrsg.) 2012, S. 95 - 115
-
High-resolution 3-D imaging for precise staging in malignant melanomaNew York (2020) 37 SeitenOnline Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Anti-PD-1 (PD1) monotherapy or in combination with anti-CTLA-4 for metastatic melanoma (MM) patients (pts) with liver metastases (mets)
ESMO Congress 2023 ; 20 - 24 October 2023, Madrid, Spain,In: Annals of Oncology Jg. 34 (2023) Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S666 - S667Online Volltext: dx.doi.org/ (Open Access) -
Anti-PD1 plus BRAF/MEK inhibitors (triplet therapy) after failure of standard therapy in patients (pts) with advanced melanoma
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 44Online Volltext: dx.doi.org/ (Open Access) -
Ausgedehntes Rezidiv eines atypischen Fibroxanthoms
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO-Jahrestagung) 06.–09. September 2023 Hamburg, S. 99Online Volltext: dx.doi.org/ (Open Access) -
Clinical characteristics and survival of patients with advanced Merkel cell carcinoma (MCC) treated with avelumab : Analysis of a prospective German MCC registry (MCC TRIM)
ESMO Congress 2023 ; 20 - 24 October 2023, Madrid, Spain,In: Annals of Oncology Jg. 34 (2023) Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S685 - S686Online Volltext: dx.doi.org/ -
Efficacy of immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD1 treatment : A EUMelareg real-world evidence study
ESMO Congress 2023 ; 20 - 24 October 2023, Madrid, Spain,In: Annals of Oncology Jg. 34 (2023) Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S665 - S666Online Volltext: dx.doi.org/ -
Identifizierung von nachteiligen Datensamples zur verbesserten KI-gestützten Klassifizierung von Hautläsionen unter Verwendung von Radiomics
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 95 - 96Online Volltext: dx.doi.org/ (Open Access) -
Initial efficacy and safety of RP1+ nivolumab in patients with anti–PD-1–failed melanoma from the ongoing phase 1/2 IGNYTE study
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September, 2023 Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 119 - 120Online Volltext: dx.doi.org/ (Open Access) -
Langfristiger Therapieerfolg von sequentieller Immun- und zielgerichteter Therapie beim metastasierten malignen Melanom
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 47 - 48Online Volltext: dx.doi.org/ (Open Access) -
Melanom mit unbekanntem Primarius (MUP) - eine monozentrische Auswertung
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 76 - 77Online Volltext: dx.doi.org/ (Open Access) -
Multi-modal and longitudinal characterization of the tumor and immune microenvironment from primary melanoma to in-transit and distant metastasis
ESMO Congress 2023 ; 20 - 24 October 2023 Madrid, Spain,In: Annals of Oncology Jg. 34 (2023) Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S694Online Volltext: dx.doi.org/ (Open Access) -
Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma : 2-year subgroup analyses from RELATIVITY-047
ESMO Congress 2023 ; 20 - 24 October 2023, Madrid, Spain,In: Annals of Oncology Jg. 34 (2023) Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S664 - S665Online Volltext: dx.doi.org/ (Open Access) -
Pain points in software interaction in the treatment of melanoma patients
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 125 - 126Online Volltext: dx.doi.org/ (Open Access) -
Preliminary Examination of Cited Literature in International Melanoma Guidelines
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 126Online Volltext: dx.doi.org/ (Open Access) -
Randomized phase II trial (PORTSIDE) evaluating encorafenib (enco) and binimetinib (bini) plus pembrolizumab (pembro) versus nivolumab (nivo) and ipilimumab (ipi) for the treatment of advanced BRAF-mutant melanoma
ESMO Congress 2023 ; 20 - 24 October 2023, Madrid, Spain,In: Annals of Oncology Jg. 34 (2023) Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S700Online Volltext: dx.doi.org/ (Open Access) -
Role of IFNγ-induced tumor-T cell equilibrium in melanoma latencyIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 34Online Volltext: dx.doi.org/ (Open Access)
-
Therapieansprechen auf Sunitinib bei Imatinib-resistentem Rezidiv eines Dermatofibrosarkoma protuberans am Capillitium
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 99 - 100Online Volltext: dx.doi.org/ (Open Access) -
Therapieoption beim lokal fortgeschrittenen kutanen Plattenepithelkarzinom nach Cemiplimab-Resistenz
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 72Online Volltext: dx.doi.org/ (Open Access) -
Tumor PD-L1 predicts the outcome of PD-1-based immunotherapy in metastatic melanoma depending on the type of tissue examined
ESMO Congress 2023 ; 20 - 24 October 2023, Madrid, Spain,In: Annals of Oncology Jg. 34 (2023) Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S695Online Volltext: dx.doi.org/ -
Context-Sensitive Modeling of a Standard Operating Procedure for Melanoma Patient Treatment
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 67Online Volltext: dx.doi.org/ -
Distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: the phase 3 KEYNOTE-716 study
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 95Online Volltext: dx.doi.org/ -
Efficacy of dabrafenib (D) trametinib (T) plus spartalizumab (S) by baseline site of metastases in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma : Post hoc analysis of phase III COMBI-i trial
ESMO Congress 2022, 9 - 13 September 2022, Paris, France,In: Annals of Oncology Jg. 33 (2022) Nr. Supplement 7, S. S921 - S922Online Volltext: dx.doi.org/ (Open Access) -
Encorafenib plus Binimetinib bei Patienten mit lokal fortgeschrittenem, nicht-resezierbarem oder metastasiertem BRAFV600-mutiertem Melanom : Aktualisierte Daten der multizentrischen, multinationalen, prospektiven, nicht-interventionellen Längsschnittstudie BERING MELANOMA
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 96 - 97Online Volltext: dx.doi.org/ -
Explainable Radiomics by the example of malignant melanoma
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 65 - 66Online Volltext: dx.doi.org/ -
Genetic and methylation analysis of CTNNB1 mutations in benign and malignant melanocytic lesions
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 84Online Volltext: dx.doi.org/ -
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis : a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 29 - 30Online Volltext: dx.doi.org/ -
Konzept-basierte Erklärung neuronaler Netze für die Dermatohistopathologie
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 68Online Volltext: dx.doi.org/ -
MAPKinase Inhibition nach Versagen einer PD-1 basierten Immuncheckpoint Blockade in Patienten:innen mit fortgeschrittenem Melanom : eine Auswertung des multizentrischen prospektiven Hautkrebsregisters ADOREG
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 28Online Volltext: dx.doi.org/ -
Mitigating Cognitive Bias with Decision Support Systems
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 64Online Volltext: dx.doi.org/ -
Molekularpathologie und Methylierungsprofile als diagnostische Unterstützung zur Differenzierung von Klarzellsarkomen und melanozytären Tumoren
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 88Online Volltext: dx.doi.org/ -
Multispectral optoacoustic tomography to differentiate between lymph node metastases and coronavirus-19 vaccine-associated lymphadenopathy
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 105Online Volltext: dx.doi.org/ -
Nivolumab (NIVO) + relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma : Additional response outcomes from RELATIVITY-047
ESMO Congress 2022, 9 - 13 September 2022, Paris, France,In: Annals of Oncology Jg. 33 (2022) Nr. Supplement 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S920 - S921Online Volltext: dx.doi.org/ (Open Access) -
Outcome of PD-1 inhibitor therapy of advanced melanoma patients according to demographic factors in a real-world setting across Europe
ESMO Congress 2022, 9 - 13 September 2022, Paris, France,In: Annals of Oncology Jg. 33 (2022) Nr. Supplement 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S931Online Volltext: dx.doi.org/ (Open Access) -
Partielle Remission auf Cemiplimab eines beidseitig Orbitae-infiltrierenden Basalzellkarzinoms des Mittelgesichts
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 44 - 45Online Volltext: dx.doi.org/ -
Persister state-directed transitioning and vulnerability in melanoma
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 35 - 36Online Volltext: dx.doi.org/ -
Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC) : Final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3
ESMO Congress 2022, 9 - 13 September 2022, Paris, France,In: Annals of Oncology Jg. 33 (2022) Nr. Supplement 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S918 - S919Online Volltext: dx.doi.org/ (Open Access) -
Predictive role of neutrophil-lymphocyte ratio (NLR) in patients (pts) with metastatic melanoma : A post hoc exploratory analysis from phase III COMBI-i trial
ESMO Congress 2022, 9 - 13 September 2022, Paris, France,In: Annals of Oncology Jg. 33 (2022) Nr. Supplement 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S947 - S948Online Volltext: dx.doi.org/ (Open Access) -
Efficacy of syphilis treatment in HIV-infected patientsIn: Infection - A Journal of Infectious Disease Jg. 49 (2021) Nr. Suppl. 1, S. 40Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAF(V600) mutated melanoma : first data from a multi-centric, multi-national, prospective, longitudinal, non-interventional study - BERINGMELANOMA
Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 01.-04. Oktober 2021, Hybrid-Kongress,In: Oncology Research and Treatment Jg. 44 (2021) Nr. Supplement 2, S. 249 - 250Online Volltext: dx.doi.org/ (Open Access) -
Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC) : follow-up at 43 months
48th Annual Scientific Meeting Cancer care and research: Learning from the past and improving the future, 16-18 November 2021,In: Asia-Pacific Journal of Clinical Oncology Jg. 17 (2021) Nr. 9, SI, S. 166Online Volltext: dx.doi.org/ (Open Access) -
Rosacea in Children - A Case Report
46. Tagung der Deutschen Dermatologischen Gesellschaft, Vereinigung Deutschsprachiger Dermatologen e. V., 30. März bis 2. April 2011, Dresden, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 9 (2011) Nr. Suppl. 1, S. 240 - 240Online Volltext: dx.doi.org/ -
3D data related to : Identification and quantification of hidden melanoma metastases in human sentinel lymph nodes using light sheet fluorescence microscopy(2020)